Urea and carbamate compounds, compositions comprising the same and their use as pharmaceuticals

Urea and carbamate compounds are developed as GIPR antagonists to treat metabolic diseases and obesity by modulating the GIPR, addressing the need for effective GIPR antagonist molecules.

WO2026236839A1PCT designated stage Publication Date: 2026-11-19SANDPIPER THERAPEUTICS INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CA2026/050691
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-11-27
Filing Date
2026-05-13
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

There is a need for the discovery of Glucose-dependent Insulinotropic Polypeptide Receptor (GIPR) antagonist molecules for the treatment of metabolic diseases and obesity, either as single agents or in combination with other incretin modulators.

Method used

Development of urea and carbamate compounds that act as GIPR antagonists, which can be used in pharmaceutical compositions to treat or prevent conditions such as diabetes, obesity, and related metabolic disorders.

Benefits of technology

The compounds effectively modulate the GIPR, providing therapeutic benefits in treating a wide range of metabolic diseases and obesity-related conditions, including diabetes, obesity, and other related comorbidities.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CA2026050691_19112026_PF_FP_ABST
    Figure CA2026050691_19112026_PF_FP_ABST
Patent Text Reader

Abstract

There is provided a compound having the Formula (I) or a pharmaceutically acceptable salt, solvate, or prodrug thereof. A pharmaceutical composition comprising the compound of Formula (I) or the pharmaceutically acceptable salt, solvate, or prodrug thereof, and a pharmaceutically acceptable carrier, diluent or excipient is also provided. The compound or pharmaceutically acceptable salt, solvate, or prodrug thereof, or the pharmaceutical composition comprising the same, can be used for the treatment or prevention of a condition, a disease or a disorder.
Need to check novelty before this filing date? Find Prior Art

Description

UREA AND CARBAMATE COMPOUNDS, COMPOSITIONS COMPRISING THE SAME AND THEIR USE AS PHARMACEUTICALSRELATED APPLICATIONS

[0001] The present application claims priority under applicable law to United States provisional application No. 63 / 805,071, filed on May 13, 2025, and United States provisional application No.63 / 926,567, filed on November 27, 2025, the contents of which are incorporated herein by reference in their entirety and for all purposes.TECHNICAL FIELD

[0002] The technical field generally relates to compounds, pharmaceutical compositions containing the compounds and their uses as Glucose-dependent Insulinotropic Polypeptide Receptor (Gl PR) antagonists.BACKGROUND

[0003] Glucose-dependent insulinotropic polypeptide (GIP, formerly called gastric inhibitory polypeptide) is a 42-amino acid peptide secreted from K-cells in the proximal small intestine in response to food ingestion. GIP is a member of the incretin family of peptides and enhances glucose-dependent insulin secretion. GIP is also known to promote fat storage in adipose tissue and also influences bone metabolism (see Baggio & Drucker Gastroenterology 2007, 132,2131; Hansen et al. Br J Pharmacol. 2016, 173, 826.; Holst et al. J Clin Endocrinol Metab. 2020,105, 2710).

[0004] The GIP receptor (GIPR) is a class B1 G protein-coupled receptor (GPCR) of the glucagon subfamily and is characterized by an extracellular domain at the N-terminus, seven transmembrane domains and an intracellular domain at the C-terminus (see Zhao et al. Nat. Commun. 2022, 72, 1057). GIPR is expressed in various tissues, including the gut, adipose tissue, the pancreas, the vasculature and the brain (see Hammoud et al. Nat. Rev. Endocrinol.2023, 18, 201). The extracellular domain serves to recognize its natural peptide agonist GIP, which results in a conformational change from inactive to active, triggering an increase in cAMP production mediated by Gas.

[0005] GIPR knockout mice are resistant to high fat diet-induced weight gain and have been shown to have improved insulin sensitivity and lipid profiles (see Yamada et al. Diabetes 2006,55, S86 and Miyawaki et al. Nature Med. 2002, 8, 738). This observation has been translated to humans, where it has been observed that heterozygous loss of function of GIPR results in lower obesity risk and overall BMI (see Akbari et al. Science 2021, 373, 6550). Pre-clinical pharmacological translation of these effects have been observed using small molecules, peptides and antibodies with antagonistic activities (see Nakamura et al. Diabetes Metab. Syndr. Obes.2021, 14, 1095; Yang et al. Mol. Metab. 2022, 66, 101638; Killion et al. Sci. Transl. Med. 2018, 10, eaat3392). Furthermore, synergy has been demonstrated between GIPR modulators and GLP-1 agonists to lead to superior weight loss (see Lu etal. Cell Rep. Med. 2021, 2, 100263).

[0006] There is thus a need for the discovery of GIPR antagonist molecules and their use in the treatment of metabolic diseases and obesity, either as single agents or in combination with other incretin modulators.SUMMARY

[0007] According to one aspect, the present technology relates to a compound of Formula I:or a pharmaceutical acceptable salt, solvate, or prodrug thereof,wherein:X is -NR2- or -O-;X1is -NH- or-O-;provided that when X is O, then X1is other than O;m is between 0 and 2;R and R’ are independently H or a linear or branched Ci-Cealkyl, the linear or branched Ci-Cealkyl being optionally substituted with one or more substituents, the substituents being preferably selected from halogens; or R and R’ are taken together with their adjacent carbon atom to form a ring, the ring being optionally substituted with one or more substituents;R1, R1’ and R2are independently selected from the group consisting of -H, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, optionally substituted with one or more substituents, the substituents being preferably selected from halogens, linear or branched Ci-Cealkyl, C3-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl, 5- to 10-membered heteroaryl, -CN, -OR3, -SR3, -NR4R4’, -NHC(=O)R5, -C(=O)-NR6R6’, -S(=O)2-R5, -NR4S(=O)2-R5, -S(=O)2-NR6R6’, wherein the linear or branched Ci-Cealkyl, C3-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally further substituted with one or more substituents, preferably selected from halogens, -OR3, -NR4R4’, -NHC(=O)R5, or-S(=O)2-NR6R6’; or R1and R2are taken together with their adjacent atoms to form a ring, the ring being optionally substituted with one or more substituents; or R1and R1’ are taken together with their adjacent carbon atom to form a ring, the ring being optionally substituted with one or more substituents;R3is selected from the group consisting of -H, -C(=O)-NR6R6’, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R4and R4’ are independently in each occurrence selected from the group consisting of -H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R5is selected from the group consisting of linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R6and R6’ are independently in each occurrence selected from the group consisting of -H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogen;is selected from the group consisting of 4- to 14-membered heterocycloalkyl, Ce- Cwaryl and 5- to 10-membered heteroaryl, optionally substituted with one or moresubstituents, the substituents being preferably selected from linear or branched Ci-Cealkyl, halogen, -CF3, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl, 5- to 10-membered heteroaryl, -OR3, -SF5 or -SR3, wherein the linear or branched Ci-Cealkyl and Cs-Cscycloalkyl are optionally further substituted with one or more substituents, the substituents being preferably selected from halogens or -CF3;( C ]wherein' is selected from the group consisting of Cs-Cscycloalkyl, 5- to 10- membered heteroaryl and 4- to 14-membered heterocycloalkyl, each being optionally substituted;n is between 0 and 5;p is between 0 and 5;Y1, Y2, Y3, Y4, Y5, Y6, Y7and Y8are independently -CR7= or-N=;R7is independently selected from -H, halogen, -CF3, -OR3and an optionally substituted linear or branched Ci-Cealkyl, with R3as defined above; andR8and R8’ are independently selected from -H, halogen and an optionally substituted linear or branched Ci-Cealkyl or R8and R8’ are taken together with their adjacent carbon atoms to form a C3-Ci2cycloalkyl or a 4- to 14-membered heterocycloalkyl, each being optionally substituted with one or more substituents,provided that when, is a Cearyl or a 6-membered heteroaryl substituted in para position, and R1and R2are taken together with their adjacent atoms to form a ring, then the ring is different from a 5-membered ring.

[0008] The present technology also relates to any examples and embodiments of these compounds as further described herein.

[0009] In another aspect, the present technology further relates to pharmaceuticals compositions comprising a compound as herein defined together with a pharmaceutically acceptable carrier, diluent or excipient.

[0010] In a further aspect, this technology also relates to uses and methods for the treatment or prevention of a condition, a disease or a disorder for which modulating the glucose-dependent insulinotropic polypeptide receptor (GIPR) is indicated.

[0011] In a further aspect, this technology also relates to uses and methods for the treatment or prevention of a condition, a disease or a disorder selected from metabolic diseases and obesity.

[0012] In a further aspect, this technology also relates to uses and methods for the treatment or prevention of selected from diabetes (e.g. Type 1 diabetes mellitus (T1D), Type 2 diabetes mellitus (T2DM), including pre-diabetes), idiopathic T1D (Type 1b), latent autoimmune diabetes in adults (LADA), early-onsetT2DM (EOD), youth-onset atypical diabetes (YOAD), maturity onset diabetes of the young (MODY), malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease (e.g., acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules, or chronic kidney disease (CKD)), diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, sleep apnea (e.g. obstructive sleep apnea (OSA)), obesity (including hypothalamic obesity and monogenic obesity) and related comorbidities (e.g., osteoarthritis and urine incontinence), eating disorders (including binge eating syndrome, bulimia nervosa, and syndromic obesity such as Prader-Willi and Bardet-Biedl syndromes), weight gain such as weight gain caused by use of other agents (e.g., caused by use of steroids and / or antipsychotics, or caused by treatment of depression, or caused by use of agents on cognitive function), excessive sugar craving, dyslipidemia [including hyperlipidemia, hypertriglyceridemia, increased total cholesterol, high LDL (low-density lipoprotein) cholesterol, and low HDL (high-density lipoprotein) cholesterol], hyperinsulinemia, nonalcoholic fatty liver disease [NAFLD, including related diseases such as steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma], cardiovascular disease, atherosclerosis (including coronary artery disease), peripheral vascular disease, hypertension, endothelial dysfunction, impaired vascular compliance, heart failure (e.g. congestive heart failure, heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF)), myocardial infarction (e.g. necrosis and apoptosis), stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, post-prandial lipemia, metabolic acidosis, ketosis, arthritis, osteoporosis, osteoarthritis, Parkinson’s disease, left ventricular hypertrophy, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, syndrome X, premenstrual syndrome, angina pectoris, thrombosis, atherosclerosis, transientischemic attacks, vascular restenosis, impaired glucose metabolism, conditions of impaired fasting plasma glucose, hyperuricemia, gout, erectile dysfunction, skin and connective tissue disorders, psoriasis, foot ulcerations, ulcerative colitis, hyper apo B lipoproteinemia, Alzheimer’s Disease, schizophrenia, impaired cognition, inflammatory bowel disease, short bowel syndrome, Crohn’s disease, colitis, irritable bowel syndrome, polycystic ovary syndrome (PCOS), and addiction (e.g., addiction to alcohol, nicotine, and / or drug).

[0013] Additional objects and features of the present compounds, compositions, methods and uses will become more apparent upon reading of the following non-restrictive description of exemplary embodiments and examples section, which should not be interpreted as limiting the scope of the invention.DETAILED DESCRIPTION

[0014] All technical and scientific terms and expressions used herein have the same definitions as those commonly understood by a person skilled in the art to which the present technology pertains. The definition of some terms and expressions used is nevertheless provided below. To the extent the definitions of terms in the publications, patents, and patent applications incorporated herein by reference are contrary to the definitions set forth in this specification, the definitions in this specification will control. The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter disclosed.General Definitions

[0015] Chemical structures described herein are drawn according to conventional standards. Also, when an atom, such as a carbon atom, as drawn seems to include an incomplete valency, then the valency is assumed to be satisfied by one or more hydrogen atoms even though these are not necessarily explicitly drawn. Hydrogen atoms should be inferred to be part of the compound.

[0016] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. It should be noted that, the singular forms "a", "an", and "the" include plural forms as well, unless the content clearly dictates otherwise. Thus, for example, reference to a composition containing "a compound" also contemplates a mixture of two or more compounds. It should also be noted that the term "or" is generally employed in its sense including "and / or" unless the context clearly dictates otherwise. Furthermore, to the extent that the terms “including”, "includes", "having", "has", "with", or variants thereof are used in either the detaileddescription and / or the claims, such terms are intended to be inclusive in a manner similar to the term "comprising”.

[0017] The term "about" or "approximately" means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, "about" can mean within 1 or more than 1 standard deviation, per the practice in the art. Alternatively, "about" can mean a range of up to 20%, preferably up to 10%, more preferably up to 5%, and more preferably still up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, preferably within 5-fold, and more preferably within 2-fold, of a value. Where particular values are described in the application and claims, unless otherwise stated the term "about" meaning within an acceptable error range for the particular value should be assumed.

[0018] As used herein, the terms "compounds”, "compounds herein described", "compounds of the present application", “compounds as defined herein” and equivalent expressions refer to compounds described in the present application, e.g. those encompassed by structural Formula I, or by Formulae la, lb and Ic, optionally with reference to any of the applicable embodiments, and also includes exemplary compounds, such as Compounds 1 to 236, as well as their pharmaceutically acceptable salts, solvates, and prodrugs when applicable. When a zwitterionic form is possible, the compound may be drawn as its neutral form for practical purposes, but the compound is understood to also include its zwitterionic form. Embodiments herein may also exclude one or more of the compounds. Compounds may be identified either by their chemical structure or their chemical name. In a case where the chemical structure and chemical name would conflict, the chemical structure will prevail.

[0019] Unless otherwise stated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure when applicable; for example, the R and S configurations for each asymmetric center. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the present description. The therapeutic compound unless otherwise noted, also encompasses all possible tautomeric forms of the illustrated compound, if any. The term also includes isotopically labeled compounds where one or more atoms have an atomic mass different from the atomic mass most abundantly found in nature. Examples of isotopes that may be incorporated into the present compounds include, but are not limited to,2H (D),3H (T),11C,13C,14C,15N,18O,17O, any one ofthe isotopes of sulfur, etc. The compound may also exist in unsolvated forms as well as solvated forms, including hydrated forms. The compound may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated herein and are intended to be within the scope of the present invention.

[0020] Where a particular enantiomer is preferred, it may, in some embodiments be provided substantially free of the corresponding enantiomer and may also be enantiomerically enriched. " Enantiomerically enriched" means that the compound is made up of a significantly greater proportion of one enantiomer. In certain embodiments the compound is made up of at least about 90% by weight of a preferred enantiomer. In other embodiments the compound is made up of at least about 95%, 98%, or 99% by weight of a preferred enantiomer. Preferred enantiomers may be isolated from racemic mixtures by any method known to those skilled in the art, including high-pressure liquid chromatography (HPLC) on chiral support and the formation and crystallization of chiral salts or be prepared by asymmetric syntheses.

[0021] The expression "pharmaceutically acceptable salt" refers to those salts of the compounds of the present description which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66: 1-19 (1977). The salts can be prepared in situ during the final isolation and purification of the compounds of the present description, or separately by reacting a free base function of the compound with a suitable organic or inorganic acid (acid addition salts) or by reacting an acidic function of the compound with a suitable organic or inorganic base (base-addition salts).

[0022] The term “solvate” refers to a physical association of one of the present compounds with one or more solvent molecules, including water and non-aqueous solvent molecules. This physical association may include hydrogen bonding. In certain instances, the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of a crystalline solid. The term “solvate” encompasses both solution-phase and isolable solvates. Exemplary solvates include, without limitation, hydrates, hemihydrates, ethanolates, hemiethanolates, n-propanolates, iso-propanolates, 1 -butanolates, 2-butanolate, and solvates of other physiologically acceptable solvents, such as the Class 3 solvents described in the International Conference on Harmonization (ICH), Guide for Industry, Q3C Impurities:Residual Solvents (1997). Accordingly, the compound as herein described also includes each of its solvates and mixtures thereof.

[0023] The expression "pharmaceutically acceptable prodrugs" as used herein refers to those prodrugs of the compounds formed by the process of the present description which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit / risk ratio, and effective fortheir intended use. " Prodrug", as used herein means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis) to afford any compound delineated by the formulae of the instant description.

[0024] Abbreviations may also be used throughout the application, unless otherwise noted, such abbreviations are intended to have the meaning generally understood by the field. Examples of such abbreviations include Me (methyl), Et (ethyl), Pr (propyl), i-Pr (isopropyl), Bu (butyl), t-Bu (tert-butyl), i-Bu (iso-butyl), s-Bu (sec-butyl), c-Bu (cyclobutyl), Ph (phenyl), Bn (benzyl), Bz (benzoyl), CBz or Cbz or Z (carbobenzyloxy), Boc or BOC (tert-butoxycarbonyl), and Su or Sue (succinimide). For more certainty, additional definitions of specific abbreviations are also included in the introduction of the Examples section.

[0025] The number of carbon atoms in a hydrocarbyl substituent can be indicated by the prefix " Cx-Cy" or " Cx-y" where x is the minimum and y is the maximum number of carbon atoms in the substituent. However, when the prefix “Cx-Cy” or " Cx-y" is associated with a group incorporating one or more heteroatom(s) by definition (e.g. heterocycloalkyl, heteroaryl, etc), then x and y define respectively the minimum and maximum number of atoms in the cycle, including carbon atoms as well as heteroatom(s).

[0026] The term "alkyl" as used herein, refers to a saturated, straight- or branched-chain hydrocarbon radical typically containing from 1 to 20 carbon atoms. For example, " Ci-Cs alkyl" contains from one to eight carbon atoms. Examples of alkyl radicals include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, fert-butyl, neopentyl, n-hexyl, heptyl, octyl radicals and the like.

[0027] The term "alkenyl" as used herein, denotes a straight- or branched-chain hydrocarbon radical containing one or more double bonds and typically from 2 to 20 carbon atoms. For example, " C2-8 alkenyl" contains from two to eight carbon atoms. Alkenyl groups include, but are not limited to, for example, ethenyl, propenyl, butenyl, l-methyl-2-buten-l-yl, heptenyl, octenyl and the like.

[0028] The term "alkynyl" as used herein, denotes a straight- or branched-chain hydrocarbon radical containing one or more triple bonds and typically from 2 to 20 carbon atoms. For example, " C2-8 alkynyl" contains from two to eight carbon atoms. Representative alkynyl groups include, but are not limited to, for example, ethynyl,1-propynyl, 1-butynyl, heptynyl, octynyl and the like.

[0029] The terms “cycloalkyl”, “alicyclic”, “carbocycle”, “carbocyclic” and equivalent expressions refer to a group comprising a saturated or partially unsaturated (non-aromatic) carbocyclic ring in a monocyclic or polycyclic ring system, including spiro (sharing one atom), fused (sharing at least one bond) or bridged (sharing two or more bonds) carbocyclic ring systems, having from three to fifteen ring members. Examples of cycloalkyl groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclopenten-1-yl, cyclopenten-2-yl, cyclopenten-3-yl, cyclohexyl, cyclohexen-1-yl, cyclohexen-2-yl, cyclohexen-3-yl, cycloheptyl, bicyclo[4,3,0]nonanyl, norbornyl, bicyclo[1,1,1]pentane, spiro[3.3]heptane and the like. The term cycloalkyl includes both unsubstituted cycloalkyl groups and substituted cycloalkyl groups. The term “Cs-Cncycloalkyl” refers to a cycloalkyl group having from 3 to the indicated “n” number of carbon atoms in the ring structure. Unless the number of carbons is otherwise specified, “lower cycloalkyl” groups as herein used, have at least 3 and equal or less than 8 carbon atoms in their ring structure.

[0030] As used herein, the term "heteroatom" includes but is not limited to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen.

[0031] As used herein, the terms "heterocycle", "heterocycloalkyl", "heterocyclyl", "heterocyclic radical", and "heterocyclic ring" are used interchangeably and refer to a chemically stable 3- to 7-membered monocyclic or 7-14-membered polycyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above. When used in reference to a ring atom of a heterocycle, the term "nitrogen" includes a substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 1-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or NR (as in N-substituted pyrrolidinyl). A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a chemically stable structure and any of the ring atoms can be optionally substituted. Examples of heterocycloalkyl groups include, but are not limited to, 1,3-dioxolanyl, pyrrolidinyl, pyrrolidonyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrodithienyl, tetrahydrothienyl,thiomorpholino, thioxanyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, 3-azabicyclo[3,1,0]hexanyl, 3-azabicyclo[4,1,0]heptanyl, quinolizinyl, quinuclidinyl, hexamethyleneimine, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, and the like. Heterocyclic groups also include groups in which a heterocyclic ring is fused to one or more aryl, heteroaryl, or cycloaliphatic rings, such as indolinyl, 3H-indolyl, chromanyl, chromenyl, phenanthridinyl, 2-azabicyclo[2.2.1]heptanyl, octahydroindolyl, benzodioxole,tetrahydroquinolinyl,where the radical or point of attachment is on the heterocyclyl ring. A heterocyclyl group may be mono- or bicyclic. The term "heterocyclylalkyl" refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted. The term “C3-nheterocycloalkyl” refers to a heterocycloalkyl group having from 3 to the indicated “n” number of atoms in the ring structure, including carbon atoms and heteroatoms.

[0032] As used herein, the term "partially unsaturated" refers to a ring moiety that includes at least one double or triple bond between ring atoms but is not aromatic. The term "partially unsaturated" is intended to encompass rings having multiple sites of unsaturation but is not intended to include aryl or heteroaryl moieties, as herein defined.

[0033] The term "aryl" used alone or as part of a larger moiety as in "aralkyl", "aralkoxy", "aryloxy", or "aryloxyalkyl", refers to aromatic groups having 4n+2 conjugated ir(pi) electrons, wherein n is an integer from 1 to 3, in a monocyclic moiety or a bicyclic or tricyclic fused ring system having a total of six to 15 ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains three to seven ring members. The term "aryl" may be used interchangeably with the term "aryl ring". In certain embodiments of the present description, "aryl" refers to an aromatic ring system which includes, but not limited to, phenyl, biphenyl, naphthyl, azulenyl, anthracyl and the like, which may bear one or more substituents. The term "aralkyl" or "arylalkyl" refers to an alkyl residue attached to an aryl ring. Examples of aralkyl include, but are not limited to, benzyl, phenethyl, and the like. Also included within the scope of the term “aryl”, as it is used herein, is a group in which an aromatic ring is fused to one or more non-aromatic rings, such as indanyl, indenyl, phthalimidyl, naphthimidyl, fluorenyl, phenanthridinyl, ortetrahydronaphthyl, and the like. The term “Ce-naryl” refers to an aryl group having from 6 to the indicated “n” number of atoms in the ring structure.

[0034] The term "heteroaryl", used alone or as part of a larger moiety, e.g., "heteroaralkyl", or "heteroaralkoxy", refers to aromatic groups having 4n+2 conjugated ir(pi) electrons, wherein n is an integer from 1 to 3 (e.g. having 5 to 18 ring atoms, preferably 5, 6, or 9 ring atoms; having 6, 10, or 14 TT electrons shared in a cyclic array); and having, in addition to carbon atoms, from one to five heteroatoms. The term "heteroatom" includes but is not limited to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen. A heteroaryl may be a single ring, or two or more fused rings. The term "heteroaryl", as used herein, also includes groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclic rings, where the radical or point of attachment is on the heteroaromatic ring. Nonlimiting examples of heteroaryl groups include thienyl, furanyl (furyl), pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolyl, 3H-indolyl, isoindolyl, indolizinyl, benzothienyl (benzothiophenyl), benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, benzotriazolyl, pyrrolopyridinyl (e.g. pyrrolo[3,2-b]pyridinyl or pyrrolo[3,2-c]pyridinyl), pyrazolopyridinyl (e.g. pyrazolo[1,5-a]pyridinyl), furopyridinyl, purinyl, imidazopyrazinyl (e.g. imidazo[4,5-b]pyrazinyl), quinolyl (quinolinyl), isoquinolyl (isoquinolinyl), quinolonyl, isoquinolonyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, naphthyridinyl, and pteridinyl carbazolyl, acridinyl, phenanthridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3-b]-l,4-oxazin-3(4H)-one. A heteroaryl group may be mono- or bicyclic. Heteroaryl groups include rings that are optionally substituted. The term "heteroaralkyl" refers to an alkyl group substituted by a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted. Examples include, but are not limited to, pyridinylmethyl, pyrimidinylethyl and the like. For instance, the term “Cs-nheteroaryl” refers to a heteroaryl group having from 5 to the indicated “n” number of atoms in the ring structure, including carbon atoms and heteroatoms.

[0035] As described herein, compounds of the present description may contain "optionally substituted" moieties. In general, the term "substituted", whether preceded by the term "optionally" or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent. Unless otherwise indicated, an "optionally substituted" group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specifiedgroup, the substituent may be either the same or different at each position. Combinations of substituents envisioned under the present description are preferably those that result in the formation of chemically stable or chemically feasible compounds. The term "chemically stable", as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.

[0036] The term “halo” designates a halogen atom, i.e. a fluorine, chlorine, bromine or iodine atom, preferably fluorine or chlorine.

[0037] The term "optionally substituted" refers to groups that are substituted or unsubstituted by independent replacement of one, two, or three or more of the hydrogen atoms thereon with substituents including, but not limited to F, Cl, Br, I, OH, CO2H, alkoxy, oxo, thiooxo, NO2, CN, CF3, NH2, NHalkyl, NHalkenyl, NHalkynyl, NHcycloalkyl, NHaryl, NHheteroaryl, NHheterocyclic, dialkylamino, diarylamino, diheteroarylamino, O-alkyl, O-alkenyl, O-alkynyl, O-cycloalkyl, O-aryl, O-heteroaryl, O-haloalkyl, O-heterocyclic, C(O)alkyl, C(O)alkenyl, C(O)alkynyl, C(O)cycloalkyl, C(O)aryl, C(O) heteroaryl, C(O)heterocycloalkyl, CO2alkyl, CO2alkenyl, CO2alkynyl, CO2cycloalkyl, CO2aryl, CO2heteroaryl, CO2heterocycloalkyl, OC(O)alkyl, OC(O)alkenyl, OC(O)alkynyl, OC(O)cycloalkyl, OC(O)aryl, OC(O)heteroaryl, OC(O)heterocycloalkyl, C(O)NH2, C(O)NHalkyl, C(O)NHalkenyl, C(O)NHalkynyl, C(O)NHcycloalkyl, C(O)NHaryl, C(O) NHheteroaryl, C(O)NHheterocycloalkyl, OCO2alkyl, OCO2alkenyl, OCO2alkynyl, OCO2cycloalkyl, OCO2aryl, OCO2heteroaryl, OCO2heterocycloalkyl, OC(O)NH2, OC(O)NHalkyl, OC(O)NHalkenyl, OC(O) NHalkynyl, OC(O)NHcycloalkyl, OC(O)NHaryl, OC(O) NHheteroaryl, OC(O)NHheterocycloalkyl, NHC(O)alkyl, NHC(O)alkenyl, NHC(O)alkynyl, NHC(O)cycloalkyl, NHC(O)aryl, NHC(O)heteroaryl, NHC(O)heterocycloalkyl, NHCO2alkyl, NHCO2alkenyl, NHCO2alkynyl, NHCO2cycloalkyl, NHCO2aryl, NHCO2heteroaryl, NHCO2heterocycloalkyl, NHC(O)NH2, NHC(O)NHalkyl, NHC(O)NHalkenyl, NHC(O)NHalkenyl, NHC(O)NHcycloalkyl, NHC(O)NHaryl, NHC(O)NHheteroaryl, NHC(O)NHheterocycloalkyl, NHC(S)NH2, NHC(S)NHalkyl, NHC(S)NHalkenyl, NHC(S)NHalkynyl, NHC(S)NHcycloalkyl, NHC(S)NHaryl, NHC(S)NHheteroaryl, NHC(S)NHheterocycloalkyl, NHC(NH)NH2, NHC(NH)NHalkyl, NHC(NH)NHalkenyl, NHC(NH)NHalkenyl, NHC(NH)NHcycloalkyl, NHC(NH)NHaryl, NHC(NH)NHheteroaryl, NHC(NH)NHheterocycloalkyl, NHC(NH)alkyl, NHC(NH)alkenyl, NHC(NH)alkenyl, NHC(NH)cycloalkyl, NHC(NH)aryl, NHC(NH)heteroaryl, NHC(NH)heterocycloalkyl, C(NH)NHalkyl, C(NH)NHalkenyl, C(NH)NHalkynyl, C(NH)NHcycloalkyl, C(NH)NHaryl, C(NH)NHheteroaryl, C(NH)NHheterocycloalkyl, S(O)alkyl,S(O)alkenyl, S(O)alkynyl, S(O)cycloalkyl, S(O)aryl, S(O)2alkyl, S(O)2alkenyl, S(O)2alkynyl, S(O)2cycloalkyl, S(O)2aryl, S(O)heteroaryl, S(O)heterocycloalkyl, SO2NH2, SO2NHalkyl, SO2NHalkenyl, SO2NHalkynyl, SO2NHcycloalkyl, SO2NHaryl, SO2NHheteroaryl, SO2NHheterocycloalkyl, NHSO2alkyl, NHSO2alkenyl, NHSO2alkynyl, NHSO2cycloalkyl, NHSO2aryl, NHSO2heteroaryl, NHSO2heterocycloalkyl, CH2NH2, CH2CN, CH2F, CH2OH, CH2OCH3, C(CH3)2OH, CH2SO2CH3, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, cycloalkyl, carbocyclic, heterocyclic, phenyl, phenol, polyalkoxyalkyl, polyalkoxy, methoxymethoxy, methoxyethoxy, SH, S-alkyl, S-alkenyl, S-alkynyl, S-cycloalkyl, S-aryl, S-heteroaryl, S-heterocycloalkyl, or methylthiomethyl.

[0038] The term “ring” as used herein, refers to a Cs-Cecycloalkyl, a 4- to 14-membered heterocycloalkyl, a Ce-C aryl, or a 5- to 10-membered heteroaryl.Compounds

[0039] The recitation of a listing of chemical groups in any definition of a variable herein includes definitions of that variable as any single group or combination of listed groups. The recitation of an embodiment for a variable herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof. The recitation of an embodiment herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof. As such, the following embodiments are present alone or in combination if applicable.

[0040] The present compounds present a core structure to which is attached defined substituents to achieve the product’s beneficial activity. Examples of compounds as defined herein are illustrated by general Formula I:or a pharmaceutical acceptable salt, solvate, or prodrug thereof,wherein:X is -NR2- or -O-;X1is -NH- or-O-;provided that when X is O, then X1is other than O;m is between 0 and 2;R and R’ are independently H or a linear or branched Ci-Cealkyl, the linear or branched Ci-Cealkyl being optionally substituted with one or more substituents, the substituents being preferably selected from halogens; or R and R’ are taken together with their adjacent carbon atom to form a ring, the ring being optionally substituted with one or more substituents;R1, R1’ and R2are independently selected from the group consisting of -H, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, optionally substituted with one or more substituents, the substituents being preferably selected from halogens, linear or branched Ci-Cealkyl, C3-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl, 5- to 10-membered heteroaryl, -CN, -OR3, -SR3, -NR4R4’, -NHC(=O)R5, -C(=O)-NR6R6’, -S(=O)2-R5, -NR4S(=O)2-R5, -S(=O)2-NR6R6’, wherein the linear or branched Ci-Cealkyl, C3-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally further substituted with one or more substituents, preferably selected from halogens, -OR3, -NR4R4’, -NHC(=O)R5, or-S(=O)2-NR6R6’; or R1and R2are taken together with their adjacent atoms to form a ring, the ring being optionally substituted with one or more substituents; or R1and R1’ are taken together with their adjacent carbon atom to form a ring, the ring being optionally substituted with one or more substituents; wherein the ring formed by R1and R2or by R1and R1’ is preferably selected from optionally substituted Cs-Cscycloalkyl and 4- to 14-membered heterocycloalkyl groups;R3is selected from the group consisting of -H, -C(=O)-NR6R6’, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R4and R4’ are independently in each occurrence selected from the group consisting of -H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R5is selected from the group consisting of linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroarylare optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R6and R6’ are independently in each occurrence selected from the group consisting of - H, linear or branched Ci-Cealkyl, Ce-C aryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogen;is selected from the group consisting of 4- to 14-membered heterocycloalkyl, Ce- Cwaryl and 5- to 10-membered heteroaryl, optionally substituted with one or more substituents, the substituents being preferably selected from linear or branched Ci-Cealkyl, halogen, -CF3, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10- membered heteroaryl, -OR3, -SF5 or -SR3, wherein the linear or branched Ci-Cealkyl and Cs-Cscycloalkyl are optionally further substituted with one or more substituents, the substituents being preferably selected from halogens or -CF3;whereinis selected from the group consisting of Cs-Cscycloalkyl, 5- to 10-membered heteroaryl and 4- to 14-membered heterocycloalkyl, each being optionally substituted;n is between 0 and 5;p is between 0 and 5;Y1, Y2, Y3, Y4, Y5, Y6, Y7and Y8are independently -CR7= or-N=;R7is independently selected from -H, halogen, -CF3, -OR3and an optionally substituted linear or branched Ci-Cealkyl, with R3as defined above; andR8and R8’ are independently selected from -H, halogen and an optionally substituted linear or branched Ci-Cealkyl or R8and R8’ are taken together with their adjacent carbon atoms to form a C3-Ci2cycloalkyl or a 4- to 14-membered heterocycloalkyl, each being optionally substituted with one or more substituents,provided that when, is a Cearyl or a 6-membered heteroaryl substituted in para position, and R1and R2are taken together with their adjacent atoms to form a ring, then the ring is different from a 5-membered ring.

[0041] In one embodiment:X is -NR2- or -O-;X1is -NH- or-O-;provided that when X is O, then X1is other than O;m is between 0;R and R’ are independently H or a linear or branched Ci-Cealkyl, the linear or branched Ci-Cealkyl being optionally substituted with one or more substituents, the substituents being preferably selected from halogens; or R and R’ are taken together with their adjacent carbon atom to form a Cs-Cscycloalkyl, the Cs-Cscycloalkyl being optionally substituted with one or more substituents;R1, R1’ and R2are independently selected from the group consisting of -H, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, optionally substituted with one or more substituents, the substituents being preferably selected from halogens, linear or branched Ci-Cealkyl, C3- Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl, 5- to 10-membered heteroaryl, -CN, -OR3, -SR3, -NR4R4’, -NHC(=O)R5, -C(=O)-NR6R6’-S(=O)2-R5, - NR4S(=O)2-R5, -S(=O)2-NR6R6’, wherein the linear or branched Ci-Cealkyl, C3- Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally further substituted with one or more substituents, preferably selected from halogens, -OR3, -NR4R4’, -NHC(=O)R5, or-S(=O)2-NR6R6’; or R1and R2are taken together with their adjacent atoms to form a 4- to 14-membered heterocycloalkyl, the 4- to 14-membered heterocycloalkyl being optionally substituted with one or more substituents; or R1and R1’ are taken together with their adjacent carbon atom to form a Cs-Cscycloalkyl, the Cs-Cscycloalkyl being optionally substituted with one or more substituents;R3is selected from the group consisting of -H, -C(=O)-NR6R6’, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the linear or branched Ci-Cealkyl, Ce-C aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R4and R4’ are independently in each occurrence selected from the group consisting of -H, linear or branched Ci-Cealkyl, Ce-C aryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R5is selected from the group consisting of linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R6and R6’ are independently in each occurrence selected from the group consisting of -H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogen;is selected from the group consisting of 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, optionally substituted with one or more substituents, the substituents being preferably selected from linear or branched Ci-Cealkyl, halogen, -CF3, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl, -OR3, -SF5 or -SR3, wherein the linear or branched Ci-Cealkyl and Cs-Cscycloalkyl are optionally further substituted with one or more substituents, the substituents being preferably selected from halogens or -CF3;whereinis selected from the group consisting of Cs-Cscycloalkyl, 5- to 10- membered heteroaryl and 4- to 14-membered heterocycloalkyl, each being optionally substituted;n is between 0 and 5;p is between 0 and 5;Y1, Y2, Y3, Y4, Y5, Y6, Y7and Y8are independently -CR7= or-N=;R7is independently selected from -H, halogen, -CF3, -OR3and an optionally substituted linear or branched Ci-Cealkyl, with R3as defined above; andR8and R8’ are independently selected from -H, halogen and an optionally substituted linear or branched Ci-Cealkyl;provided that when, is a Cearyl or a 6-membered heteroaryl substituted in para position, and R1and R2are taken together with their adjacent atoms to form a 4- to 14-membered heterocycloalkyl, then the 4- to 14-membered heterocycloalkyl is different from 5-membered heterocycloalkyl.

[0042] In another embodiment,is a 4- to 14-membered heterocycloalkyl or Ce-Cwaryl optionally substituted with one or more substituents, the substituents being preferably selected from halogen, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl, 5- to 10-membered heteroaryl, -SFs, -OR3or -SR3, wherein the linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl are optionally further substituted with one or more substituents, the substituents being preferably selected from halogens or-CFs and wherein R3is as defined above.wherein R9is independently in each occurrence selected from the group consisting of halogen, -OR3, -SR3, -SF5, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, or two R9on adjacent atoms are taken together to form a Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl or 5- to 10-membered heteroaryl, wherein the Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents preferably selected from halogens, -CF3, linear or branched Ci-Cealkyl, C3-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl; and wherein R3is selected from the group consisting of-H and linear or branched Ci-Cealkyl optionally substituted with one or more substituents preferably selected from halogens.

[0044] In another embodiment, R9is independently selected from the group consisting of -Cl, -F, -CF3, -OCF3, -SCF3, -SF5, -OCH3, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, each optionally further substituted, preferably with one or more -CF3.

[0047] In some embodiments,is B5, B9, or B10, preferably B5or B10, whereinis a Cs-Cscycloalkyl group optionally substituted with one or more substituents.

[0048] In other embodiments,is a spiro Cs-Cscycloalkyl group (e.g. Cy-Cscycloalkyl) optionally substituted with one or more substituents.

[0049] In yet other embodiments,is a monocyclic C4-Cycycloalkyl group (e.g. C4- Cecycloalkyl, or Cscycloalkyl) or a bridged bicyclic Cs-Cscycloalkyl group (e.g. Cs-Cycycloalkyl), each optionally substituted with one or more substituents.

[0050] In another embodiment,is a monocyclic C^Cscycloalkyl group.with one or more substituents, or is preferablyoptionally substituted with one or more substituents.

[0052] In some instances, B1, B5, B7, B9or B10is:wherein p is between 0 and 5;R7is independently selected from the group consisting of halogen, -CF3, -OR3and linear or branched Ci-Cealkyl, with R3selected from the group consisting of -H, -CF3, -CHF2and linear or branched Ci-Cealkyl;R8and R8’ are independently selected from -H, halogen and an optionally substituted linear or branched Ci-Cealkyl;provided that when, is a Cearyl or a 6-membered heteroaryl substituted in para position, and R1and R2are taken together with their adjacent atoms to form a 4- to 14-membered heterocycloalkyl, then the 4- to 14-membered heterocycloalkyl is different from 5-membered heterocycloalkyl.

[0053] In some embodiments, R7is independently selected from the group consisting of -Cl, -F, -CF3, -CHF2, -OCH3, -CH3, -CH2CH3, -CH2CH2CH3and -CH(CH3)2.heteroaryl substituted in para position; andR1and R2are taken together with their adjacent atoms to form a 4- to 14-membered heterocycloalkyl, then the 4- to 14-membered heterocycloalkyl is different from 5-membered heterocycloalkyl.

[0055] In some embodiments, R and R’ are independently selected from -H and -CH3.

[0056] In another embodiment, R and R’ are -H.

[0057] In yet another embodiment, R and R’ are -CH3.

[0058] In yet other embodiments, R is -H and R’ is -CH3.

[0059] In some instances, R1’ is -H.

[0060] In one embodiment, X is -NR2- and R2is as defined herein.

[0061] In another embodiment, X is -O-.

[0062] In one embodiment, X1is -NH-.

[0063] In another embodiment, X1is -O-.

[0064] In some embodiments, the compound is of Formula la, or a pharmaceutical acceptable salt, solvate, or prodrug thereof:wherein R1, R2,are as defined herein.

[0065] In other embodiments, the compound is of Formula lb, or a pharmaceutical acceptable salt, solvate, or prodrug thereof:wherein R1, R2,are as defined herein.

[0066] In one embodiment, R1and R2are independently selected from the group consisting of -H, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, optionally substituted with one or more substituents, the substituents being preferably selected from halogens, linear or branched Ci-Cealkyl, C3-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl, 5- to 10-membered heteroaryl, -CN, -OR3, -SR3, -NR4R4’, -NHC(=O)R5, -C(=O)-NR6R6’,-S(=O)2-R5, -NR4S(=O)2-R5, -S(=O)2-NR6R6’, wherein the linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally further substituted with one or more substituents, preferably selected from halogens, -OR3, -NR4R4’, -NHC(=O)R5, or -S(=O)2-NR6R6’;R3is selected from the group consisting of -H, -C(=O)-NR6R6’, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R4and R4’ are independently in each occurrence selected from the group consisting of -H, linear or branched Ci-Cealkyl, Ce-C aryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R5is selected from the group consisting of linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R6and R6’ are independently in each occurrence selected from the group consisting of -H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogen.

[0067] In another embodiment, R1and R2are independently selected from the group consisting of -H, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, optionally substituted with one or more substituents, the substituents being preferably selected from halogens, linear or branched Ci-Cealkyl, C3-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl, -CN, -OCH3, -OCF3, and -SF5.

[0068] In yet another embodiment, R1and R2are independently selected from the group consisting of -H, linear or branched Ci-Cealkyl, Ce-Cwaryl, -CH₂-C₃-C₈cycloalkyl and -CH₂Ph.

[0069] In some instances, R1and R2are independently selected from the group consisting of -H, -CH3, -CH2CH3, -CH2(CH3)2, phenyl, cyclopropyl, cyclopentyl, cyclohexyl, -CH2-cyclopropyl, -CH2-cyclohexyl and -CH₂Ph.

[0070] Non-limiting examples of R1include: -CH3, -CH2CH3, phenyl, cyclopropyl and -CH2-cyclopropyl.

[0071] Non-limiting examples of R2include: -H, -CH3, -CH2(CH3)2, phenyl, cyclopropyl, cyclopentyl, cyclohexyl, -CH2-cyclohexyl and -CH₂Ph.

[0072] In some embodiments, R1and R2are different.

[0073] In other embodiments, R1and R2are identical.

[0074] In yet other embodiments, R1and R2are taken together with their adjacent atoms to form a 4- to 14-membered heterocycloalkyl, the 4- to 14-membered heterocycloalkyl being optionally substituted with one or more substituents.

[0075] In some instances, R1and R2are taken together with their adjacent atoms to form a 6- to 14-membered heterocycloalkyl, the 6- to 14-membered heterocycloalkyl being optionally substituted with one or more substituents.

[0076] Non-limiting examples of the 6- to 14-membered heterocycloalkyl include:wherein:q is between 1 and 2;X5is -CH2-, -NR11-, -S- or-O-;R11is selected from the group consisting of -H, linear or branched Ci-Cealkyl, C3- Cscycloalkyl, 4- to 14-membered heterocycloalkyl and Ce-C aryl, optionally substituted with one or more substituents; andwherein the 6- to 14-membered heterocycloalkyl is optionally further substituted with one or more substituents.

[0077] Non-limiting examples of the 6- to 14-membered heterocycloalkyl include:

[0078] In other instances, R1and R2are taken together with their adjacent atoms to form a 4- or 5-membered heterocycloalkyl, the 4- or 5-membered heterocycloalkyl being optionally substituted with one or more substituents.

[0079] Non-limiting examples of the 4- or 5-membered heterocycloalkyl include:

[0080] In some instances, the heterocycloalkyl is substituted with one or more R10substituents independently in each occurrence selected from the group consisting of halogen, -CN, OR3, SR3, -NR4R4’, -NR4C(=O)R5, -C(=O)-NR6R6’, =0 (oxo), -S(=O)2-R5, -NR4S(=O)2R5, -S(=O)2-NR6R6’, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, or two R10are taken together with their adjacent carbon atom(s) to form a fused, spiro or bridged Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl or 5- to 10-membered heteroaryl, wherein the Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents preferably selected from halogens, -CN, OR3, -NR4R4’, -NHC(=O)R5, -C(=O)-NR6R6’, -CF3, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl, wherein R3, R4, R4’, R5, R6and R6’ are previously defined.

[0081] A non-limiting example of the substituted 5-membered heterocycloalkyl include:

[0082] In other instances, the heterocycloalkyl is unsubstituted.

[0083] In yet another embodiment, the compound is of Formula Ic, or a pharmaceutical acceptable salt, solvate, or prodrug thereof:

[0084] In some instances, R1is selected from the group consisting of -H, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, optionally substituted with one or more substituents, the substituents being preferably selected from halogens, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl, 5- to 10-membered heteroaryl, -CN, -OR3, -SR3, -NR4R4’, -NHC(=O)R5, -C(=O)-NR6R6’,-S(=O)2-R5, -NR4S(=O)2-R5, -S(=O)2-NR6R6’, wherein the linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally further substituted with one or more substituents, preferably selected from halogens, -OR3, -NR4R4’, -NHC(=O)R5, or -S(=O)2-NR6R6’;R3is selected from the group consisting of -H, -C(=O)-NR6R6’, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R4and R4’ are independently in each occurrence selected from the group consisting of -H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R5is selected from the group consisting of linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-C aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R6and R6’ are independently in each occurrence selected from the group consisting of -H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogen.

[0085] In other instances, R1is selected from the group consisting of -H, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, optionally substituted with one or more substituents, the substituents being preferably selected from halogens, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl, -CN, -OCH3, -OCF3, and -SF5.

[0086] In yet other instances, R1is selected from the group consisting of linear or branched Ci-Cealkyl and Ce-Cwaryl.

[0087] Non-limiting examples of R1include -CH3 and phenyl.

[0001] Exemplary compounds as defined herein include each single compound described in the present application, including Compounds 1 to 236 in Table 1 or a pharmaceutically acceptable salt, solvate or prodrug thereof.

[0003] Examples of preferred compounds include, namely, Compounds 1, 4, 6-13, 32, 34, 36-43, 61-73, 77-81, 89-99, 103-104, 120, 122, 124, 126-129, 130-133, 143-146, 151-152, 155, 166-167, 169, 191-199, 232, and 233 as defined herein, or a salt, solvate and / or prodrug thereof.

[0004] The present technology also covers isomers of the compounds as defined herein. For instance, isomers of the Compounds are identified using a letter after the compound number. Isomers of the above compounds include, for example, Compounds 1(a), 4(a), 64(a), 64(b), 122(a), 155(a), 166(a)(a), 166(a)(b), 197(a), 232(a), 233(a)(a), and 233(a)(b) as defined in the Examples section, or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

[0005] It is understood that any of the above compounds may be in any amorphous, crystalline or polymorphic form, including any salt or solvate form, or a mixture thereof. The compounds of the present description may be further modified by appending various functionalities via any synthetic means delineated herein to enhance selective biological properties. Such modifications are known in the art and include those which increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.

[0006] These compounds may be prepared by conventional chemical synthesis, such as those exemplified in the Schemes and Examples of the present disclosure. As can be appreciated by the skilled artisan, further methods of synthesizing the compounds of the formulae herein will be evident to those of ordinary skill in the art. Additionally, the various synthetic steps may be performed in an alternate sequence or order to give the desired compounds.Methods, Uses, Formulations and Administration

[0007] As used herein, the term "effective amount" means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician. Furthermore, the term"therapeutically effective amount" means any amount which, as compared to a corresponding subject who has not received such amount, results in treatment, healing, prevention, or amelioration of a disease, disorder, or symptom thereof, or a decrease in the rate of advancement of a disease or disorder. The term also includes within its scope amounts effective to enhance normal physiological function.

[0008] As used herein, the terms "treatment," "treat," and "treating" refer to reversing, alleviating, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, as described herein. In some embodiments, treatment may be administered after one or more symptoms have developed. In other embodiments, treatment may be administered in the absence of symptoms. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and / or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example to prevent or delay their recurrence.

[0009] According to one embodiment, the condition, disease or disorder is characterized by dysregulation of the glucose-dependent insulinotropic polypeptide receptor (GIPR).

[0010] For example, the condition, disease or disorder is selected from metabolic diseases and obesity.

[0011] In one embodiment, the condition, disease or condition to be treated is a GIPR-related condition, disease, or disorder. The GIPR-related condition, disease, or disorder includes one selected from diabetes [e.g. Type 1 diabetes mellitus (T1D), Type 2 diabetes mellitus (T2DM), including pre-diabetes], idiopathic T1D (Type 1b), latent autoimmune diabetes in adults (L DA), early-onset T2DM (EOD), youth-onset atypical diabetes (YOAD), maturity onset diabetes of the young (MODY), malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease [e.g., acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules, or chronic kidney disease (CKD)], diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, sleep apnea [e.g. obstructive sleep apnea (OSA)], obesity (including hypothalamic obesity and monogenic obesity) and related comorbidities (e.g., osteoarthritis and urine incontinence), eating disorders (including binge eating syndrome, bulimia nervosa, and syndromic obesity such as Prader-Willi and Bardet-Biedl syndromes), weight gain such as weight gain caused by use of other agents (e.g., caused by use of steroids and / or antipsychotics, or caused by treatment of depression, or caused by use of agents on cognitive function), excessive sugar craving, dyslipidemia [including hyperlipidemia, hypertriglyceridemia,increased total cholesterol, high LDL (low-density lipoprotein) cholesterol, and low HDL (high-density lipoprotein) cholesterol], hyperinsulinemia, nonalcoholic fatty liver disease [NAFLD, including related diseases such as steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma], cardiovascular disease, atherosclerosis (including coronary artery disease), peripheral vascular disease, hypertension, endothelial dysfunction, impaired vascular compliance, heart failure [e.g. congestive heart failure, heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF)], myocardial infarction (e.g. necrosis and apoptosis), stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, post-prandial lipemia, metabolic acidosis, ketosis, arthritis, osteoporosis, osteoarthritis, Parkinson’s disease, left ventricular hypertrophy, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, syndrome X, premenstrual syndrome, angina pectoris, thrombosis, atherosclerosis, transient ischemic attacks, vascular restenosis, impaired glucose metabolism, conditions of impaired fasting plasma glucose, hyperuricemia, gout, erectile dysfunction, skin and connective tissue disorders, psoriasis, foot ulcerations, ulcerative colitis, hyper apo B lipoproteinemia, Alzheimer’s Disease, schizophrenia, impaired cognition, inflammatory bowel disease, short bowel syndrome, Crohn’s disease, colitis, irritable bowel syndrome, polycystic ovary syndrome (PCOS), and addiction (e.g., addiction to alcohol, nicotine, and / or drug).

[0012] The term "patient or subject" as used herein refers to an animal such as a mammal. A subject may therefore refer to, for example, mice, rats, dogs, cats, horses, cows, pigs, guinea pigs, primates including humans and the like. Preferably the subject is a human.

[0013] The present description therefore further relates to a method of treating or preventing metabolic diseases or diabetes in a subject, such as a human subject. The method comprises administering a therapeutically effective amount of a GIPR antagonist, such as a compound as defined herein, to a subject in need of such treatment.

[0014] In another embodiment, the present description further relates to a method of treating or preventing a condition, a disease, or a disorder for which modulation of the glucose-dependent insulinotropic polypeptide receptor (GIPR) is indicated. The method comprises administering a therapeutically effective amount of a GIPR antagonist, such as a compound as defined herein, to a subject in need of such treatment.

[0015] In another embodiment, the present description further relates to a method of treating or preventing a condition, a disease, or a disorder for use in the treatment or prevention of acondition, a disease or a disorder selected from diabetes (e.g. Type 1 diabetes mellitus (T1D), Type 2 diabetes mellitus (T2DM), including pre-diabetes), idiopathic T1D (Type 1b), latent autoimmune diabetes in adults (LADA), early-onset T2DM (EOD), youth-onset atypical diabetes (YOAD), maturity onset diabetes of the young (MODY), malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease (e.g., acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules, or chronic kidney disease (CKD)), diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, sleep apnea (e.g. obstructive sleep apnea (OSA)), obesity (including hypothalamic obesity and monogenic obesity) and related comorbidities (e.g., osteoarthritis and urine incontinence), eating disorders (including binge eating syndrome, bulimia nervosa, and syndromic obesity such as Prader-Willi and Bardet-Biedl syndromes), weight gain such as weight gain caused by use of other agents (e.g., caused by use of steroids and / or antipsychotics, or caused by treatment of depression, or caused by use of agents on cognitive function), excessive sugar craving, dyslipidemia [including hyperlipidemia, hypertriglyceridemia, increased total cholesterol, high LDL (low-density lipoprotein) cholesterol, and low HDL (high-density lipoprotein) cholesterol], hyperinsulinemia, nonalcoholic fatty liver disease [NAFLD, including related diseases such as steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma], cardiovascular disease, atherosclerosis (including coronary artery disease), peripheral vascular disease, hypertension, endothelial dysfunction, impaired vascular compliance, heart failure (e.g. congestive heart failure, heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF)), myocardial infarction (e.g. necrosis and apoptosis), stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, post-prandial lipemia, metabolic acidosis, ketosis, arthritis, osteoporosis, osteoarthritis, Parkinson’s disease, left ventricular hypertrophy, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, syndrome X, premenstrual syndrome, angina pectoris, thrombosis, atherosclerosis, transient ischemic attacks, vascular restenosis, impaired glucose metabolism, conditions of impaired fasting plasma glucose, hyperuricemia, gout, erectile dysfunction, skin and connective tissue disorders, psoriasis, foot ulcerations, ulcerative colitis, hyper apo B lipoproteinemia, Alzheimer’s Disease, schizophrenia, impaired cognition, inflammatory bowel disease, short bowel syndrome, Crohn’s disease, colitis, irritable bowel syndrome, polycystic ovary syndrome (PCOS), and addiction (e.g., addiction to alcohol, nicotine, and / or drug). Themethod comprises administering a therapeutically effective amount of a GIPR antagonist, such as a compound as defined herein, to a subject in need of such treatment.

[0016] In certain embodiments, the present description provides a method of treating a disorder (as described herein) in a subject, comprising administering to the subject identified as in need thereof, GIPR antagonist, such as a compound of the present description. The identification of those patients who are in need of treatment for the disorders described above is well within the ability and knowledge of one skilled in the art. Certain of the methods for identification of patients which are at risk of developing the above disorders which can be treated by the subject method are appreciated in the medical arts, such as family history, and the presence of risk factors associated with the development of that disease state in the subject patient. A clinician skilled in the art can readily identify such candidate patients, by the use of, for example, clinical tests, physical examination, medical / family history, and genetic determination.

[0017] A method of assessing the efficacy of a treatment in a subject includes determining the pre-treatment symptoms of a disorder by methods well known in the art and then administering a therapeutically effective amount of a compound of the present description, to the subject. After an appropriate period of time following the administration of the compound (e.g., 1 week, 2 weeks, one month, six months), the symptoms of the disorder are determined again. The modulation (e.g., decrease) of symptoms and / or of a biomarker of the disorder indicates efficacy of the treatment. The symptoms and / or biomarker of the disorder may be determined periodically throughout treatment. For example, the symptoms and / or biomarker of the disorder may be checked every few days, weeks or months to assess the further efficacy of the treatment. A decrease in symptoms and / or biomarker of the disorder indicates that the treatment is efficacious.

[0018] In some embodiments, the therapeutically effective amount of a GIPR antagonist, such as a compound as defined herein, can be administered to a patient alone or in a composition, admixed with a pharmaceutically acceptable carrier, adjuvant, or vehicle.

[0019] The expression "pharmaceutically acceptable carrier, adjuvant, or vehicle" and equivalent expressions, refer to a non-toxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated. Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions of this disclosure include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate,sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.

[0020] Compositions described herein may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Other modes of administration also include intradermal or transdermal administration.

[0021] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, surfactants, sweetening, flavoring, and perfuming agents.

[0022] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.

[0023] Injectable formulations can be sterilized, for example, by filtration through a bacterial -retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

[0024] In order to prolong the effect of a provided compound, it is often desirable to slow the absorption of the compound from subcutaneous or intramuscular injection. This may beaccomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of compound to polymer and the nature of the particular polymer employed, the rate of compound release can be controlled.

[0025] Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.

[0026] Compositions for rectal administration are preferably suppositories which can be prepared by mixing the compounds of the present description with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum and release the active compound.

[0027] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and / or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone (PVP), sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

[0028] Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatingswell known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

[0029] The composition can also be in micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.

[0030] Dosage forms for topical or transdermal administration of a compound of the present description include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, ear drops, and eye drops are also contemplated as being within the scope of the present description. Additionally, the description contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.

[0031] Pharmaceutically acceptable compositions provided herein may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employingbenzyl alcohol or other suitable preservatives, absorption promotors to enhance bioavailability, fluorocarbons, and / or other conventional solubilizing or dispersing agents.

[0032] Pharmaceutically acceptable compositions provided herein may be formulated for oral administration. Such formulations may be administered with or without food. In some embodiments, pharmaceutically acceptable compositions of this disclosure are administered without food. In other embodiments, pharmaceutically acceptable compositions of this disclosure are administered with food.

[0033] The amount of compound that may be combined with carrier materials to produce a composition in a single dosage form will vary depending upon the patient to be treated and the particular mode of administration. Provided compositions may be formulated such that a dosage of between 0.01 - 100 mg / kg body weight / day of the inhibitor can be administered to a patient receiving these compositions.

[0034] It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, the judgment of the treating physician, and the severity of the symptoms associated with the proliferative disease or disorder. The amount of a provided compound in the composition will also depend upon the particular compound in the composition.

[0035] Compounds or compositions described herein may be administered using any amount and any route of administration effective for treating or lessening the severity of the symptoms as contemplated herein. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like. Provided compounds are preferably formulated in unit dosage form for ease of administration and uniformity of dosage. The expression "unit dosage form" as used herein refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present disclosure will be decided by the attending physician within the scope of sound medical judgment.

[0036] Pharmaceutically acceptable compositions of this disclosure can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intraperitoneally, topically (as by powders, ointments, or drops), buccally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated. In certain embodiments, provided compounds maybe administered orally or parenterally at dosage levels of about 0.01 mg / kg to about 50 mg / kg and preferably from about 1 mg / kg to about 25 mg / kg of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.

[0037] It will be understood that the total daily usage of the compounds and compositions of the present description will be decided by the attending physician within the scope of sound medical judgment. The total daily inhibiting dose of the compound of the present description administered to a subject in single or in divided doses can be in amounts, for example, from 0.01 to 50 mg / kg body weight or more usually from 0.1 to 25 mg / kg body weight. Single dose compositions may contain such amounts or submultiples thereof to make up the daily dose. In one embodiment, treatment regimens according to the present description comprise administration to a patient in need of such treatment from about 10 mg to about 1000 mg of the compound(s) of the present description per day in single or multiple doses.

[0038] Depending upon the condition, disease or disorder to be treated, additional therapeutic agents may also be present in the compositions of this disclosure or administered separately as part of a dosage regimen, e.g. an additional incretin modulator. Non-limiting examples of additional therapeutic agents which could be used in combination with the present compounds include: semaglutide, liraglutide, danuglipron or orforglipron.

[0039] The recitation of an embodiment for a variable herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof. The recitation of an embodiment herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof.EXAMPLES

[0040] The following non-limiting examples are illustrative embodiments and should not be construed as further limiting the scope of the present invention.General Methods:

[0041] The Examples set forth herein below provide syntheses and experimental results obtained for certain exemplary compounds. As it is well known to a person skilled in the art, reactions are performed in an inert atmosphere (nitrogen or argon) where necessary to protect reaction components from air and moisture. Temperatures are given in degrees Celsius (°C). Solution percentages and ratios express a volume-to-volume relationship, unless otherwise stated. The reactants used in the examples below may be obtained either as described herein, or if notdescribed herein, are themselves either commercially available or may be prepared from commercially available materials by methods known in the art.

[0042] All chemicals were of the highest purity and commercially available ones were used without further purification. Purification by column chromatography was performed with silica gel on CombiFlash and Teledyne-Isco with solvent mixtures specified for each compound where applicable. Purification by preparative HPLC were performed on Agilent system with an elution phase of methanol, water and 0.1% formic acid, NH4OAC, or others when specified. NMR spectra were recorded using Varian or Bruker 300 MHz or 400 MHz spectrometer. Chemical shifts are reported as parts per million and referenced according to the residual solvent peak and coupling constants (J) are reported in hertz (Hz). LCMS data were acquired on a Shimadzu LCMS-2020 with electrospray ionization in positive / negative ion detection mode with 20ADXR pump, SIL-20ACXR autosampler, LCMS 2020 MS detector, Alltech ELSD 3300HP detector, (CTO-40C column oven and SPD-M40 PDA detector) or (CTO-20AC column oven and SPD-M20A PDA detector), Shim pack Scepter C18-120 columns, (Kinetex EVO C18 columns or XSelect HSS T3 columns or HALO 90A C18 columns), acetonitrile / water gradients, and either trifluoroacetic acid, formic acid, or ammonium bicarbonate modifiers. All new compounds have been characterized by1H NMR, LCMS and / or HRMS.

[0043] Unless otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, concentrations, properties, stabilities, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” At the very least, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Accordingly, unless indicated to the contrary, the numerical parameters set forth in the present specification and attached claims are approximations that may vary depending upon the properties sought to be obtained. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the embodiments are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors resulting from variations in experiments, testing measurements, statistical analyses and such.

[0044] Abbreviations:Ac AcetylACN AcetonitrileAq. AqueousBoc terf-butyloxycarbonylBSA Bovin serum albumin°C Degrees CelsiuscAMP Cyclic adenosine monophosphoateCbz BenzyloxycarbonylGDI Carbonyldiimidazoled Doubletdd Doublet of doubletsdt Doublets of tripletsDBU 1,8-Diazabicyclo[5.4.0]undec-7-eneDCC / V, / V’-DicyclohexylcarbodiimideDCM DichloromethaneDIG / V, / V'-DiisopropylcarbodiimideDIEA / V, / V-DiisopropylethylamineDMA / V, / V-DimethylacetamideDMAc / V, / V-DimethylacetamideDMAP 4-(Dimethylamino)pyridinedme 1,2-DimethoxyethaneDMF DimethylformamideDMSO Dimethylsulfoxide5 Chemical shiftEA Ethyl acetateEC50 Drug concentration that gives 50% of EmaxEC80 Drug concentration that gives 80% of EmaxEDCI 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride Equiv. Equivalent(s)Emax Maximal signal obtained by an appropriate agonistES ElectrosprayEu-cAMP Europium-labeled antibody paired with a cAMP analog FA Formic acidGIP Glucose-dependent insulinotropic polypeptideGIPR Glucose-dependent insulinotropic polypeptide receptor HBSS Hanks Buffered Salt SolutionHEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) Hex HexaneHFIP HexafluoroisopropanolHCI Hydrochloric acidHz HertzIBMX 3-isobutyl-1 -methylxanthineIC50 Half maximal inhibitory concentrationI PA IsopropanolL LigandJ Coupling constantAex Excitation wavelengthAem Emission wavelengthLCMS Liquid chromatography coupled with mass spectrometry m Multipletmg Milligramsmin MinutesmL MillilitermM Millimolar (mmol / L)mmol MillimolesMeCN Acetonitrilem / z Mass to charge rationm NanometersNMI / V-MethylimidazoleNMM N-methylmorpholine1H NMR Proton nuclear magnetic resonancePd / C Palladium on carbonPd(OH)2 / C Palladium(ll) hydroxide on carbonPE Petroleum etherPPm Parts per millionPrep-HPLC Preparative high-performance liquid chromatography Prep-SFC Preparative supercritical-fluid chromatographyPy Pyridineq Quartetrpm Revolutions per minuteRT Room temperature or retention times SingletSat Saturatedt TripletTBAI Tetrabutylammonium iodideTCFH Chloro-N,N,N',N'-tetramethylformamidinium hexafluorophosphateTEA TriethylamineTFA Trifluoroacetic acidTHF TetrahydrofuranTMS TrimethylsilylTR-FRET Time-resolved fluorescence energy transferTs 4-ToluenesulfonylpL MicroliterUV UltravioletVol. VolumeWt% Weight percentExample 1: Synthetic procedures(i) (R)-4-(3-(2-(3-(4-isopropylbenzyl)-1-methylureido)propanamido)bicyclo[1.1.1] pentan-1 -yl)benzoic acid (Compound 1(a))

[0045] Step 1: To a stirred solution of tert-butyl 4-(3-aminobicyclo[1.1.1]pentan-1-yl)benzoate (500 mg, 1.928 mmol, 1 equiv) and N-(((9H-fluoren-9-yl)methoxy)carbonyl)-N-methyl-D-alanine (627 mg, 1.927 mmol, 1.00 equiv) in DMF (5 mL) were added HOBT (260 mg, 1.924 mmol, 1.00 equiv) and EDCI (449 mg, 2.892 mmol, 1.50 equiv) at room temperature. The reaction was stirred at room temperature for 1 hour, then the resulting mixture was poured into water and the desired product extracted with EtOAc (3 x50 mL). The combined organic layers were washed with water (2 x 50 mL), dried over anhydrous Na2SO4 and filtered. The filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography, eluted with PE / EA (4:1) to afford tert-butyl (R)-4-(3-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino) propanamido)bicyclo[1.1.1]pentan-1-yl)benzoate (1 g, 92% yield, 90% purity) as an off-white solid. LCMS (ES, m / z): 567.3 [M+H]+.

[0046] Step 2: To a stirred solution of tert-butyl (R)-4-(3-(2-((((9H-fluoren-9-yl)methoxy)carbonyl) (methyl)amino)propanamido)bicyclo[1.1.1]pentan-1-yl)benzoate (1 g, 1.765 mmol, 1 equiv) in DMF (8 mL) was added piperidine (2 mL) at room temperature. The mixture was stirred at room temperature for 1 hour, then poured into water (50 mL). The desired product was extracted with EtOAc (3 x 30 mL). The combined organic layers were washed with water (2 x 30 mL), dried over anhydrous Na2SO4 and filtered. The filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography, eluted with CH2Cl2 / MeOH (4:1) to afford tert-butyl (R)-4-(3-(2-(methylamino)propanamido)bicyclo[1.1.1]pentan-1-yl)benzoate (480 mg, 79% yield, 95% purity) as a light yellow solid. LCMS (ES, m / z): 345.2 [M+H]+.

[0047] Step 3: A solution of tert-butyl (R)-4-(3-(2-(methylamino)propanamido)bicyclo [1.1.1]pentan-1-yl)benzoate (500 mg, 1.450 mmol, 1 equiv) in HFIP / TFA (v / v=40:1, 5 mL) was stirred at room temperature for 1 day. The reaction mixture was concentrated under reduced pressure to afford (R)-4-(3-(2-(methylamino)propanamido)bicyclo[1.1.1] pentan-1-yl)benzoic acid (70 mg, 95% purity) as an off-white solid. The crude product was used in the next step directly without further purification. LCMS (ES, m / z): 289.1 [M+H]+.

[0048] Step 4: To a stirred solution of 4-nitrophenyl carbonochloridate (5 g, 0.025 mmol, 3.70 equiv) in DCM (8 mL) was added a solution of (4-isopropylphenyl)methanamine (1 g, 0.007 mmol, 1 equiv) in pyridine (2 mL) dropwise at 0 °C. The reaction was stirred at room temperature for 1 h. The resulting mixture was poured into water (20 mL) and extracted with CH2CI2 (3 x 30 mL). The combined organic layers were washed with water (3 x 30 mL), dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified bysilica gel column chromatography, eluted with PE / EA (20:1) to afford 4-nitrophenyl (4-isopropylbenzyl)carbamate (700 mg, 50%) as a light brown solid. LCMS (ES, m / z): 415.1 [M+H]+.

[0049] Step 5: To a stirred solution of (R)-4-(3-(2-(methylamino)propanamido)bicyclo[1.1.1] pentan-1-yl)benzoic acid (114 mg, 0.395 mmol, 0.25 equiv) in ACN (5 mL) were added K2CO3 (165 mg, 1.194 mmol, 0.75 equiv) and 4-nitrophenyl (4-isopropylbenzyl)carbamate (500 mg, 1.591 mmol, 4 equiv) at room temperature. The resulting mixture was stirred at 90°C for 1 hour. The residue was purified by reversed-phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, MeCN in Water, 0% to 100% gradient in 10 min (35%); detector, UV 254 nm. This resulted in (R)-4-(3-(2-(3-(4-isopropylbenzyl)-1-methylureido) propanamido)bicyclo [1.1.1]pentan-1-yl)benzoic acid (6.1 mg, 99.7% purity) as an off-white solid.

[0050] Compound 1(a):

[0051] LCMS (ES, m / z): 464.2 [M+H]+.1H NMR (400 MHz, DMSO-6) 68.38 (s, 1H), 7.91 - 7.85 (m, 2H), 7.36 - 7.30 (m, 2H), 7.23 - 7.14 (m, 4H), 6.88 (d, J = 5.6 Hz, 1H), 4.77 - 4.68 (m, 1H), 4.29 -4.14 (m, 2H), 2.90 - 2.81 (m, 1H), 2.75 (s, 3H), 2.27 (s, 6H), 1.21 - 1.16 (m, 9H).(II) (R)-4-(3-(2-((((4-isopropylbenzyl)oxy)carbonyl)(methyl)amino)propanamido)bicyclo[1.1.1]pentan-1-yl)benzoic acid (Compound 122(a))Scheme 2

[0052] Step 1: To a stirred solution of 4-nitrophenyl carbonochloridate (10.7 g, 53.086 mmol, 3.99 equiv) in DCM (80 mL) was added a solution of (4-isopropylphenyl)methanol (2 g, 13.314 mmol, 1 equiv) in pyridine (20 mL) dropwise at 0°C. The reaction was stirred at room temperature for 1 h, then the resulting mixture was poured into water (30 mL) and extracted with DCM (3 x 30mL). The combined organic layers were washed with brine (1x10 mL) and dried over anhydrous Na2SC>4. After filtration, the filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography, eluted with PE I EA (3:1) to afford (4-isopropylphenyl)methyl 4-nitrobenzoate (1.46 g, crude product) as a yellow solid. LCMS (ES, m / z): 316.2 [M+H]+

[0053] Step 2: To a stirred solution of (4-isopropylphenyl)methyl 4-nitrobenzoate (70 mg, 0.234 mmol, 1 equiv) in THF (0.1 mL) was added TEA (31.47 mg, 0.311 mmol, 1.33 equiv) and tert-butyl (R)-4-(3-(2-(methylamino)propanamido)bicyclo[1.1.1]pentan-1-yl)benzoate (9 mg, 0.031 mmol, 0.93 equiv) at room temperature. The resulting mixture was concentrated under reduced pressure and the residue was purified by reversed-phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, MeCN in Water, 0% to 100% gradient in 10 min; detector, UV 254 nm to afford tert-butyl (R)-4-(3-(2-((((4-isopropylbenzyl)oxy)carbonyl) (methyl)amino)propanamido)bicyclo[1.1.1]pentan-1-yl)benzoate (24 mg, 84% purity) as a white solid. LCMS (ES, m / z): 521.2 [M+H]+

[0054] Step 3: A solution of tert-butyl (R)-4-(3-(2-((((4-isopropylbenzyl)oxy)carbonyl) (methyl)amino)propanamido)bicyclo[1.1.1]pentan-1-yl)benzoate (20 mg, 0.038 mmol, 1 equiv) in HFIP (2 mL) and TFA (0.02 mL) was stirred at room temperature for 1 hour, then concentrated under vacuum. The residue was purified by reversed-phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, MeCN in Water, 0% to 100% gradient in 10 min; detector, UV 254 nm to afford (R)-4-(3-(2-((((4-isopropylbenzyl)oxy)carbonyl) (methyl)amino)propanamido)bicyclo[1.1.1]pentan-1-yl)benzoic acid (10.3 mg, 58% yield, 96% purity) as a white solid.

[0055] Compound 122(a)

[0056] LCMS (ES, m / z): 465.1 [M+H]+.1H NMR (400 MHz, DMSO-6) 68.57 (s, 1H), 7.92 - 7.84 (m, 2H), 7.39 - 7.20 (m, 6H), 5.10 - 4.98 (m, 2H), 4.62 - 4.32 (m, 1H), 2.94 - 2.84 (m, 1 H), 2.81 (s, 3H), 2.31 -2.21 (m, 6H), 1.27 (d, J= 7.2 Hz, 3H), 1.20 (d, J = 6.8 Hz, 6H).(Hi) (R)-4-(3-(2-(((4-isopropylbenzyl)carbamoyl)oxy)propanamido)bicyclo[1.1.1 ] pentan-Scheme 3

[0057] Step 1: To a stirred solution of tert-butyl 4-(3-aminobicyclo [1.1.1] pentan-1-yl) benzoate (420 mg, 1.619 mmol, 1 equiv) and Py (260 mg, 3.287 mmol, 2.03 equiv) in DCM (5 mL) was added (2 R)-1 -chloro- 1-oxopropan-2-yl acetate (316 mg, 2.099 mmol, 1.30 equiv) at 0 °C. The resulting mixture was stirred at room temperature for 1 hour before the reaction was quenched with sat. NH4CI (aq.) at room temperature. The resulting mixture was poured into water (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with water (2 x 50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography, eluted with PE I EA (1:1) to afford tert-butyl (R)-4-(3-(2-acetoxypropanamido) bicyclo[1.1.1 ] pentan-1 -yl)benzoate (500 mg, 83% yield, 5% purity) as a light yellow semi-solid. LCMS (ES, m / z): 374.2 [M+H]+

[0058] Step 2: tert-butyl (R)-4-(3-(2-acetoxypropanamido) bicyclo[1.1.1] pentan- 1-yl) benzoate (430 mg, 1.151 mmol, 1 equiv) in a solution of NH3 in MeOH (7M, 5 mL) was stirred at room temperature for 1 hour. The resulting mixture was concentrated under reduced pressure and the residue was used directly in the next step without further purification. LCMS (ES, m / z): 332.2 [M+H]+

[0059] Step 3: To a stirred solution of tert-butyl (R)-4-(3-(2-hydroxypropanamido) bicyclo[1.1.1] pentan- 1-yl) benzoate (200 mg, 0.603 mmol, 1 equiv) in MeCN (4 mL) was added K2CO3 (271 mg, 1.961 mmol, 3.25 equiv) and 4-nitrophenyl N-[(4-isopropylphenyl)methyl]carbamate (940 mg, 2.990 mmol, 4.96 equiv) at room temperature. The reaction was stirred at 90 °C for 1 hour before the resulting mixture was poured into water (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with water (1 x 50 mL) and dried over anhydrous Na2SC>4. After filtration, the filtrate was concentrated under reduced pressure and the residue was purified by reversed-phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, MeCN in Water, 10% to 50% gradient in 10 min; detector, UV 254 nm. This resulted in tert-butyl (R)-4-(3-(2-(((4-isopropylbenzyl) carbamoyl) oxy) propanamido)bicyclo[1.1.1]pentan-1-yl)benzoate (80 mg, 26% yield, 80% purity) as an off-white solid. LCMS (ES, m / z): 507.3 [M+H]+

[0060] Step 4: To a stirred solution of t tert-butyl (R)-4-(3-(2-(((4-isopropylbenzyl) carbamoyl) oxy) propanamido)bicyclo[1.1.1]pentan-1-yl)benzoate (70 mg, 0.138 mmol, 1 equiv) in HFIP (2.5 mL) was added TFA (0.05 mL) at room temperature. The reaction was stirred at room temperature for 1 h, then the resulting mixture was concentrated under reduced pressure. The residue was purified by reversed-phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, MeCN in Water, 10% to 50% gradient in 10 min; detector, UV 254 nm. This resulted in (R)-4-(3-(2-(((4-isopropylbenzyl)carbamoyl)oxy)propanamido)bicyclo[1.1.1]pentan-1-yl) benzoic acid (10.6 mg, 17% yield, 99% purity) as an off-white solid.

[0061] Compound 197(a)

[0062] LCMS (ES, m / z): 451.1 [M+H]+.1H NMR (400 MHz, DMSO-6) 6 12.84 (s, 1H), 8.53 (s, 1H), 7.95 - 7.85 (m, 2H), 7.75 - 7.67(m, 1H), 7.43 - 7.31 (m, 2H), 7.19 (s, 4H), 4.86 - 4.71 (m, 1H), 4.26 -4.11 (m, 2H), 2.90 - 2.80 (m, 1H), 2.29 (s, 6H), 1.30 (d, J= 6.8 Hz, 3H), 1.19 (d, J = 6.8 Hz, 6H).(iv) 2-(6-((R)-1-((4-isopropylbenzyl)carbamoyl)piperidine-2-Scheme 4

[0088] Step 1: To a stirred suspension of LiCl (65.5 g, 1.55 mol, 2.4 equiv) in THF (1.6 L) was added tert-butyl 2-(diethoxyphosphoryl)acetate (162.4 g, 643.8 mmol, 1 equiv) at room temperature. After stirring for 30 min, the reaction mixture was cooled to 0 °C and DBU (215.6 g, 1.416 mol, 2.2 equiv) and a solution of fert-butyl (6-oxospiro[3.3]heptan-2-yl)carbamate (145 g, 644 mmol, 1 equiv) in THF (400 mL) were added. The resulting mixture was removed from cooling, stirred overnight, diluted with DCM, concentrated, and purified by silica gel column chromatography (eluting with 9:1 PE / EA) to afford tert-butyl 2-(6-((fert-butoxycarbonyl)amino)spiro[3.3]heptan-2-ylidene)acetate (170 g, 82% yield).1H NMR (400 MHz, CD3OD) 5 5.52 - 5.43 (m, 1H), 3.97 - 3.82 (m, 1H), 3.17 - 2.72 (m, 4H), 2.42 - 2.32 (m, 2H), 2.04 - 1.93 (m, 2H), 1.51 - 1.35 (m, 18H).

[0089] Step 2: To a stirred solution of tert-butyl 2-(6-((fert-butoxycarbonyl)amino)spiro[3.3]heptan-2-ylidene)acetate (170 g, 526 mmol, 1 equiv) in MeOH (2 L) was added Pd / C (10 wt%, 10 g, 9.4 mmol, 0.02 equiv) at room temperature. The resulting mixture was stirred overnight under hydrogen atmosphere and filtered. The filter cake was rinsed with MeOH (3 x 20 mL). The filtrate was concentrated to afford tert-butyl 2-(6-((tert-butoxycarbonyl)amino)spiro[3.3]heptan-2-yl)acetate (170 g, 99% yield).1H NMR (300 MHz, CD3OD) 5 3.96 - 3.78 (m, 1H), 2.56 - 2.36 (m, 2H), 2.32 - 2.16 (m, 4H), 2.14 - 2.03 (m, 1H), 1.96 - 1.64 (m, 4H), 1.44 (d, J = 3.0 Hz, 18H).

[0090] Step 3: To a stirred solution of terf-butyl 2-(6-((fert-butoxycarbonyl)amino)spiro[3.3]heptan-2-yl)acetate (95.0 g, 292 mmol, 1 equiv) in MeCN (1 L) and water (20 mL) was added bismuth(lll) chloride (92.1 g, 292 mmol, 1 equiv) at room temperature. The resulting mixture was stirred at 50 °C overnight and filtered. The filter cake was rinsed with MeCN (3 x 30 mL). The filtrate was concentrated to afford crude tert-butyl 2-(6-aminospiro[3.3]heptan-2-yl)acetate. The crude material was used in the subsequent step without further purification. LCMS (ES, m / z): 226.2 [M+H]+.

[0091] Step 4: To a stirred solution of tert-butyl 2-(6-aminospiro[3.3]heptan-2-yl)acetate (65.7 g, 292 mmol, 1 equiv) in DCM (700 mL) and TEA (88.6 g, 875 mmol, 3 equiv) was added CbzCI (74.6 g, 438 mmol, 1.5 equiv) at 0 °C. The resulting mixture was removed from cooling, stirred for 3 h, diluted with water, concentrated, and purified by silica gel column chromatography (eluting with 85:15 PE / EA) followed by chiral prep-SFC (column: Lux 5 pm Cellulose-3 5*25 cm, 5 pm; mobile phase: 60:20:20 CCh / MeCN / MeOH; flow rate: 100 mL / min; wavelength monitored: 220 nm) to afford, in order of elution, Isomer 1 (retention time: 4.5 min) (55 g, 46% yield) and Isomer2 (retention time: 6.5 min) (53 g, 42% yield) of terf-butyl 2-(6- (((benzyloxy)carbonyl)amino)spiro[3.3]heptan-2-yl)acetate. The absolute stereochemistry of Isomer 1 and Isomer 2 were not determined, but one is terf-butyl (F?)-2-(6- (((benzyloxy)carbonyl)amino)spiro[3.3]heptan-2-yl)acetate and the other is ferf-butyl (S)-2-(6-(((benzyloxy)carbonyl)amino)spiro[3.3]heptan-2-yl)acetate. LCMS (ES, m / z): 304.1 [M+H]+.

[0092] Step 5: To a stirred solution of Isomer 1 of terf-butyl 2-(6-(((benzyloxy)carbonyl)amino)spiro[3.3]heptan-2-yl)acetate (43 g, 120 mmol, 1 equiv) in MeOH (500 mL) was added Pd / C (10 wt%, 2.5 g, 2.3 mmol, 0.02 equiv) at room temperature. The resulting mixture was stirred for 3 h under hydrogen atmosphere and filtered. The filter cake was washed with MeOH (3 x 50 mL). The filtrate was concentrated to afford Isomer 1 of terf-butyl 2-(6-aminospiro[3.3]heptan-2-yl)acetate (21.1 g, 78% yield). LCMS (ES, m / z): 226.2 [M+H]+.

[0093] Step 6: To a stirred solution of (F?)-1-((benzyloxy)carbonyl)piperidine-2-carboxylic acid (888 mg, 3.37 mmol, 2 equiv) in DCM (4 mL) were added EDCI (967 mg, 5.04 mmol, 3 equiv) and Isomer 1 of terf-butyl 2-(6-aminospiro[3.3]heptan-2-yl)acetate (380 mg, 1.69 mmol, 1 equiv) at room temperature. The resulting mixture was stirred for 1 h, diluted with water (25 mL), and extracted with DCM (3 x 20 mL). The combined organic extracts were washed with brine (3 x 5 mL), dried over anhydrous Na2SO4, filtered, concentrated, and purified by silica gel column chromatography (eluting with 2:1 PE / EA) to afford Isomer 1 of benzyl (2F?)-2-((6-(2-(terf-butoxy)-2-oxoethyl)spiro[3.3]heptan-2-yl)carbamoyl)piperidine-1 -carboxylate (470 mg, 59% yield). LCMS (ES, m / z): 471.2 [M+H]+.

[0094] Step 7: To a solution of Isomer 1 of benzyl (2F?)-2-((6-(2-(terf-butoxy)-2-oxoethyl)spiro[3.3]heptan-2-yl)carbamoyl)piperidine-1-carboxylate (450 mg, 0.956 mmol, 1 equiv) in EA (5 mL) was added Pd / C (10 wt%, 100 mg, 0.94 mmol, 1 equiv). The mixture was stirred at room temperature for 40 min under hydrogen atmosphere, filtered through diatomaceous earth, and concentrated to afford Isomer 1 of terf-butyl 2-(6-((F?)-piperidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetate (280 mg, 87% yield). LCMS (ES, m / z): 337.2 [M+H]+.

[0095] Step 8: A solution of Isomer 1 of terf-butyl 2-(6-((F?)-piperidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetate (280 mg, 0.832 mmol, 1 equiv) in TFA (0.2 mL) and HFIP (4 mL) was stirred at room temperature for 40 min and concentrated to afford crude Isomer 1 of 2-(6-((?)-piperidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetic acid (300 mg). The crude material was used directly in the next step without further purification. LCMS (ES, m / z): 281.1 [M+H]+.

[0096] Step 9: To a stirred solution of Isomer 1 of 2-(6-((F?)-piperidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetic acid (100 mg, 0.357 mmol, 1 equiv) in DMF (1 mL) were added TEA (108 mg, 1.07 mmol, 3 equiv) and / V-(4-isopropylbenzyl)-1 / 7-imidazole-1-carboxamide (synthesized in 1 step by treating (4-isopropylphenyl)methanamine with GDI) (85.0 mg, 0.357 mmol, 1 equiv) at room temperature. The resulting mixture was stirred for 40 min under nitrogen atmosphere and directly purified by reversed-phase flash chromatography (column: C18; mobile phase: gradient of 40% to 50% MeCN / 0.1% aq. TFA over 10 min; detector: UV 254 nm) to afford Isomer 1 of 2-(6-((?)-1-((4-isopropylbenzyl)carbamoyl)piperidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetic acid (Compound 166(a)(lsomer 1)) (36.5 mg, 22% yield). The stereochemistry of Compound 166(a)(lsomer 1) was not assigned but corresponds to one of Compound 166(a)(a) and Compound 166(a)(b).Compound 166(a)(lsomer 1):Compound 166(a)(a) Compound 166(a)(b)

[0097] LCMS (ES, m / z): 456.3 [M+H]+.1H NMR (400 MHz, DMSO-6) 5 11.88 (s, 1H), 7.76 (d, J = 7.6 Hz, 1H), 7.16 (s, 4H), 6.98 -6.95 (m, 1H), 4.63 -4.56 (m, 1H), 4.27 - 4.01 (m, 3H), 3.05 -2.99 (m, 1H), 2.90 - 2.80 (m, 1H), 2.45 - 2.37 (m, 1H), 2.35 - 2.23 (m, 1H), 2.20 - 2.10 (m 3H), 2.05 - 1.99 (m, 2H), 1.93 - 1.85 (m, 2H), 1.73 - 1.62 (m, 2H), 1.56 - 1.51 (m, 2H), 1.19 (d, J = 6.8 Hz, 3H), 4.29 - 3.99 (m, 2H), 1.26 (d, J = 10.4 Hz, 6H).

[0098] Step 10: To a stirred solution of Isomer 2 of terf-butyl 2-(6-(((benzyloxy)carbonyl)amino)spiro[3.3]heptan-2-yl)acetate (45 g, 130 mmol, 1 equiv) in MeOH (500 mL) was added Pd / C (10 wt%, 3.0 g, 2.8 mmol, 0.02 equiv) at room temperature. The resulting mixture was stirred for 3 h under hydrogen atmosphere and filtered. The filter cake was washed with MeOH (3 x 50 mL). The filtrate was concentrated to afford Isomer 2 of fert-butyl 2-(6-aminospiro[3.3]heptan-2-yl)acetate (21.3 g, 76% yield). LCMS (ES, m / z): 226.2 [M+H]+.

[0099] Step 11: To a stirred solution of Isomer 2 of terf-butyl 2-(6-aminospiro[3.3]heptan-2-yl)acetate (200 mg, 0.888 mmol, 1 equiv) in DCM (2 mL) were added (R)-1-((benzyloxy)carbonyl)piperidine-2-carboxylic acid (280 mg, 1.06 mmol, 1.2 equiv) and EDCI (340 mg, 1.77 mmol, 2 equiv) and at room temperature. The resulting mixture was stirred for 1 h, concentrated, and purified by silica gel column chromatography (eluting with gradient of 50% to 60% EA / PE) to afford Isomer 2 of benzyl (2?)-2-((6-(2-(terf-butoxy)-2-oxoethyl)spiro[3.3]heptan-2-yl)carbamoyl)piperidine-1 -carboxylate (300 mg, 72% yield). LCMS (ES, m / z): 470.6 [M+H]+.

[0100] Step 12: To a solution of Isomer 2 of benzyl (2R)-2-((6-(2-(tert-butoxy)-2-oxoethyl)spiro[3.3]heptan-2-yl)carbamoyl)piperidine-1-carboxylate (300 mg, 0.637 mmol, 1 equiv) in MeOH (3 mL) was added Pd / C (10 wt%, 300 mg, 0.282 mmol, 0.4 equiv). The mixture was stirred at room temperature for 1 h under hydrogen atmosphere, filtered, (the solid was washed with methanol (2x10ml)), and concentrated to afford Isomer 2 of terf-butyl 2-(6-((F?)-piperidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetate (200 mg, 88% yield). LCMS (ES, m / z): 337.5 [M+H]+.

[0101] Step 13: A solution of Isomer 2 of fert-butyl 2-(6-((F?)-piperidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetate (280 mg, 0.832 mmol, 1 equiv) in TFA (0.25 mL) and HFIP (4.75 mL) was stirred at room temperature for 1 h, concentrated, and purified by column chromatography (gradient of 60% to 70% EA / PE) to afford Isomer 2 of 2-(6-((F?)-piperidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetic acid (200 mg, 80% yield). LCMS (ES, m / z): 281.4 [M+H]+.

[0102] Step 14: To a stirred solution of Isomer 2 of 2-(6-((F?)-piperidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetic acid (200 mg, 0.713 mmol, 1 equiv) in THF (1 mL) were added / V-(4-isopropylbenzyl)-1 / 7-imidazole-1-carboxamide (synthesized in 1 step by treating (4-isopropylphenyl)methanamine with GDI) (208 mg, 0.856 mmol, 1.2 equiv) and NMM (217 mg, 2.15 mmol, 3 equiv) and at room temperature. The resulting mixture was stirred for 1 h, concentrated, and purified by reversed-phase flash chromatography (eluting with gradient of 40% to 55% MeCN / water) to afford Isomer 2 of 2-(6-((?)-1-((4-isopropylbenzyl)carbamoyl)piperidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetic acid (Compound 166(a)(lsomer 2)) (26.0 mg, 8% yield). The stereochemistry of Compound 166(a)(lsomer 2) was not assigned but corresponds to one of Compound 166(a)(a) and Compound 166(a)(b).Compound 166(a)(lsomer 2):Compound 166(a)(a) Compound 166(a)(b)

[0103] 1H NMR (400 MHz, DMSO-6) 6 11.95 (s, 1 H), 7.79 - 7.71 (m, 1 H), 7.15 (s, 4H), 6.99 -6.87 (m, 1 H), 4.61 - 4.50 (m, 1 H), 4.28 - 4.18 (m, 1 H), 4.15 - 4.08 (m, 1 H), 4.05 - 3.97 (m, 1 H), 3.79 - 3.67 (m, 1 H), 3.01 - 2.91 (m, 1 H), 2.85 - 2.75 (m, 1 H), 2.70 - 2.62 (m, 1 H), 2.45 - 2.30 (m, 3H), 2.28 - 2.22 (m, 2H), 2.20 - 2.08 (m, 2H), 2.06 - 1.92 (m, 2H), 1.88 - 1.79 (m, 2H), 1.66 - 1.59 (m, 3H), 1.52-1.40 (m, 2H), 1.17 (d, J = 6.8 Hz, 6H).(v) (S)-4 '-(2-(((4-isopropylbenzyl)carbamoyl)oxy)propanamido)-[1, 1 '-biphenyl]-4-Scheme 5

[0104] Step 1: To a stirred solution of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (25 g, 114 mmol, 1 equiv) and K2CO3 (47.31 g, 342.3 mmol, 3 equiv) in dioxane (10 mL) were added Pd(dppf)Ch (18.37 g, 25.10 mmol, 0.2 equiv) and tert-butyl 4-bromobenzoate (31.39 g, 122.1 mmol, 1.1 equiv) at room temperature. The resulting mixture was stirred at 80 °C for 3 h under nitrogen atmosphere, poured into water (200 mL), and extracted with EtOAc (3 x 200 mL). The combined organic extracts were dried over anhydrous Na2SO4, filtered, concentrated, and purified by silica gel column chromatography (eluting with 5:1 PE / EA) to afford tert-butyl 4'-amino-[1,1'-biphenyl]-4-carboxylate (25.0 g, 81% yield). LCMS (ES, m / z): 270.1 [M+H]+.

[0105] Step 2: To a stirred solution of 1-(4-isopropylphenyl)methanamine (1.00 g, 6.70 mmol, 1 equiv) in DCM (10 mL) was added GDI (1.40 g, 8.63 mmol, 1.3 equiv) at 0 °C. The resulting mixture was stirred at room temperature 1 h and concentrated to afford crude / \ / -(4-isopropylbenzyl)-1 / 7-imidazole-1-carboxamide (1.5 g). The crude product was carried forward to step 6 without further purification. LCMS (ES, m / z): 244.1 [M+H]+.

[0106] Step 3: To a stirred solution of (S)-2-(benzyloxy)propanoic acid (500 mg, 2.78 mmol, 1 equiv) in DCM (5 mL) were added (COCI)2 (704 mg, 5.55 mmol, 2 equiv) and DMF (10 pL) at 0 °C. The resulting mixture was briefly stirred at room temperature and concentrated to afford (S)-2-(benzyloxy)propanoyl chloride (500 mg, crude). The crude product was used in the next step without further purification. LCMS (ES, m / z): 199.0 [M+H]+.

[0107] Step 4: To a stirred solution of tert-butyl 4'-amino-[1,1'-biphenyl]-4-carboxylate (677 mg, 2.51 mmol, 1 equiv) in Py (1 mL) was added dropwise a solution of (S)-2-(benzyloxy)propanoyl chloride (500 mg, 2.52 mmol, 1 equiv) in DCM (4 mL) at 0 °C. The resulting mixture was stirred at 0 °C for 1 h, poured into water (50 mL), and extracted with DCM (3 x 50 mL). The combined organic extracts were washed with water (3 x 50 mL), dried over anhydrous Na2SO4, filtered, concentrated, and purified by silica gel column chromatography (eluting with 5:1 PE / EA) to afford tert-butyl (S)-4'-(2-(benzyloxy)propanamido)-[1,1'-biphenyl]-4-carboxylate (400 mg, 37% yield). LCMS (ES, m / z): 432.2 [M+H]+.

[0108] Step 5: To a stirred solution of tert-butyl (S)-4'-(2-(benzyloxy)propanamido)-[1, T-biphenyl]-4-carboxylate (400 mg, 0.927 mmol, 1 equiv) in EA (50 mL) was added Pd / C (10 wt%, 200 mg, 0.185 mmol, 0.2 equiv) at room temperature. The resulting mixture was stirred at room temperature for 12 h under hydrogen atmosphere and filtered. The filter cake was rinsed with EA (3 x 20 mL). The filtrate was concentrated to afford crude tert-butyl (S)-4'-(2-hydroxypropanamido)-[1,1'-biphenyl]-4-carboxylate (250 mg) as an off-white solid. The crudeproduct was used directly in the next step without further purification. LCMS (ES, m / z): 342.2 [M+H]+.

[0109] Step 6: To a stirred solution of tert-butyl (S)-4'-(2-hydroxypropanamido)-[1,1'-biphenyl]-4-carboxylate (250 mg, 0.732 mmol, 1 equiv) in THF (3 mL) were added / \ / -(4-isopropylbenzyl)-1 / 7-imidazole-1 -carboxamide (2.25 g, 9.25 mmol, 13 equiv) and K2CO3 (999 mg, 7.23 mmol, 10 equiv) at room temperature. The resulting mixture was stirred at 60 °C for 1 h, poured into water (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic extracts were washed with water (3 x 50 mL), dried over anhydrous Na2SO4, filtered, concentrated, and purified by silica gel column chromatography (eluting with 1:1 PE / EA) to afford tert-butyl (S)-4'-(2-(((4-isopropylbenzyl)carbamoyl)oxy)propanamido)-[1,1'-biphenyl]-4-carboxylate (150 mg, 40% yield). LCMS (ES, m / z): 517.3 [M+H]+.

[0110] Step 7: A solution of tert-butyl (S)-4'-(2-(((4-isopropylbenzyl)carbamoyl)oxy)propanamido)-[1,1'-biphenyl]-4-carboxylate (150 mg, 0.290 mmol, 1 equiv) in HFIP (1.9 mL) and TFA (0.1 mL) was stirred at room temperature for 1 h, concentrated, and purified by reversed-phase flash chromatography (column: C18; mobile phase: gradient of 0% to 100% MeCN / water over 10 min; detector: UV 254 nm) to afford (S)-4'-(2-(((4-isopropylbenzyl)carbamoyl)oxy)propanamido)-[1,1'-biphenyl]-4-carboxylic acid (Compound 64(b)) (42.5 mg, 32% yield).Compound 64(b):

[0111] LCMS (ES, m / z): 461.1 [M+H]+.1H NMR (400 MHz, DMSO-6) 6 (ppm) 12.99 (s, 1H), 10.18 (s, 1H), 8.00 (d, J = 8.0 Hz, 2H), 7.89 (t, J = 6.0 Hz, 1H), 7.81 - 7.69 (m, 6H), 7.18 (s, 4H), 5.04 -4.95 (m, 1H), 4.20 - 4.10 (m, 2H), 2.92 - 2.80 (m, 1H), 1.43 (d, J = 6.8 Hz, 3H), 1.18 (d, J = 6.8 Hz, 6H).(vi) (R)-4'-(1-((4-isopropylbenzyl)carbamoyl)piperidine-2-carboxamido)-[1, 1 '-biphenyl]-4-carboxylic acid (Compound 232(a))Compound 232(a)Scheme 6

[0112] Step 1: To a stirred solution of (R)-1-((benzyloxy)carbonyl)piperidine-2-carboxylic acid (550 mg, 2.09 mmol, 1 equiv) and terf-butyl 4'-amino-[1,1'-biphenyl]-4-carboxylate (see Scheme 5) (844 mg, 3.13 mmol, 1.5 equiv) in MeCN (5 mL) were added TCFH (1.20 g, 4.18 mmol, 2 equiv) and NMI (515 mg, 6.27 mmol, 3 equiv) at 25 °C. The resulting solution was stirred for 1 h, concentrated, and purified by reversed-phase column chromatography (column: C18; mobile phase: gradient of 5% to 50% MeCN / water over 50 min) to afford benzyl (R)-2-((4'-(terf-butoxycarbonyl)-[1,1'-biphenyl]-4-yl)carbamoyl)piperidine-1-carboxylate (944 mg, 87% yield). LCMS (ES, m / z): 515.3 [M+H]+.

[0113] Step 2: A mixture of benzyl (R)-2-((4'-(tert-butoxycarbonyl)-[1, T-biphenyl]-4-yl)carbamoyl)piperidine-1-carboxylate (420 mg, 0.820 mmol, 1 equiv) and Pd / C (10 wt%, 9 mg, 0.08 mmol, 0.1 equiv) in MeOH (5 mL) was stirred at 25 °C for 1 h under hydrogen atmosphere and filtered. The filter cake was rinsed with MeOH (3x 10 mL). The filtrate was concentrated and purified by reversed-phase column chromatography (column: C18; mobile phase: gradient of 5% to 60% MeCN / water over 50 min) to afford terf-butyl ( / ?)-4'-(piperidine-2-carboxamido)-[1, T-biphenyl]-4-carboxylate (132 mg, 43% yield). LCMS (ES, m / z): 381.2 [M+H]+.

[0114] Step 3: To a stirred solution of terf-butyl (R)-4'-(piperidine-2-carboxamido)-[1, T-biphenyl]-4-carboxylate (112 mg, 0.290 mmol, 1 equiv) in DCM (5 mL) was added a solution of HCI in dioxane (4 M, 1.5 mL) dropwise at 25 °C. The resulting mixture was stirred for 3 h andconcentrated to afford (R)-4'-(piperidine-2-carboxamido)-[1, T-biphenyl]-4-carboxylic acid (107 mg, 99% yield). LCMS (ES, m / z): 325.1 [M+H]+.

[0115] Step 4: To a stirred solution of (R)-4'-(piperidine-2-carboxamido)-[1, T-biphenyl]-4-carboxylic acid (81 mg, 0.25 mmol, 1 equiv) in THF (3 mL) was added NMM (126 mg, 0.750 mmol, 5 equiv) at 25 °C. After stirring for 10 min, 1-(isocyanatomethyl)-4-isopropylbenzene (174 mg, 1.00 mmol, 4 equiv) was added. The resulting solution was stirred for 1 h at 25 °C, concentrated, and purified by reversed-phase column chromatography (column: C18; mobile phase: gradient of 5% to 50% MeCN / waterover 50 min) to afford (R)-4'-(1-((4-isopropylbenzyl)carbamoyl)piperidine-2-carboxamido)-[1,1'-biphenyl]-4-carboxylic acid (16.6 mg, 13% yield).Compound 232(a):

[0116] LCMS (ES, m / z): 500.3 [M+H]+.1H NMR (300 MHz, DMSO-6) 6 (ppm) 12.94 (s, 1 H), 9.98 (s, 1 H), 8.05 - 7.97 (m, 2H), 7.83 - 7.68 (m, 6H), 7.23 - 7.07 (m, 5H), 4.89 - 4.82 (m, 1 H), 4.32 - 4.14 (m, 2H), 3.82 - 3.72 (m, 1 H), 2.92 - 2.79 (m, 1 H), 2.20 - 2.09 (m, 1 H), 1.77 - 1.30 (m, 6H), 1.18 (d, J = 6.9 Hz, 6H).(vii) (R)-3-(4-(1-((4-isopropylbenzyl)carbamoyl)pyrrolidine-2-Scheme 7

[0117] Step 1: A mixture of fert-butyl 3-(4-aminophenyl)propanoate (100 mg, 0.452 mmol, 1 equiv), (terf-butoxycarbonyl)-D-proline (107 mg, 0.497 mmol, 1.1 equiv), and EDCI (91 mg, 0.59 mmol, 1.3 equiv) in DCM (2 mL) was stirred at room temperature for 1 h, concentrated, andpurified by silica gel column chromatography (eluting with 3:1 PE / EA) to afford fert-butyl (R)-2-((4-(3-(tert-butoxy)-3-oxopropyl)phenyl)carbamoyl)pyrrolidine-1-carboxylate (190 mg, 96% yield). LCMS (ES, m / z): 419.3 [M+H]+.

[0118] Step 2: A solution of terf-butyl (R)-2-((4-(3-(tert-butoxy)-3-oxopropyl)phenyl)carbamoyl)pyrrolidine-1-carboxylate (180 mg, 0.430 mmol, 1 equiv) in HCI / dioxane (4.0 M HCI, 2 mL) was stirred at room temperature for 1 h and concentrated to afford crude (R)-3-(4-(pyrrolidine-2-carboxamido)phenyl)propanoic acid (150 mg). The crude material was used directly in the next step without further purification. LCMS (ES, m / z): 263.1 [M+H]+.

[0119] Step 3: A mixture of (R)-3-(4-(pyrrolidine-2-carboxamido)phenyl)propanoic acid (140 mg, 0.534 mmol, 1 equiv), / V-(4-isopropylbenzyl)-1 / 7-imidazole-1-carboxamide (see Scheme 5) (156 mg, 0.641 mmol, 1.2 equiv), and TEA (81 mg, 0.80 mmol, 1.5 equiv) in DMF (2 mL) was stirred at room temperature for 1 h and purified directly by prep-HPLC (column: XBridge Prep OBD C18, 30*150 mm, 5 pm; mobile phase A O mM aq. NH4HCO3; mobile phase B: MeCN; flow rate: 60 mL / min; gradient: 5% B for 2 min, then 19% B to 39 % B over 10 min; wavelengths monitored: 220, 254 nm) to afford (R)-3-(4-(1-((4-isopropylbenzyl)carbamoyl)pyrrolidine-2-carboxamido)phenyl)propanoic acid (33.8 mg, 14% yield).Compound 155(a):

[0120] LCMS (ES, m / z): 438.2 [M+H]+.1H NMR (400 MHz, DMSO-6) 6 (ppm) 9.86 (s, 1H), 7.48 (d, J = 8.4 Hz, 2H), 7.19 - 7.12 (m, 6H), 6.82 - 6.79 (m, 1H), 4.37 - 4.33 (m, 1H), 4.25 - 4.12 (m, 2H), 3.49-3.46 (m, 1H), 3.38-3.34 (m, 1H), 2.87 - 2.81 (m, 1H), 2.77 - 2.73 (m, 2H), 2.51 - 2.43 (m, 2H), 2.13 - 1.82 (m, 4H), 1.18 (d, J = 6.8 Hz, 6H).(viii) (R)-4-(3-(1-((4-isopropylbenzyl)carbamoyl)pyrrolidine-2-carboxamido)bicyclo[1.1.1]pentan-1-yl)benzoic acid (Compound 4(a))

[0121] Step 1: To a stirred solution of 3-((terf-butoxycarbonyl)amino)bicyclo[1.1.1]pentane-1-carboxylic acid (10.0 g, 44.0 mmol, 1 equiv) and / V-hydroxyphthalimide (7.90 g, 48.4 mmol, 1.1 equiv) in DCM (176 mL) were added DIC (5.50 g, 43.6 mmol, 1 equiv) and DMAP (537 mg, 4.40 mmol, 0.1 equiv) portionwise at 0 °C. The resulting mixture was stirred at room temperature for 2 h and filtered. The filter cake was rinsed with DCM (3 x 20 mL). The filtrate was concentrated to afford crude 1,3-dioxoisoindolin-2-yl 3-((terf-butoxycarbonyl)amino)bicyclo[1.1.1]pentane-1-carboxylate (17 g). The crude material was used directly in the next step without further purification. LCMS (ES, m / z): 373.0 [M+H]+.

[0122] Step 2: A solution of Ni(dme)Ch (10.0 g, 45.5 mmol, 0.4 equiv) and pyridine-2-carboximidamide hydrochloride (7.20 g, 45.7 mmol, 0.4 equiv) in DMA (100 mL) was stirred at room temperature for 10 min under nitrogen atmosphere. To the above mixture was added a solution of 1,3-dioxoisoindolin-2-yl 3-((terf-butoxycarbonyl)amino)bicyclo[1.1.1]pentane-1-carboxylate (42.0 g, 113 mmol, 1 equiv), terf-butyl 4-iodobenzoate (35.0 g, 115 mmol, 1 equiv), TBAI (42.0 g, 114 mmol, 1 equiv), TFA (6.5 g, 57 mmol, 0.5 equiv), and Zn (112 g, 1.71 mol, 15equiv) in DMA (250 mL). The resulting mixture was stirred for 2 h, poured into water (200 mL), and extracted with EtOAc (3x 100 mL). The combined organic extracts were dried over anhydrous Na2SC>4, filtered, concentrated, and purified by silica gel column chromatography (eluting with 4:1 PE / EA) to afford te / t-butyl 4-(3-((te / t-butoxycarbonyl)amino)bicyclo[1.1.1]pentan-1-yl)benzoate (7.10 g, 17% yield). LCMS (ES, m / z): 360.0 [M+H]+.

[0123] Step 3: A solution of TMSCI (17.0 g, 156 mmol, 8 equiv) in MeOH (20 mL) and f-BuOH (20 mL) was stirred at room temperature for 10 min. To the above mixture was added te / t-butyl 4-(3-((te / t-butoxycarbonyl)amino)bicyclo[1.1.1]pentan-1-yl)benzoate (7.10 g, 19.8 mmol, 1 equiv) portionwise. The resulting mixture was stirred for 2 h, basified with sat. aq. NaHCCh, poured into water, and extracted with EtOAc (3 x 50 mL). The combined organic extracts were dried over anhydrous Na2SO4, filtered, and concentrated to provide tert-butyl 4-(3-aminobicyclo[1.1.1]pentan-1-yl)benzoate (4.30 g, 17% yield). LCMS (ES, m / z): 260.0 [M+H]+.

[0124] Step 4: A solution of ((benzyloxy)carbonyl)-D-proline (240 mg, 0.960 mmol, 1 equiv), te / t-butyl 4-(3-aminobicyclo[1.1.1]pentan-1-yl)benzoate (300 mg, 1.16 mmol, 1.2 equiv), and EDCI (369 mg, 1.93 mmol, 2 equiv) in DCM (2.6 mL) was stirred at room temperature for 4 h, diluted with DCM (50 mL), washed with water (3 x 10 mL), dried over anhydrous Na2SO4, filtered, concentrated, and purified by silica gel column chromatography (eluting with 1:1 PE / EA) to afford benzyl (R)-2-((3-(4-(te / t-butoxycarbonyl)phenyl)bicyclo[1.1.1]pentan-1-yl)carbamoyl)pyrrolidine-1-carboxylate (380 mg, 81% yield). LCMS (ES, m / z): 491.25 [M+H]+.

[0125] Step 5: To a stirred solution of benzyl (R)-2-((3-(4-(te / t-butoxycarbonyl)phenyl)bicyclo[1.1.1]pentan-1-yl)carbamoyl)pyrrolidine-1 -carboxylate (362 mg, 0.74 mmol, 1 equiv) in EA (9 mL) was added Pd / C (10 wt%, 140 mg, 0.132 mmol, 0.2 equiv) at room temperature. The resulting mixture was stirred for 1 h under hydrogen atmosphere and filtered. The filter cake was rinsed with EtOAc (3x 10 mL). The filtrate was concentrated to afford tert-butyl (R)-4-(3-(pyrrolidine-2-carboxamido)bicyclo[1.1.1]pentan-1-yl)benzoate (202 mg, 77% yield). LCMS (ES, m / z): 357.25 [M+H]+.

[0126] Step 6: A suspension of tert-butyl (R)-4-(3-(pyrrolidine-2-carboxamido)bicyclo[1.1.1]pentan-1-yl)benzoate (120 mg, 0.340 mmol, 1 equiv), 4-nitrophenyl (4-isopropylbenzyl)carbamate (see Scheme 1) (270 mg, 0.860 mmol, 2.5 equiv), and K2CO3(139 mg, 1.01 mmol, 3 equiv) in MeCN (1.3 mL) was stirred at 90 °C for 1 h, concentrated, diluted with EtOAc (50 mL), washed with water (3 x 10 mL), dried over anhydrous Na2SO4, filtered, concentrated, and purified by silica gel column chromatography (eluting with 1:1 PE / EA) to afford tert-butyl (R)-4-(3-(1-((4-isopropylbenzyl)carbamoyl)pyrrolidine-2-carboxamido)bicyclo[1.1.1]pentan-1-yl)benzoate (91.8 mg, 51% yield). LCMS (ES, m / z): 532.25 [M+H]+.

[0127] Step 7: To a stirred solution of tert-butyl (R)-4-(3-(1-((4-isopropylbenzyl)carbamoyl)pyrrolidine-2-carboxamido)bicyclo[1.1.1]pentan-1-yl)benzoate (84 mg, 0.16 mmol, 1 equiv) in HFIP (1.33 mL) was added TFA (70 pL) at room temperature. The resulting mixture was stirred for 1 h, concentrated, and purified by prep-SFC (Column: DAICEL DCpak PMPC, 30*250 mmm 5 pm; mobile phase: 0.047% FA in 53:47 CO2 / IPA; flow rate: 75 mL / min; run length: 16 min; wavelength monitored: 254 nm) to afford (R)-4-(3-(1-((4-isopropylbenzyl)carbamoyl)pyrrolidine-2-carboxamido)bicyclo[1.1.1]pentan-1-yl)benzoic acid (13.6 mg, 18% yield).Compound 4(a):

[0128] LCMS (ES, m / z): 476.2 [M+H]+.1H NMR (400 MHz, DMSO-6) 6 (ppm) 8.41 (s, 1H), 7.91 - 7.84 (m, 2H), 7.37 - 7.30 (m, 2H), 7.23 - 7.13 (m, 4H), 6.70 (t, J = 5.9 Hz, 1H), 4.34 - 4.24 (m, 1H), 4.19 -4.07 (m, 2H), 3.55-3.42 (m, 1H), 3.28-3.20 (m, 1H), 2.91 -2.80 (m, 1H), 2.26 (s, 6H), 2.02 - 1.94 (m, 1H), 1.87-1.83 (m, 3H), 1.18 (d, J = 6.8 Hz, 6H).(ix) 2-(6-((R)-1-((4-isobutylbenzyl)carbamoyl)piperidine-2-Compound 233(a)(a) Compound 233(a)(b)

[0129] Compounds 233(a)(a) and 233(a)(b) were prepared via the procedure shown in Scheme 4, with the following modifications: (a) / \ / -(4-isobutylbenzyl)-1 / 7-imidazole-1 -carboxamide was used instead of / V-(4-isopropylbenzyl)-1 / 7-imidazole-1-carboxamide in steps 9 and 14; (b) TEA in DMF was used instead of NMM in THF in step 14. / \ / -(4-lsobutylbenzyl)-1 / 7-imidazole-1-carboxamide was synthesized in 1 step by treating (4-isobutylphenyl)methanamine with GDI.Compound 233(a)(lsomer 1):

[0130] The absolute stereochemistry of Compound 233(a)(lsomer 1) was not assigned but corresponds to one of Compounds 233(a)(a) and 233(a)(b). Peak 1: retention time: 4.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 470.3 [M+H]+.1H NMR (400 MHz, DMSO-6) 5 11.96 (s, 1 H), 7.76 (d, J = 7.6 Hz, 1 H), 7.15 (d, J = 8.0 Hz, 2H), 7.07 (d, J = 8.0 Hz, 2H), 6.99 - 6.96 (m, 1 H), 4.61 - 4.59 (m, 1 H), 4.31 - 4.00 (m, 3H), 3.76 (d, J = 12.4 Hz, 1 H), 3.06 - 2.99 (m, 1 H), 2.49 -2.35 (m, 3H), 2.35 - 2.23 (m, 3H), 2.20 - 2.10 (m, 2H), 2.05 - 1.99 (m, 2H), 1.96 - 1.74 (m, 3H), 1.72 - 1.61 (m, 2H), 1.57 - 1.42 (m, 3H), 1.31 - 1.22 (m, 2H), 0.86 (d, J = 6.4 Hz, 6H).Compound 233(a)(lsomer 2):

[0131] The absolute stereochemistry of Compound(a)(lsomer 2) was not assigned but corresponds to the other of Compounds 233(a)(a) and 233(a)(b). Peak 2: retention time: 6.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 469.6 [M+H]+.1H NMR (400 MHz, DMSO-6) 5 11.94 (s, 1 H), 7.82 - 7.71 (m, 1 H), 7.22 - 7.12 (m, 2H), 7.11 - 7.03 (m, 2H), 7.01 - 6.93 (m, 1 H), 4.66 -4.53 (m, 1 H), 4.32 - 4.13 (m, 2H), 4.12 - 4.02 (m, 1 H), 3.82 - 3.71 (m, 1 H), 3.09 - 2.96 (m, 1 H), 2.46 - 2.36 (m, 3H), 2.34 - 2.24 (m, 3H), 2.20 - 2.07 (m, 2H), 2.06 - 1.98 (m, 2H), 1.96 - 1.89 (m, 1 H), 1.89 - 1.74 (m, 2H), 1.72 - 1.59 (m, 2H), 1.57 - 1.47 (m, 2H), 1.48 - 1.39 (m, 1 H), 1.36 - 1.16 (m, 2H), 0.92 - 0.79 (m, 6H).(x) (R)-4 '-(2-(((4-isopropylbenzyl)carbamoyl)oxy)propanamido)-[1, 1 '-biphenyl]-4-

[0132] Compound 64(a) was prepared via the procedure shown in Scheme 3, with the following modifications: (a) terf-butyl 4'-amino-[1,1'-biphenyl]-4-carboxylate (see Scheme 5) was usedinstead of fert-butyl 4-(3-aminobicyclo[1.1.1]pentan-1-yl)benzoate in step 1; (b) DIEA was used instead of Py in step 1; (c) / V-(4-isopropylbenzyl)-1 / 7-imidazole-1 -carboxamide (see Scheme 5) was used instead of 4-nitrophenyl (4-isopropylbenzyl)carbamate in step 3; (d) THF was used instead of ACN in step 3.

[0133] LCMS (ES, m / z): 461.2 [M+H]+.1H NMR (400 MHz, DMSO-6) 6 (ppm) 12.92 (s, 1H), 10.17 (s, 1H), 8.01 (d, J = 8.0 Hz, 2H), 7.91 - 7.85 (m, 1H), 7.83 - 7.70 (m, 6H), 7.21 - 7.14 (m, 4H), 5.04 - 4.94 (m, 1H), 4.20 - 4.10 (m, 2H), 2.92 - 2.78 (m, 1H), 1.45 - 1.40 (m, 3H), 1.21 -1.14 (m, 6H).(xi) 2-(6-((R)-4-((4-isopropylbenzyl)carbamoyl)morpholine-3-carboxamido)spiro[3.3]heptan-2-yl)acetic acid (Compounds 167(a)(a) and 167(a)(b))Compound 167(a)(a) Compound 167(a)(b)

[0134] Compounds 167(a)(a) and 167(a)(b) were prepared via the procedure shown in Scheme 4, with the following modifications: (a) (R)-4-(terf-butoxycarbonyl)morpholine-3-carboxylic acid was used instead of (R)-1-((benzyloxy)carbonyl)piperidine-2-carboxylic acid in steps 6 and 11; (b) tosylic acid in DCM was used instead of H2 and Pd / C in EtOAc in steps 7 and 12; (c) urea formation (steps 9 and 14) was performed prior to ester hydrolysis (steps 8 and 13); (d) potassium carbonate was used instead of NMM in step 14.Compound 167(a)(lsomer 1):

[0135] The absolute stereochemistry of Compound167(a)(lsomer 1) was not assigned but corresponds to one of Compounds 167(a)(a) and 167(a)(b). Peak 1: retention time: 4.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 458.2 [M+H]+.1H NMR (400 MHz, DMSO- cfe) 5 11.87 (s, 1H), 7.93 (d, J= 7.6 Hz, 1H), 7.25 - 7.15 (m, 4H), 7.07 - 7.00 (m, 1H), 4.35 - 3.98 (m, 5H), 3.76 (d, J = 7.2 Hz, 1H), 3.60 -3.45 (m, 2H), 3.32 - 3.29 (m, 2H), 2.89 - 2.81 (m, 1H), 2.47 -2.36 (m, 1H), 2.35 - 2.26 (m, 3H), 2.22 - 2.10 (m, 2H), 2.06 - 1.98 (m, 1H), 1.96 - 1.84 (m, 2H), 1.75 - 1.61 (m, 2H), 1.18 (d, J= 6.8 Hz, 6H).Compound 167(a)(lsomer 2):

[0136] The absolute stereochemistry of Compound 167(a)(lsomer 2) was not assigned but corresponds to the other of Compounds 167(a)(a) and 167(a)(b). Peak 2: retention time: 6.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 458.2 [M+H]+.1H NMR (400 MHz, DMSO-6) 6 11.91 (s, 1H), 7.91 (d, J= 8.0 Hz, 1H), 7.16 - 7.06 (m, 4H), 7.03- 7.00 (m, 1H), 4.31 -4.30 (m, 1H), 4.24 - 4.22 (m, 1H), 4.19 - 4.17 (m, 2H), 4.14 - 4.06 (m, 1H), 3.76 - 3.75 (m, 1H), 3.56 - 3.51 (m, 2H), 3.31 - 3.28 (m, 2H), 2.87 - 2.83 (m, 1 H), 2.51 - 2.42 (m, 1 H), 2.40 - 2.31 (m, 1 H), 2.31 -2.25 (m, 2H), 2.16 - 2.14 (m, 2H), 2.04 - 2.03 (m, 1H), 1.89 - 1.85(m, 2H), 1.71 - 1.68 (m, 2H), 1.19 - 1.18 (m, 6H).(xii) 2-(6-((R)-2-(((4-isopropylbenzyl)carbamoyl)oxy)propanamido)spiro[3.3]heptan-2-Compound 90(a)(a) Compound 90(a)(b)

[0137] Compounds 90(a)(a) and 90(a)(b) were prepared via the procedure shown in Scheme 4, with the following modifications: (a) (R)-1-chloro-1-oxopropan-2-yl acetate and diisopropylethylamine were used instead of (R)-1-((benzyloxy)carbonyl)piperidine-2-carboxylic acid and EDCI in steps 6 and 11; (b) methanolic ammonia was used instead of H2 and Pd / C in EtOAc in steps 7 and 12; (c) urea formation (steps 9 and 14) was performed prior to ester hydrolysis (steps 8 and 13); (d) 1-(isocyanatomethyl)-4-isopropylbenzene and dibutyltin dilaurate in DCM was used instead of / V-(4-isopropylbenzyl)-1 / 7-imidazole-1-carboxamide and TEA in DMF in step 9; (e) 1-(isocyanatomethyl)-4-isopropylbenzene and dibutyltin dilaurate in DCM was used instead of / V-(4-isopropylbenzyl)-1 / 7-imidazole-1-carboxamide and NMM in THF in step 14.Compound 90(a)(lsomer 1):

[0138] The absolute stereochemistry of Compound 90(a)(lsomer 1) was not assigned but corresponds to one of Compounds 90(a)(a) and 90(a)(b). Peak 1: retention time: 4.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 417.3 [M+H]+.1H NMR (400 MHz, DMSO-6) 6 7.96 (d, J = 7.6 Hz, 1H), 7.72 - 7.63 (m, 1H), 7.18 (s, 4H), 4.82 -4.71 (m, 1H), 4.16 - 3.97 (m, 3H), 2.91 - 2.81(m, 1 H), 2.45-2.38 (m, 1 H), 2.35-2.25 (m, 3H), 2.21 -2.10 (m, 2H), 2.06 - 1.97 (m, 1 H), 1.92 - 1.81 (m, 2H), 1.73- 1.59 (m, 2H), 1.26 (d, J= 6.8 Hz, 3H), 1.19 (d, J = 6.8 Hz, 6H).Compound 90(a)(lsomer 2):

[0139] The absolute stereochemistry of Compound 90(a)(lsomer 2) was not assigned but corresponds to the other of Compounds 90(a)(a) and 90(a)(b). Peak 2: retention time: 6.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 417.2 [M+H]+.1H NMR (400 MHz, DMSC ) 6 11.96 (s, 1H), 7.97 (d, J= 8.0 Hz, 1H), 7.71 - 7.68 (m, 1H), 7.19 - 7.15 (s, 4H), 4.77 -4.75 (m, 1H), 4.15 - 4.13 (m, 2H), 4.04 - 4.00 (m, 1H), 2.87 - 2.84 (m, 1H), 2.44 - 2.38 (m, 1H), 2.33 - 2.27 (m, 3H), 2.19 - 2.11 (m, 2H), 2.04 - 1.99 (m, 1H), 1.93 - 1.88 (m, 1H), 1.84 - 1.79 (m, 1H), 1.70 -1.61 (m, 2H), 1.25 (d, J= 6.8 Hz, 3H), 1.18 (d, J = 6.8 Hz, 6H).(xiii) 4'-((R)-2-((((S)-1-(4-isopropylphenyl)ethoxy)carbonyl)amino)propanamido)-[1, 1 biphenyl]-4-carboxylic acid (Compound 234(a)(a)) and 4'-((R)-2-((((R)-1-(4-isopropylphenyl)ethoxy)carbonyl)amino)propanamido)-[1, 1 '-biphenyl]-4-carboxylic acidScheme 9

[0140] Step 1: To a solution of fert-butyl 4'-amino-[1,1'-biphenyl]-4-carboxylate (see Scheme 5) (1.0 g, 4.0 mmol, 1.0 equiv) in DCM (20 mL) were added EDCI (2.30 g, 14.8 mmol, 3.7 equiv) and (terf-butoxycarbonyl)-D-alanine (1.1 g, 6.0 mmol, 1.5 equiv) at room temperature. The reaction mixture was stirred for 1 h, diluted with water (500 mL), and extracted with CH2CI2 (3 x 200 mL). The combined organic extracts were dried over anhydrous Na2SO4, filtered, concentrated, and purified by silica gel column chromatography (eluting with 2:1 PE / EA) to afford terf-butyl (R)-4'-(2-((terf-butoxycarbonyl)amino)propanamido)-[1, T-biphenyl]-4-carboxylate (1.2 g, 68% yield). LCMS (ES, m / z): 441.2 [M+HJ+.

[0141] Step 2: A solution of fert-butyl (R)-4'-(2-((terf-butoxycarbonyl)amino)propanamido)-[1, T-biphenyl]-4-carboxylate (1.2 g, 2.7 mmol, 1.0 equiv) in HCI / dioxane (4.0 M, 15 mL) was stirred at room temperature for 1 h and concentrated to afford ( / ?)-4'-(2-aminopropanamido)-[1,1'-biphenyl]-4-carboxylic acid (1.0 g, crude). The crude product was used directly in the subsequent step without further purification. LCMS (ES, m / z): 285.1 [M+H]+.

[0142] Step 3: To a solution of 1-(4-isopropylphenyl)ethanol (300 mg, 1.82 mmol, 1 equiv) in DCM (10 mL) were added TEA (450 mg, 4.4 mmol, 2.4 equiv), DMAP (375 mg, 3.06 mmol, 1.7 equiv), and bis(4-nitrophenyl) carbonate (280 mg, 0.92 mmol, 0.50 equiv) at room temperature. The resulting mixture was stirred for 2 h and concentrated to afford 1-(4-isopropylphenyl)ethyl (4-nitrophenyl) carbonate (400 mg, crude). The crude product was used directly in the subsequent step without further purification. LCMS (ES, m / z): 330.2 [M+H]+.

[0143] Step 4: To a solution of ( / ?)-4'-(2-aminopropanamido)-[1,1'-biphenyl]-4-carboxylic acid (500 mg, 1.8 mmol, 1.2 equiv) in THF (10 mL) were added K2CO3 (1.0 g, 7.2 mmol, 4.8 equiv) and 1-(4-isopropylphenyl)ethyl 4-nitrophenyl carbonate (500 mg, 1.5 mmol, 1 equiv) at room temperature. The reaction mixture was stirred at 50 °C for 2 h, removed from heating, diluted with water (1 mL), acidified to pH 5 with HCI (1 M, 2 mL), and extracted with CH2CI2 (3 x 50 mL). The combined organic extracts were dried over anhydrous Na2SO4, filtered, concentrated, and purified by reversed-phase flash chromatography (column: C18 silica gel; mobile phase: MeCN / water, 15% to 55% gradient over 15 min) followed by chiral prep-HPLC [column: CHIRALPAK IM 2*25 cm, 5 pm; mobile phase A: Hex (0.2% FA); mobile phase B: 1:1 EtOH / DCM; flow rate: 20 mL / min; gradient: isocratic 20% B in 16 min; RT1 (min): 9.8; RT2 (min): 13.5] to afford, in order of elution, Compound 234(a)(lsomer 1) (2.5 mg, 4% yield) and Compound 234(a)(lsomer 2) (20.3 mg, 36% yield).Compound 234(a)(lsomer 1):

[0144] The absolute stereochemistry of Compound 234(a)(lsomer 1) was not assigned but corresponds to one of Compounds 234(a)(a) and 234(a)(b). Peak 1: retention time: 9.8 min. LCMS (ES, m / z): 475.2 [M+H]+.1H NMR: (400 MHz, DMSO-6) 6 13.10 - 12.91 (m, 1 H), 10.20 -10.04 (m, 1 H), 8.04 - 7.95 (m, 2H), 7.84 - 7.66 (m, 6H), 7.59 - 7.53 (m, 1 H), 7.31 - 7.20 (m, 3H), 7.19 - 6.76 (m, 1 H), 5.69 - 5.60 (m, 1 H), 4.28 - 4.03 (m, 1 H), 2.93 - 2.80 (m, 1 H), 1.48 - 1.37 (m, 3H), 1.33 - 1.26 (m, 3H), 1.25 - 1.16 (m, 6H).Compound 234(a)(lsomer 2):

[0145] The absolute stereochemistry of Compound 234(a)(lsomer 2) was not assigned but corresponds to the other of Compounds 234(a)(a) and 234(a)(b). Peak 2: retention time: 13.5 min. LCMS (ES, m / z): 475.2 [M+H]+.1H NMR: (400 MHz, DMSO-6) 5 13.10 - 12.91 (m, 1 H), 10.20 -10.04 (m, 1 H), 8.04 - 7.95 (m, 2H), 7.84 - 7.66 (m, 6H), 7.59 - 7.53 (m, 1 H), 7.31 - 7.20 (m, 3H), 7.19 - 6.76 (m, 1 H), 5.69 - 5.60 (m, 1 H), 4.28 - 4.03 (m, 1 H), 2.93 - 2.80 (m, 1 H), 1.48 - 1.37 (m, 3H), 1.33 - 1.26 (m, 3H), 1.25 - 1.16 (m, 6H).(xiv) 2-(6-((R)-1-((3-fluoro-4-(trifluoromethyl)benzyl)carbamoyl)pyrrolidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetic acid (Compounds 9(a)(a) and 9(a)(b))Scheme 10

[0146] Step 1: To a stirred solution of (2R)-1-[(benzyloxy)carbonyl]pyrrolidine-2-carboxylic acid (6.50 g, 26.1 mmol, 1.0 equiv) and EDCI (6.10 g, 39.1 mmol, 1.5 equiv) in DCM (60 mL) was added Isomer 1 of tert-butyl 2-(6-aminospiro[3.3]heptan-2-yl)acetate (see Scheme 4) (5.90 g, 26.1 mmol, 1 equiv) at room temperature. The reaction mixture was stirred at room temperature for 1 h. The mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE I EA (1:1) to afford Isomer 1 of benzyl (2R)-2-((6-(2-(tert-butoxy)-2-oxoethyl)spiro[3.3]heptan-2-yl)carbamoyl)pyrrolidine-1-carboxylate (9.0 g, 72% yield). LCMS (ES, m / z): 457.2 [M+H]+.

[0147] Step 2: To a stirred solution of Isomer 1 of benzyl (2R)-2-((6-(2-(tert-butoxy)-2-oxoethyl)spiro[3.3]heptan-2-yl)carbamoyl)pyrrolidine-1 -carboxylate (9.0 g, 20 mmol, 1.0 equiv) in MeOH (100 mL) was added Pd / C (10 wt%, 900 mg, 0.85 mmol, 0.04 equiv) at room temperature. The reaction mixture was stirred at room temperature for 1 h under hydrogen atmosphere. The mixture was filtered. The filter cake was washed with MeOH (3 x 30 mL). The filtrate was concentrated under reduced pressure to afford Isomer 1 of tert-butyl 2-(6-((R)-pyrrolidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetate (6.4 g, 91% yield) as an off-white solid. LCMS (ES, m / z): 323.2 [M+H]+.

[0148] Step 3: To a stirred solution of N-(3-fluoro-4-(trifluoromethyl)benzyl)-1H-imidazole-1-carboxamide [prepared by reacting (3-fluoro-4-(trifluoromethyl)phenyl)methanamine with GDI] (100 mg, 0.35 mmol, 1 equiv) in THF (2 mL) were added NMM (70 mg, 0.69 mmol, 2 equiv) and Isomer 1 of tert-butyl 2-(6-((R)-pyrrolidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetate (134 mg, 0.420 mmol, 1.2 equiv) at room temperature. The reaction mixture was stirred at room temperature for 1 h. The mixture was poured into water (10 mL) and extracted with EtOAc (3x 10 mL). The combined organic layers were washed with water (3 x 5 mL) and dried over anhydrous Na2SC>4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reversed-phase flash chromatography (column, C18 silica gel; mobile phase: MeCN / water, 10% to 50% gradient in 10 min) to afford Isomer 1 of tert-butyl 2-(6-((R)-1-((3-fluoro-4-(trifluoromethyl)benzyl)carbamoyl)pyrrolidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetate (110 mg, 58% yield). LCMS (ES, m / z): 542.1 [M+H]+.

[0149] Step 4: To a stirred solution of Isomer 1 of tert-butyl 2-(6-((R)-1-((3-fluoro-4-(trifluoromethyl)benzyl)carbamoyl)pyrrolidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetate (100 mg, 0.19 mmol, 1 equiv) in HFIP (2 mL) was added TFA (0.1 mL) at room temperature. The reaction mixture was stirred at room temperature for 2 h. The mixture was concentrated underreduced pressure. The residue was purified by reversed-phase flash chromatography [column:C18 silica gel; mobile phase: MeCN / water (0.1% TFA), 10% to 50% gradient in 10 min) to affordIsomer 1 of 2-(6-((R)-1-((3-fluoro-4-(trifluoromethyl)benzyl)carbamoyl)pyrrolidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetic acid (Compound 9(a)(lsomer 1)) (73.4 mg, 82% yield). The stereochemistry of Compound 9(a)(lsomer 1) was not assigned but corresponds to one ofCompound 9(a)(a) and Compound 9(a)(b).Compound 9(a)(a) Compound 9(a)(b)Compound 9(a)(lsomer 1):

[0150] LCMS (ES, m / z): 486.2 [M+H]+.1H NMR (400 MHz, DMSO-6) 5 11.95 (s, 1H), 7.87 (d, J = 7.6 Hz, 1 H), 7.75 - 7.65 (m, 1 H), 7.40 - 7.27 (m, 2H), 6.92 - 6.85 (m, 1 H), 4.39 - 4.21 (m, 2H), 4.14 - 4.08 (m, 1H), 4.07 - 3.94 (m, 1H), 3.51 - 3.40 (m, 1H), 3.34 - 3.21 (m, 1H), 2.45 - 2.34 (m, 1H), 2.33 -2.22 (m, 3H), 2.21 -2.05 (m, 2H), 2.04 - 1.92 (m, 2H), 1.92 - 1.75 (m, 5H), 1.72 - 1.57 (m, 2H).

[0151] Step 5: To a stirred solution of (2R)-1-[(benzyloxy)carbonyl]pyrrolidine-2-carboxylic acid (1.0 g, 4.0 mmol, 1.0 equiv) in DCM (15 mL) were added EDCI (925 mg, 5.96 mmol, 1.5 equiv) and Isomer 2 of tert-butyl 2-(6-aminospiro[3.3]heptan-2-yl)acetate (see Scheme 4) (1.0 g, 4.4 mmol, 1.1 equiv) portionwise at room temperature. The reaction mixture was stirred at room temperature for 1 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by reversed-phase flash chromatography (column: C18 silica gel; mobile phase: MeCN / water, 40% to 60% gradient in 20 min) to afford Isomer 2 of benzyl (2R)-2-((6-(2-(tert-butoxy)-2-oxoethyl)spiro[3.3]heptan-2-yl)carbamoyl)pyrrolidine-1-carboxylate (1.2 g, 66% yield). LCMS (ES, m / z): 457.1[M+H]+.

[0152] Step 6: To a stirred solution of Isomer 2 of benzyl (2R)-2-((6-(2-(tert-butoxy)-2-oxoethyl)spiro[3.3]heptan-2-yl)carbamoyl)pyrrolidine-1-carboxylate (1.0 g, 2.2 mmol, 1.0 equiv) in MeOH (20 mL) was added Pd / C (10 wt%, 996 mg, 0.940 mmol, 0.4 equiv) at room temperature. The reaction mixture was stirred at room temperature for 1 h under hydrogen atmosphere. Thereaction mixture was filtered. The filter cake was washed with MeOH (2 x 10 mL). The filtrate was concentrated under reduced pressure to afford Isomer 2 of tert-butyl 2-(6-((R)-pyrrolidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetate (679 mg, crude). The crude product was used in the subsequent step without further purification. LCMS (ES, m / z): 323.1[M+H]+.

[0153] Step 7: To a stirred solution of N-(3-fluoro-4-(trifluoromethyl)benzyl)-1H-imidazole-1-carboxamide [prepared by reacting (3-fluoro-4-(trifluoromethyl)phenyl)methanamine with GDI] (150 mg, 0.68 mmol, 1.3 equiv) in DMF (1.5 mL) were added TEA (260 mg, 2.6 mmol, 5 equiv) and Isomer 2 of tert-butyl 2-(6-((R)-pyrrolidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetate (165 mg, 0.510 mmol, 1 equiv) at room temperature. The reaction mixture was stirred at room temperature for 1 h, concentrated, and purified by reversed-phase flash chromatography (column: C18 silica gel; mobile phase: MeCN / water, 50% to 70% gradient in 20 min) to afford Isomer 2 of tert-butyl 2-(6-((R)-1-((3-fluoro-4-(trifluoromethyl)benzyl)carbamoyl)pyrrolidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetate (106 mg, 29% yield). LCMS (ES, m / z): 542.1 [M+H]+.

[0154] Step 8: A solution of Isomer 2 of tert-butyl 2-(6-((R)-1-((3-fluoro-4-(trifluoromethyl)benzyl)carbamoyl)pyrrolidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetate (100 mg, 0.18 mmol, 1 equiv) and TFA (0.1 mL) in HFIP (1.9 mL) was stirred at room temperature for 1 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by reversed-phase flash chromatography (column: C18 silica gel; mobile phase: MeCN / water, 30% to 50% gradient in 20 min) to afford Isomer 2 of 2-(6-((R)-1-((3-fluoro-4-(trifluoromethyl)benzyl)carbamoyl)pyrrolidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetic acid (Compound 9(a)(lsomer2)) (46.6 mg, 52% yield). The stereochemistry of Compound 9(a)(lsomer 2) was not assigned but corresponds to one of Compound 9(a)(a) and Compound 9(a)(b).Compound 9(a)(a) Compound 9(a)(b)Compound 9(a)(lsomer2):

[0155] LCMS (ES, m / z): 486.2 [M+H]+.1H NMR (400 MHz, DMSC s) 511.93 (s, 1H), 7.87-7.85 (m, 1 H), 7.69 (d, J = 7.6 Hz, 1 H), 7.38 - 7.29 (m, 2H), 6.90 - 6.86 (m, 1 H), 4.37 - 4.22 (m, 2H),4.12 - 3.97 (m, 2H), 3.47 - 3.45 (m, 1 H), 3.31 -.25 (m, 1 H), 2.42 - 2.35 (m, 1 H), 2.30 - 2.24 (m, 3H), 2.19 -2.07 (m, 2H), 2.00 - 1.94 (m, 2H), 1.91 - 1.78 (m, 5H), 1.71 - 1.58 (m, 2H).(xv) 2-(6-((R)-1-((4-isobutylbenzyl)carbamoyl)pyrrolidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetic acid (Compounds 14(a)(a) and 14(a)(b))Compound 14(a)(a) Compound 14(a)(b)

[0156] Compounds 14(a)(a) and 14(a)(b) were prepared via the procedure shown in Scheme 10, with the following modifications: (a) N-(4-isobutylbenzyl)-1H-imidazole-1-carboxamide was used instead of N-(3-fluoro-4-(trifluoromethyl)benzyl)-1H-imidazole-1-carboxamide in steps 3 and 7; (b) NMM and THF were used instead of TEA and DMF in step 7. N-(4-lsobutylbenzyl)-1H-imidazole-1-carboxamide was prepared by reacting (4-isobutylphenyl)methanamine with GDI.Compound 14(a)(lsomer 1):

[0157] The absolute stereochemistry of Compound 14(a)(lsomer 1) was not assigned but corresponds to one of Compounds 14(a)(a) and 14(a)(b). Peak 1: retention time: 4.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 456.3 [M+H]+.1H NMR (400 MHz, DMSO-6) 5 11.88 (s, 1H), 7.88 (d, J = 8.0 Hz, 1H), 7.19 - 7.03 (m, 4H), 6.74 - 6.64 (m, 1H), 4.30 - 4.09 (m, 3H), 4.08 -3.94 (m, 1H), 3.47 - 3.39 (m, 1H), 3.28 - 3.16 (m, 1H), 2.46 -2.35 (m, 3H), 2.35 -2.22 (m, 3H), 2.22 - 2.06 (m, 2H), 2.07 - 1.92 (m, 2H), 1.93 - 1.73 (m, 6H), 1.73 - 1.58 (m, 2H), 0.86 (d, J = 6.4 Hz, 6H).Compound 14(a)(lsomer 2):

[0158] The absolute stereochemistry of Compound 14(a)(lsomer 2) was not assigned but corresponds to the other of Compounds 14(a)(a) and 14(a)(b). Peak 2: retention time: 6.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 456.3 [M+H]+.1H NMR (400 MHz, DMSO- cfe) 5 11.94 (s, 1H), 7.88 (d, J = 7.6 Hz, 1H), 7.17 (d, J = 8.0 Hz, 2H), 7.07 (d, J = 8.0 Hz, 2H), 6.68 - 6.66 (m, 1H), 4.27 - 4.12 (m, 3H), 4.02 - 3.99 (m, 1H), 3.43 - 3.42 (m, 1H), 3.24 - 3.22 (m, 1H), 2.41 -2.38 (m, 3H), 2.29 -2.26 (m, 3H), 2.22 - 2.08 (m, 2H), 2.06 - 1.74 (m, 8H), 1.66 - 1.60 (m, 2H), 0.86 (d, J= 6.8 Hz, 6H).(xvi) 2-(6-((R)-1-((4-cyclopropyl-3-(trifluoromethyl)benzyl)carbamoyl)pyrrolidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetic acid (Compounds 15(a)(a) and 15(a)(b))Compound 15(a)(a) Compound 15(a)(b)

[0159] Compounds 15(a)(a) and 15(a)(b) were prepared via the procedure shown in Scheme 10, with the following modifications: (a) N-(4-cyclopropyl-3-(trifluoromethyl)benzyl)-1H-imidazole-1-carboxamide was used instead of N-(3-fluoro-4-(trifluoromethyl)benzyl)-1H-imidazole-1-carboxamide in steps 3 and 7; (b) NMM and THF were used instead of TEA and DMF in step 7. N-(4-Cyclopropyl-3-(trifluoromethyl)benzyl)-1H-imidazole-1-carboxamide was prepared in 4 steps: (a) cross-coupling of 4-bromo-3-(trifluoromethyl)benzaldehyde and cyclopropylboronic acid using Pd(dppf)Cl2; (b) reductive amination of the resulting aldehyde with B0CNH2, triethylsilane, and TFA in DCM / MeCN; (c) Boc deprotection with HCI in dioxane; (d) reaction of the resulting amine with GDI.Compound 15(a)(lsomer 1):

[0160] The absolute stereochemistry of Compound 15(a)(lsomer 1) was not assigned but corresponds to one of Compounds 15(a)(a) and 15(a)(b). Peak 1: retention time: 4.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 508.2 [M+H]+.1H NMR (400 MHz, DMSO-6) 5 11.93 (s, 1H), 7.84 (d, J = 7.6 Hz, 1 H), 7.56 (s, 1 H), 7.49 - 7.38 (m, 1 H), 7.08 (d, J = 8.0 Hz, 1 H), 6.83 - 6.73 (m, 1H), 4.31 -4.22 (m, 1H), 4.21 -4.13 (m, 1H), 4.13 -4.07 (m, 1H), 4.07 - 3.92 (m, 1H), 3.44 - 3.38 (m, 1H), 3.28 - 3.17 (m, 1H), 2.46 - 2.36 (m, 1H), 2.32 - 2.23 (m, 3H), 2.20 - 2.05 (m, 3H), 2.05 - 1.89 (m, 2H), 1.89 - 1.73 (m, 5H), 1.73 - 1.57 (m, 2H), 1.06 - 0.95 (m, 2H), 0.82 -0.66 (m, 2H).Compound 15(a)(lsomer 2):

[0161] The absolute stereochemistry of Compound 15(a)(lsomer 2) was not assigned but corresponds to the other of Compounds 15(a)(a) and 15(a)(b). Peak 2: retention time: 6.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 508.2 [M+H]+.1H NMR (400 MHz, DMSO-6) 67.87 (d, J= 7.6 Hz, 1 H), 7.56 - 7.55 (m, 1 H), 7.44 - 7.42 (m, 1 H), 7.07 (d, J = 8.0 Hz, 1 H), 6.84 - 6.81 (m, 1H), 4.29 - 4.14 (m, 2H), 4.11 - 4.08 (m, 1H), 4.01 - 3.95 (m, 1H), 3.44 - 3.38 (m, 1H), 3.26 -3.20 (m, 1H), 2.40 -2.34 (m, 1H), 2.29 - 2.21 (m, 3H), 2.18 -2.03 (m, 3H), 2.01 - 1.58 (m, 7H), 1.70 - 1.58 (m, 2H), 1.05 - 0.94 (m, 2H), 0.80 - 0.71 (m, 2H).(xvii) 2-(6-((R)-1-((3-cyclopropyl-4-(trifluoromethyl)benzyl)carbamoyl)pyrrolidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetic acid (Compounds 30(a)(a) and 30(a)(b))Compound 30(a)(a) Compound 30(a)(b)

[0162] Compounds 30(a)(a) and 30(a)(b) were prepared via the procedure shown in Scheme 10, with the following modifications: (a) N-(3-cyclopropyl-4-(trifluoromethyl)benzyl)-1H-imidazole-1-carboxamide was used instead of N-(3-fluoro-4-(trifluoromethyl)benzyl)-1H-imidazole-1-carboxamide in steps 3 and 7; (b) NMM was used instead of TEA in step 7. N-(3-Cyclopropyl-4-(trifluoromethyl)benzyl)-1H-imidazole-1-carboxamide was prepared in 4 steps: (a) cross-coupling of 3-bromo-4-(trifluoromethyl)benzaldehyde and cyclopropylboronic acid using Pd(dppf)Ch; (b) reductive amination of the resulting aldehyde with B0CNH2, triethylsilane, and TFA in DCM / MeCN; (c) Boc deprotection with HCI in dioxane; (d) reaction of the resulting amine with GDI.Compound 30(a)(lsomer 1):

[0163] The absolute stereochemistry of Compound 30(a)(lsomer 1) was not assigned but corresponds to one of Compounds 30(a)(a) and 30(a)(b). Peak 1: retention time: 4.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 508.3 [M+H]+.1H NMR (400 MHz, DM SO-cfe) 511.94 (s, 1H), 7.87 (d, J= 7. Q Hz, 1H), 7.57 (d, J= 8.1 Hz, 1H), 7.22 (d, J= 8.0 Hz, 1H), 7.04 (s, 1H), 6.82 -6.75 (m, 1 H), 4.25 - 4.21 (m, 2H), 4.20 - 4.01 (m, 2H), 3.42 - 3.34 (m, 1 H), 3.26 - 3.24 (m, 1 H), 2.50 -2.40 (m, 1H), 2.28 -2.26 (m, 3H), 2.16 - 2.11 (m, 3H), 2.09 -2.08 (m, 2H), 2.00 - 1.69 (m, 5H), 1.68 - 1.61 (m, 2H), 1.04 - 1.01 (m, 2H), 0.79 - 0.78 (m, 2H).Compound 30(a)(lsomer 2):

[0164] The absolute stereochemistry of Compound 30(a)(lsomer 2) was not assigned but corresponds to the other of Compounds 30(a)(a) and 30(a)(b). Peak 2: retention time: 6.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 508.5 [M+H]+.1H NMR (400 MHz, DMSO-6) 5 11.95 (s, 1H), 7.88 (s, 1H), 7.65-7.50 (m, 1H), 7.30-7.21 (m, 1H), 7.04 (s, 1H), 6.88-6.74 (m, 1H), 4.31 - 4.15 (m, 2H), 4.13 - 4.07 (m, 1H), 4.06 - 3.90 (m, 1H), 3.48 - 3.39 (m, 1H), 3.28 - 3.20 (m, 1H), 2.46 - 2.34 (m, 1H), 2.33 - 2.23 (m, 3H), 2.19 - 2.05 (m, 3H), 2.05 - 1.91 (m, 2H), 1.90 -1.73 (m, 5H), 1.72 - 1.58 (m, 2H), 1.08 - 0.96 (m, 2H), 0.86 - 0.75 (m, 2H).(xviii) 2-(6-((R)-1-((2-fluoro-4-isopropylbenzyl)carbamoyl)pyrrolidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetic acid (Compound 208(a)(a) or 208(a)(b))Compound 208(a)(a) Compound 208(a)(b)

[0165] Compound 208(lsomer 1) was prepared via steps 1 to 4 of the procedure shown in Scheme 10, with the following modifications: (a) N-(2-fluoro-4-isopropylbenzyl)-1H-imidazole-1-carboxamide was used instead of N-(3-fluoro-4-(trifluoromethyl)benzyl)-1H-imidazole-1-carboxamide in steps 3 and 7; (b) TEA and DMF were used instead of NMM and THF in step 3. N-(2-Fluoro-4-isopropylbenzyl)-1H-imidazole-1-carboxamide was prepared by reacting (2-fluoro-4-isopropylphenyl)methanamine with GDI.Compound 208(a)(lsomer 1):

[0166] The absolute stereochemistry of Compound 208(a)(lsomer 1) was not assigned but corresponds to one of Compounds 208(a)(a) and 208(a)(b). Peak 1: retention time: 4.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 460.2 [M+H]+.1H NMR (400 MHz, DMSO-6) 6 11.93 (s, 1H), 7.86 (d, J = 8.0 Hz, 1H), 7.30 - 7.18 (m, 1H), 7.08 - 6.92 (m, 2H), 6.73 - 6.60 (m, 1H), 4.30 -4.22 (m, 1H), 4.21 - 4.13 m, 1H), 4.13 - 4.08 (m, 1H), 4.04 - 3.49 (m, 1H), 3.47 - 3.38 (m, 1H), 3.29 - 3.20 (m, 1H), 2.93 - 2.80 (m, 1H), 2.46 - 2.35 (m, 1H), 2.34 - 2.24 (m, 3H), 2.22 - 2.07 (m, 2H), 2.06- 1.90 (m, 2H), 1.90 - 1.74 (m, 5H), 1.73 - 1.54 (m, 2H), 1.19 (d, J= 7.2 Hz, 6H).(xix) 2-(6-((R)-1-(((R)-1-(4-isopropylphenyl)ethyl)carbamoyl)pyrrolidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetic acid (Compounds 230(a)(a)(a) and 230(a)(b)(a))and 2-(6-((R)-1-(((S)-1-(4-isopropylphenyl)ethyl)carbamoyl)pyrrolidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetic acid (Compounds 230(a)(a)(b) and 230(a)(b)(b))Compound 230(a)(b)(a) Compound 230(a)(b)(b)

[0167] Compounds 230(a)(a)(a), 230(a)(a)(b), 230(a)(b)(a), and 230(a)(b)(b) were prepared via the procedure shown in Scheme 10, with the following modifications: (a) N-(1-(4-isopropylphenyl)ethyl)-1H-imidazole-1-carboxamide was used instead of N-(3-fluoro-4-(trifluoromethyl)benzyl)-1H-imidazole-1-carboxamide in steps 3 and 7; (b) TEA and DMF were used instead of NMM and THF in step 3, and vice versa in step 7. N-(1-(4-lsopropylphenyl)ethyl)-1H-imidazole-1-carboxamide was prepared by reacting 1-(4-isopropylphenyl)ethan-1-amine with GDI.

[0168] The racemic product of step 4 was separated by chiral prep-HPLC [column: CHIRALPAK IC, 2*25 cm, 5 pm; mobile phase A: Hex (0.2% FA); mobile phase B: MeOH: DCM = 1:1; flow rate: 20 mL / min; gradient: isocratic 30% B in 13 min; RT1 (min): 8.0; RT2 (min): 10.6] to afford, in order of elution, Isomer 1,1 and Isomer 1,2 of Compound 230(a).

[0169] The racemic product of step 8 was separated by chiral prep-HPLC [column: CHIRALPAK IC, 2*25 cm, 5 pm; mobile phase A: Hex (0.2% FA); mobile phase B: MeOH: DCM = 1:1; flow rate: 20 mL / min; gradient: isocratic 30% B in 15 min; RT1 (min): 9.4; RT2 (min): 14.4] to afford, in order of elution, Isomer 2,1 and Isomer 2,2 of Compound 230(a).Compound 230(a)(lsomer 1,1)

[0170] The absolute stereochemistry of Compound 30(a)(lsomer 1,1) was not assigned but corresponds to one of Compounds 230(a)(a)(a), 230(a)(a)(b), 230(a)(b)(a), and 230(a)(b)(b). Separation 1 (step 4 of Scheme 4): peak 1: retention time: 4.5 min; separation 2: peak 1: retention time: 8.0 min. LCMS (ES, m / z): 456.3.1H NMR (400 MHz, DMSO-6) 5 11.52 (s, 1H), 7.80 (d, J = 8.0 Hz, 1H), 7.32 - 7.10 (m, 4H), 6.29 (d, J= 8.0 Hz, 1H), 4.85 - 4.73 (m, 1H), 4.16 -4.09 (m, 1H), 4.05 - 3.93 (m, 1H), 3.48 - 3.41 (m, 1H), 3.27 - 3.19 (m, 1H), 2.91 - 2.79 (m, 1H), 2.44 -2.33 (m, 1H), 2.31 -2.20 (m, 3H), 2.19 - 2.04 (m, 2H), 2.03 - 1.96 (m, 1H), 1.96 - 1.88 (m, 1H), 1.87 - 1.71 (m, 5H), 1.71 - 1.58 (m, 2H), 1.40 - 1.32 (m, 3H), 1.21 (d, J= 6.4 Hz, 6H).Compound 230(a)(lsomer 1,2)

[0171] The absolute stereochemistry of Compound 30(a)(lsomer 1,2) was not assigned but corresponds to one of Compounds 230(a)(a)(a), 230(a)(a)(b), 230(a)(b)(a), and 230(a)(b)(b). Separation 1 (step 4 of Scheme 4): peak 1: retention time: 4.5 min; separation 2: peak 2: retention time: 10.6 min. LCMS (ES, m / z): 456.3.1H NMR (400 MHz, DMSO-6) 5 11.92 (s, 1H), 7.87 (d, J = 8.0 Hz, 1H), 7.25 - 7.09 (m, 4H), 6.31 (d, J= 8.0 Hz, 1H), 4.81 - 4.73 (m, 1H), 4.10 - 3.96 (m, 2H), 3.47 - 3.40 (m, 1 H), 3.29 - 3.23 (m, 1 H), 2.90 - 2.79 (m, 1 H), 2.46 - 2.36 (m, 1 H), 2.33 -2.25 (m, 3H), 2.21 - 2.07 (m, 2H), 2.06 - 1.98 (m, 1H), 1.96 - 1.60 (m, 8H), 1.36 (d, J = 7.2 Hz, 3H), 1.18 (d, J= 7.2 Hz, 6H).Compound 230(a)(lsomer 2,1)

[0172] The absolute stereochemistry of Compound 30(a)(lsomer 2,1) was not assigned but corresponds to one of Compounds 230(a)(a)(a), 230(a)(a)(b), 230(a)(b)(a), and 230(a)(b)(b). Separation 1 (step 4 of Scheme 4): peak 2: retention time: 6.5 min; separation 2: peak 1: retention time: 9.4 min. LCMS (ES, m / z): 456.3 [M+H]+.1H NMR (300 MHz, DMSO-6) 5 11.95 (s, 1 H), 7.82 (d, J= 7.8 Hz, 1H), 7.29-7.20 (m, 2H), 7.20 -7.11 (m, 2H), 6.31 (d, J= 8.0 Hz, 1H), 4.78-4.75 (m, 1H), 4.17 - 4.08 (m, 1H), 3.99 - 3.96 (m, 1H), 3.49 - 3.40 (m, 1H), 3.34 - 3.23(m, 1H), 2.87 - 2.83 (m, 1H), 2.47 - 2.27 (m, 1H), 2.30 - 2.17 (m, 3H), 2.14 - 1.99 (m, 4H), 1.84 - 1.70 (m, 5H), 1.67 - 1.55 (m, 2H), 1.34 (d, J = 6.8 Hz, 3H), 1.19 (d, J= 6.8 Hz, 6H).Compound 230(a)(lsomer 2,2)

[0173] The absolute stereochemistry of Compound 30(a)(lsomer 2,2) was not assigned but corresponds to one of Compounds 230(a)(a)(a), 230(a)(a)(b), 230(a)(b)(a), and 230(a)(b)(b). Separation 1 (step 4 of Scheme 4): peak 2: retention time: 6.5 min; separation 2: peak 2: retention time: 14.4 min. LCMS (ES, m / z): 456.3 [M+H]+.1H NMR (300 MHz, DMSO-6) 5 11.95 (s, 1H), 7.89 (d, J= 7.8 Hz, 1H), 7.26 - 7.20 (m, 2H), 7.15 - 7.13 (m, 2H), 6.33 (d, J = 8.0 Hz, 1H), 4.79- 4.75 (m, 1H), 4.11 - 3.92 (m, 2H), 3.48 - 3.39 (m, 1H), 3.31 - 3.20 (m, 1H), 2.86 - 2.82 (m, 1 H), 2.49 - 2.29 (m, 1 H), 2.29 - 2.28 (m, 3H), 2.20 - 2.02 (m, 2H), 1.93 - 1.89 (m, 1 H), 1.87 -1.60 (m, 8H), 1.35 (d, J= 6.8 Hz, 3H), 1.18 (d, J = 6.8 Hz, 6H).(xx) (R)-4 '-(2-((((4-isopropylbenzyl)oxy)carbonyl)amino)propanamido)-[1, 1 '-biphenyl]-4-

[0174] Compound 235(a) was prepared via the procedure shown in Scheme 9, with the following modifications: (a) (4-isopropylphenyl)methanol was used instead of 1-(4-isopropylphenyl)ethan-1-ol in step 3; (b) 4-nitrophenyl carbonochloridate was used instead of bis(4-nitrophenyl) carbonate in step 3; (c) pyridine was used instead of TEA and DMAP in step 3; (d) MeCN was used instead of THF in step 4; (e) no chiral separation was performed at the end of the synthesis.

[0175] LCMS (ES, m / z): 461.2 [M+H]+.1H N MR (400 MHz, DMSO-6) 67.92 - 7.86 (m, 2H), 7.72 - 7.62 (m, 4H), 7.61 - 7.56 (m, 2H), 7.34 - 6.89 (m, 4H), 5.03 - 4.92 (m, 2H), 4.23 - 4.12 (m, 1H), 2.90 -2.79 (m, 1H), 1.33 - 1.26 (m, 3H), 1.23 - 0.99 (m, 6H).(xxi) (S)-4 '-(2-((((4-isopropylbenzyl)oxy)carbonyl)amino)propanamido)-[1, 1 '-biphenyl]-4-

[0176] Compound 235(b) was prepared via the procedure shown in Scheme 9, with the following modifications: (a) (tert-butoxycarbonyl)-L-alanine was used instead of (tert-butoxycarbonyl)- D-alanine in step 1; (b) TsOH in DCM was used instead of HCI in dioxane in step 2; (c) (4-isopropylphenyl)methanol was used instead of 1-(4-isopropylphenyl)ethan-1-ol in step 3; (d) 4-nitrophenyl carbonochloridate was used instead of bis(4-nitrophenyl) carbonate in step 3; (e)pyridine was used instead of TEA and DMAP in step 3; (f) MeCN was used instead of THF in step 4; (g) no chiral separation was performed at the end of the synthesis.

[0177] LCMS (ES, m / z): 461.3 [M+H]+.1H NMR (400 MHz, DMSO-6) 5 10.21 (s, 1H), 8.04-7.95 (m, 2H), 7.76 - 7.62 (m, 7H), 7.30 - 7.02 (m, 4H), 5.04 - 4.95 (m, 2H), 4.27 - 4.20 (m, 1 H), 2.93 -2.88 (m, 1H), 1.32 (d, J= 7.2 Hz, 3H), 1.19 (d, J = 6.8 Hz, 6H).(xxii) 2-(6-((R)-1-(benzylcarbamoyl)piperidine-2-carboxamido)spiro[3.3]heptan-2-Compound 236(a)(a) Compound 236(a)(b)

[0178] Compound 236(lsomer 2) was prepared via steps 1 to 4 and 10 to 14 of the procedure shown in Scheme 4, with the following modification: N-benzyl-1H-imidazole-1-carboxamide was used instead of N-(4-isopropylbenzyl)-1H-imidazole-1 -carboxamide in step 14.Compound 236(a)(lsomer 2):

[0179] The absolute stereochemistry of Compound 236(a)(lsomer 2) was not assigned but corresponds to one of Compounds 236(a)(a) and 236(a)(b). Peak 2: retention time: 6.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 414.2 [M+H]+.1H NMR (400 MHz, DMSO-6) 6 11.95 (s, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.32 - 7.17 (m, 5H), 7.03 - 6.99 (m, 1H), 4.64 - 4.58 (m, 1H), 4.32 -4.17 (m, 2H), 4.11 -4.00 (m, 1H), 3.79 - 3.73 (m, 1H), 3.08 -2.98 (m, 1H), 2.45 -2.36 (m, 1H), 2.34 - 2.23 (m, 3H), 2.20 - 2.07 (m, 2H), 2.06 - 1.98 (m, 2H), 1.97 - 1.90 (m, 1H), 1.88 - 1.82 (m, 1H), 1.73- 1.65 (m, 1H), 1.65 - 1.60 (m, 1H), 1.59 - 1.40 (m, 3H), 1.35 - 1.17 (m, 2H).(xxiii) 2-(6-((R)-1-(((5-isopropylthiazol-2-yl)methyl)carbamoyl)pyrrolidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetic acid (Compounds 5(a)(a) and 5(a)(b))Compound 5(a)(a) Compound 5(a)(b)

[0180] Compounds 5(a)(a) and 5(a)(b) were prepared via the procedure shown in Scheme 10, with the following modifications: (a) 4-nitrophenyl ((5-isopropylthiazol-2-yl)methyl)carbamate was used instead of N-(3-fluoro-4-(trifluoromethyl)benzyl)-1H-imidazole-1-carboxamide in steps 3 and 7; (b) potassium carbonate and MeCN were used instead of NMM and THF in step 3; (c) potassium carbonate and MeCN were used instead of TEA and DMF in step 7. 4-Nitrophenyl ((5-isopropylthiazol-2-yl)methyl)carbamate was prepared in 4 steps: (a) cross-coupling of tert-butyl ((5-bromothiazol-2-yl)methyl)carbamate and 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane using Pd(dppf)Ch; (b) hydrogenation of the resulting alkene over Pd(OH)2 / C; (c) Boc deprotection with HCI in dioxane; (d) reaction of the resulting amine with 4-nitrophenyl carbonochloridate.Compound 5(a)(lsomer 1):

[0181] The absolute stereochemistry of Compound 5(a)(lsomer 1) was not assigned but corresponds to one of Compounds 5(a)(a) and 5(a)(b). Peak 1: retention time: 4.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 449.1 [M+H]+.1H NMR (300 MHz, DMSO-6) 67.92 - 7.83 (m, 1H), 7.42 - 7.35 (m, 1H), 7.16 - 7.08 (m, 1H), 4.51 - 4.29 (m, 2H), 4.15 - 3.98 (m, 2H), 3.49 - 3.39 (m, 1 H), 3.28 - 3.07 (m, 2H), 2.46 - 2.36 (m, 1 H), 2.32 - 2.24 (m, 3H), 2.21 - 2.07 (m, 2H), 2.05 - 1.75 (m, 7H), 1.73 - 1.57 (m, 2H), 1.26 (d, J = 6.8 Hz, 6H).Compound 5(a)(lsomer2):

[0182] The absolute stereochemistry of Compound 5(a)(lsomer 2) was not assigned but corresponds to the other of Compounds 5(a)(a) and 5(a)(b). Peak 2: retention time: 6.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 449.2 [M+H]+.1H NMR (400 MHz, DMSO-6) 6 12.00 (s, 1H), 7.86 (d, J= 8.0 Hz, 1H), 7.38 (d, J= 1.2 Hz, 1H), 7.11 - 7.08 (m, 1H), 4.47 - 4.42 (m, 1H), 4.37 - 4.32 (m, 1H), 4.14 - 4.12 (m, 1H), 4.07 - 3.97 (m, 1H), 3.43 - 3.41 (m, 1H), 3.26 - 3.20 (m, 1H), 3.18 - 3.13 (m, 1H), 2.42 - 2.38 (m, 1H), 2.29 - 2.21 (m, 3H), 2.16 - 2.06 (m, 2H), 2.01 -1.89 (m, 3H), 1.86 - 1.71 (m, 4H), 1.71 - 1.59 (m, 2H), 1.26 (d, J= 6.8 Hz, 6H).(xxiv) 2-(6-((R)-1-((4-isopropylbenzyl)carbamoyl)pyrrolidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetic acid (Compounds 6(a)(a) and 6(a)(b))Compound 6(a)(a) Compound 6(a)(b)

[0183] Compounds 6(a)(a) and 6(a)(b) were prepared via the procedure shown in Scheme 10, with the following modifications: (a) N-(4-isopropylbenzyl)-1H-imidazole-1-carboxamide was used instead of N-(3-fluoro-4-(trifluoromethyl)benzyl)-1H-imidazole-1-carboxamide in step 3; (b) 4-nitrophenyl (4-isopropylbenzyl)carbamate was used instead of N-(3-fluoro-4-(trifluoromethyl)benzyl)-1H-imidazole-1-carboxamide in step 7; (c) potassium carbonate and MeCN were used instead of TEA and DMF in step 7. N-(4-lsopropylbenzyl)-1H-imidazole-1-carboxamide was prepared by reacting (4-isopropylphenyl)methanamine with GDI.Compound 6(a)(lsomer 1):

[0184] The absolute stereochemistry of Compound 6(a)(lsomer 1) was not assigned but corresponds to one of Compounds 6(a)(a) and 6(a)(b). Peak 1: retention time: 4.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 442.2 [M+H]+.1H NMR (400 MHz, DMSO-6) 67.87 (d, J= 7.6 Hz, 1H), 7.22 - 7.12 (m, 4H), 6.67 (t, J = 6.0 Hz, 1H), 4.28 - 4.18 (m, 1H), 4.18 - 4.09 (m, 2H), 4.07- 3.96 (m, 1H), 3.42 - 3.35 (m, 1H), 3.29 - 3.18 (m, 1H), 2.92 - 2.78 (m, 1H), 2.47 - 2.36 (m, 1H), 2.34 - 2.23 (m, 3H), 2.21 - 2.09 (m, 2H), 2.06 - 1.74 (m, 7H), 1.73 - 1.59 (m, 2H), 1.18 (d, J = 6.8 Hz, 6H).Compound 6(a)(lsomer2):

[0185] The absolute stereochemistry of Compound 6(a)(lsomer 2) was not assigned but corresponds to the other of Compounds 6(a)(a) and 6(a)(b). Peak 2: retention time: 6.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 442.2 [M+H]+.1H NMR (400 MHz, DMSO-6) 67.86 (d, J= 8.0 Hz, 1H), 7.19 - 7.13 (m, 4H), 6.66 -6.62 (m, 1H), 4.21 -4.14 (m, 1H), 4.12 -4.10 (m, 2H), 4.02- 4.00 (m, 1H), 3.42 - 3.32 (m, 1H), 3.26 - 3.22 (m, 1H), 2.86 - 2.83 (m, 1H), 2.42 - 2.38 (m, 1H), 2.28 - 2.24 (m, 3H), 2.16 - 2.10 (m, 2H), 2.01 - 1.86 (m, 3H), 1.83 - 1.78 (m, 4H), 1.71 -1.60 (m, 2H), 1.18 (d, J= 6.8 Hz, 6H).(xxv) 2-(6-((R)-1-((4-cyclopropylbenzyl)carbamoyl)pyrrolidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetic acid (Compounds 8(a)(a) and 8(a)(b))Compound 8(a)(a) Compound 8(a)(b)

[0186] Compounds 8(a)(a) and 8(a)(b) were prepared via the procedure shown in Scheme 10, with the following modifications: (a) N-(4-cyclopropylbenzyl)-1H-imidazole-1-carboxamide was used instead of N-(3-fluoro-4-(trifluoromethyl)benzyl)-1H-imidazole-1-carboxamide in steps 3 and 7; (b) TEA and DMF were used instead of NMM and THF in step 3. N-(4-Cyclopropylbenzyl)-1H-imidazole-1 -carboxamide was prepared by reacting (4-cyclopropylphenyl)methanamine hydrochloride with GDI.Compound 8(a)(lsomer 1):

[0187] The absolute stereochemistry of Compound 8(a)(lsomer 1) was not assigned but corresponds to one of Compounds 8(a)(a) and 8(a)(b). Peak 1: retention time: 4.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 440.1 [M+H]+.1H NMR (300 MHz, DMSO-6) 5 11.95 (s, 1H)7.88 (d, J= 7.6 Hz, 1H), 7.17-7.10 (m, 2H), 7.02 -6.95 (m, 2H), 6.67 (t, J = 6.0 Hz, 1H), 4.30-3.99 (m, 4H), 3.27-3.17 (m, 1H), 3.45-3.19 (m, 1H), 2.44 -2.34 (m, 1H), 2.33 -2.23 (m, 3H), 2.20- 2.01 (m, 3H), 1.99 - 1.73 (m, 7H), 1.73 - 1.58 (m, 2H), 0.95 - 0.87 (m, 2H), 0.66 - 0.57 (m, 2H).Compound 8(a)(lsomer2):

[0188] The absolute stereochemistry of Compound 8(a)(lsomer 2) was not assigned but corresponds to the other of Compounds 8(a)(a) and 8(a)(b). Peak 2: retention time: 6.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 440.3 [M+H]+.1H NMR (400 MHz, DMSO-6) 611.98 (s, 1H), 7.87 - 7.85 (m, 1H), 7.14 (d, J= 8.0 Hz, 2H), 6.99 (d, J= 8.0 Hz, 2H), 6.68 -6.62 (m, 1H), 4.24- 4.17 (m, 1H), 4.14 - 4.08 (m, 2H), 4.04 - 3.97 (m, 1H), 3.43 - 3.38 (m, 1H), 3.25 - 3.19 (m, 1H), 2.45 - 2.36 (m, 1H), 2.31 - 2.24 (m, 3H), 2.19 - 2.07 (m, 2H), 2.04 - 1.74 (m, 8H), 1.71 -1.60 (m, 2H), 0.92 - 0.90 (m, 2H), 0.63 - 0.60 (m, 2H).(xxvi) 2-(6-((R)-1-((4-(trifluoromethyl)benzyl)carbamoyl)pyrrolidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetic acid (Compounds 10(a)(a) and 10(a)(b))Compound 10(a)(a) Compound 10(a)(b)

[0189] Compounds 10(a)(a) and 10(a)(b) were prepared via the procedure shown in Scheme 10, with the following modifications: (a) N-(4-(trifluoromethyl)benzyl)-1H-imidazole-1-carboxamide was used instead of N-(3-fluoro-4-(trifluoromethyl)benzyl)-1H-imidazole-1-carboxamide in steps 3 and 7; (b) TEA and DMF were used instead of NMM and THF in step 3. N-(4-(Trifluoromethyl)benzyl)-1H-imidazole-1 -carboxamide was prepared by reacting (4-(trifluoromethyl)phenyl)methanamine hydrochloride with GDI.Compound 10(a)(lsomer 1):

[0190] The absolute stereochemistry of Compound 10(a)(lsomer 1) was not assigned but corresponds to one of Compounds 10(a)(a) and 10(a)(b). Peak 1: retention time: 4.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 468.2 [M+H]+.1H NMR (400 MHz, DMSO-6) 5 11.93 (s, 1H), 7.86 (d, J = 7.6 Hz, 1 H), 7.65 (d, J = 8.0 Hz, 2H), 7.49 (d, J = 8.0 Hz, 2H), 6.89 - 6.81 (m, 1 H), 4.39 - 4.30 (m, 1H), 4.30 - 4.20 (m, 1H), 4.15 - 4.07 (m, 1H), 4.07 - 3.93 (m, 1H), 3.49 - 3.39 (m, 1 H), 3.30 - 3.21 (m, 1 H), 2.45 - 2.34 (m, 1 H), 2.32 - 2.24 (m, 3H), 2.20 - 2.05 (m, 2H), 2.04 - 1.92 (m, 2H), 1.89 - 1.75 (m, 5H), 1.73 - 1.57 (m, 2H).Compound 10(a)(lsomer 2):

[0191] The absolute stereochemistry of Compound 10(a)(lsomer 2) was not assigned but corresponds to the other of Compounds 10(a)(a) and 10(a)(b). Peak 2: retention time: 6.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 468.2 [M+H]+.1H NMR (400 MHz, DMSO-6) 5 11.94 (s, 1 H), 7.88 (d, J = 8.0 Hz, 1 H), 7.65 (d, J = 8.0 Hz, 2H), 7.49 (d, J = 8.0 Hz, 2H), 6.89 - 6.86 (m, 1 H), 4.37 - 4.32 (m, 1 H), 4.27 - 4.22 (m, 1 H), 4.12 - 4.09 (m, 1 H), 4.04 - 3.98 (m, 1 H), 3.47 -3.42 (m, 1 H), 3.29 - 3.23 (m, 1 H), 2.43 - 2.36 (m, 1 H), 2.34 - 2.23 (m, 3H), 2.20 - 2.07 (m, 2H), 2.05 - 1.93 (m, 2H), 1.90 - 1.72 (m, 5H), 1.70 - 1.60 (m, 2H).(xxvii) 2-(6-((R)-1-((3-fluoro-4-methylbenzyl)carbamoyl)pyrrolidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetic acid (Compounds 11(a)(a) and 11(a)(b))Compound 11(a)(a) Compound 11(a)(b)

[0192] Compounds 11(a)(a) and 11(a)(b) were prepared via the procedure shown in Scheme 10, with the following modification: N-(3-fluoro-4-methylbenzyl)-1H-imidazole-1-carboxamide used instead of N-(3-fluoro-4-(trifluoromethyl)benzyl)-1H-imidazole-1-carboxamide in steps 3 and 7. N-(3-Fluoro-4-methylbenzyl)-1H-imidazole-1-carboxamide was prepared by reacting (3-fluoro-4-methylphenyl)methanamine hydrochloride with GDI.Compound 11(a)(lsomer 1):

[0193] The absolute stereochemistry of Compound 11(a)(lsomer 1) was not assigned but corresponds to one of Compounds 11 (a)(a) and 11 (a)(b). Peak 1: retention time: 4.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 431.5 [M+H]+.1H NMR (400 MHz, DMSO-6) 5 11.91 (s, 1H), 7.85 (d, J = 8.0 Hz, 1H), 7.22 - 7.13 (m, 1H), 7.05 - 6.95 (m, 2H), 6.76 - 6.67 (m, 1H), 4.29 -3.94 (m, 4H), 3.48 - 3.36 (m, 1H), 3.28 - 3.19 (m, 1H), 2.32 -2.24 (m, 3H), 2.23 -2.07 (m, 5H), 2.06 - 1.90 (m, 3H), 1.90 - 1.73 (m, 5H), 1.72 - 1.58 (m, 2H).Compound 11(a)(lsomer 2):

[0194] The absolute stereochemistry of Compound 11(a)(lsomer 2) was not assigned but corresponds to the other of Compounds 11(a)(a) and 11(a)(b). Peak 2: retention time: 6.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 432.1 [M+H]+.1H NMR (400 MHz, DMSO-6) 5 11.95 (s, 1H), 7.87 - 7.85 (m, 1H), 7.19 - 7.15 (m, 1H), 7.02 - 6.92 (m, 2H), 6.75 - 6.70 (m, 1H), 4.21 -3.99 (m, 4H), 3.43 - 3.39 (m, 1 H), 3.24 - 3.20 (m, 1 H), 2.42 - 2.39 (m, 1 H), 2.29 - 2.25 (m, 3H), 2.18 -2.02 (m, 5H), 1.99 - 1.66 (m, 7H), 1.70 - 1.59 (m, 2H).(xxviii) 2-(6-((R)-1-((3,4-dichlorobenzyl)carbamoyl)pyrrolidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetic acid (Compounds 12(a)(a) and 12(a)(b))Compound 12(a)(a) Compound 12(a)(b)

[0195] Compounds 12(a)(a) and 12(a)(b) were prepared via the procedure shown in Scheme 10, with the following modifications: (a) N-(3,4-dichlorobenzyl)-1H-imidazole-1-carboxamide was used instead of N-(3-fluoro-4-(trifluoromethyl)benzyl)-1H-imidazole-1-carboxamide in steps 3 and 7; (b) TEA and DMF were used instead of NMM and THF in step 3. N-(3,4-Dichlorobenzyl)-1H-imidazole-1 -carboxamide was prepared by reacting (3,4-dichlorophenyl)methanamine with GDI.Compound 12(a)(lsomer 1):

[0196] The absolute stereochemistry of Compound 12(a)(lsomer 1) was not assigned but corresponds to one of Compounds 12(a)(a) and 12(a)(b). Peak 1: retention time: 4.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 468.0 [M+H]+.1H NMR (400 MHz, DMSO-6) 5 11.89 (s, 1H), 7.90 - 7.85 (m, 1H), 7.59 - 7.50 (m, 2H), 7.30 - 7.24 (m, 1H), 6.86 - 6.81 (m, 1H), 4.34 - 4.15 (m, 2H), 4.13-4.07 (m, 1H), 4.04 - 3.96 (m, 1H), 3.47 - 3.40(m, 1H), 3.28 - 3.20 (m, 1H), 2.46 - 2.36(m, 1 H), 2.33 - 2.24 (m, 3H), 2.21 - 2.07 (m, 2H), 2.05 - 1.94 (m, 2H), 1.89- 1.74 (m, 5H), 1.71 - 1.59 (m, 2H).Compound 12(a)(lsomer 2):

[0197] The absolute stereochemistry of Compound 12(a)(lsomer 2) was not assigned but corresponds to the other of Compounds 12(a)(a) and 12(a)(b). Peak 2: retention time: 6.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 468.1 [M+H]+.1H NMR (400 MHz, DMSO-6) 67.87 (d, J = 8.0 Hz, 1H), 7.54-7.50 (m, 2H), 7.28 - 7.21 (m, 1H), 6.83 - 6.79 (m, 1H), 4.23 -4.09 (m, 3H), 4.02 - 3.98 (m, 1 H), 3.44 - 3.42 (m, 1 H), 3.25 - 3.22 (m, 1 H), 2.42 - 2.38 (m, 1 H), 2.27 - 2.24 (m, 3H), 2.15-2.09 (m, 2H), 2.00- 1.70 (m, 7H), 1.68- 1.60 (m, 2H).(xxix) 2-(6-((R)-1-((3-chloro-4-(trifluoromethyl)benzyl)carbamoyl)pyrrolidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetic acid (Compounds 13(a)(a) and 13(a)(b))Compound 13(a)(a) Compound 13(a)(b)

[0198] Compounds 13(a)(a) and 13(a)(b) were prepared via the procedure shown in Scheme 10, with the following modification: N-(3-chloro-4-(trifluoromethyl)benzyl)-1H-imidazole-1-carboxamide was used instead of N-(3-fluoro-4-(trifluoromethyl)benzyl)-1H-imidazole-1-carboxamide in steps 3 and 7. N-(3-Chloro-4-(trifluoromethyl)benzyl)-1H-imidazole-1-carboxamide was prepared by reacting (3-chloro-4-(trifluoromethyl)phenyl)methanamine with GDI.Compound 13(a)(lsomer 1):

[0199] The absolute stereochemistry of Compound 13(a)(lsomer 1) was not assigned but corresponds to one of Compounds 13(a)(a) and 13(a)(b). Peak 1: retention time: 4.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 502.2 [M+H]+.1H NMR (400 MHz, DMSO-6) 5 11.88 (s, 1H), 7.88 (d, J = 8.0 Hz, 1 H), 7.78 (d, J = 8.4 Hz, 1 H), 7.60 (s, 1 H), 7.43 (d, J = 8.0 Hz, 1 H), 6.95 -6.84 (m, 1H), 4.39 -4.19 (m, 2H), 4.18 - 4.09 (m, 1H), 4.06 - 3.93 (m, 1H), 3.51 - 3.41 (m, 1H), 3.31 - 3.21 (m, 1H), 2.40 - 2.32 (m, 1H), 2.32 - 2.23 (m, 3H), 2.21 - 2.04 (m, 2H), 2.03 - 1.92 (m, 2H), 1.92 - 1.74 (m, 5H), 1.71 - 1.57 (m, 2H).Compound 13(a)(lsomer 2):

[0200] The absolute stereochemistry of Compound 13(a)(lsomer 2) was not assigned but corresponds to the other of Compounds 13(a)(a) and 13(a)(b). Peak 2: retention time: 6.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 502.2 [M+H]+.1H NMR (400 MHz, DMSO-6) 5 11.95 (s, 1H),7.88 (d, J= 8.0 Hz, 1H), 7.78 (d, J= 8.0 Hz, 1H), 7.60 (s, 1H), 7.43 (d, J= 8.0 Hz, 1H), 6.91 - 6.88 (m, 1H), 4.35 - 4.20 (m, 2H), 4.12 - 3.96 (m, 2H), 3.47 - 3.42 (m, 1H), 3.28 - 3.22 (m, 1H), 2.43 - 2.34 (m, 1H), 2.31 - 2.23 (m, 3H), 2.19 - 2.04 (m, 2H), 2.03 - 1.93 (m, 2H), 1.93 -1.74 (m, 5H), 1.70 - 1.58 (m, 2H).(xxx) 2-(6-((R)-1-(benzylcarbamoyl)pyrrolidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetic acid (Compounds 26(a)(a) and 26(a)(b))Compound 26(a)(a) Compound 26(a)(b)

[0201] Compounds 26(a)(a) and 26(a)(b) were prepared via the procedure shown in Scheme 10, with the following modifications: (a) 4-nitrophenyl benzylcarbamate was used instead of N-(3-fluoro-4-(trifluoromethyl)benzyl)-1H-imidazole-1-carboxamide in steps 3 and 7; (b) potassium carbonate and MeCN were used instead of NMM and THF in step 3; (c) potassium carbonate and MeCN were used instead of TEA and DMF in step 7.Compound 26(a)(lsomer 1):

[0202] The absolute stereochemistry of Compound 26(a)(lsomer 1) was not assigned but corresponds to one of Compounds 26(a)(a) and 26(a)(b). Peak 1: retention time: 4.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 400.2 [M+H]+.1H NMR (300 MHz, DMSO-6) 6 7.90 (d, J = 7.8 Hz, 1 H), 7.34 - 7.16 (m, 5H), 6.73 -6.71 (m, 1H), 4.33 -4.18 (m, 2H), 4.17 -4.07 (m, 1H), 4.05- 3.90 (m, 1H), 3.29 - 3.20 (m, 2H), 2.45 - 2.35 (m, 1H), 2.34 - 2.23 (m, 3H), 2.21 - 2.06 (m, 2H), 2.04 - 1.92 (m, 2H), 1.92 - 1.73 (m, 5H), 1.73 - 1.58 (m, 2H).Compound 26(a)(lsomer 2):

[0203] The absolute stereochemistry of Compound 26(a)(lsomer 2) was not assigned but corresponds to the other of Compounds 26(a)(a) and 26(a)(b). Peak 2: retention time: 6.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 400.2 [M+H]+.1H NMR (400 MHz, DMSO-6) 5 11.94 (s, 1H), 7.87 (d, J= 8.0 Hz, 1H), 7.33 - 7.16 (m, 5H), 6.73- 6.71 (m, 1H), 4.31 -4.25 (m, 1H), 4.19- 4.13 (m, 1H), 4.12 - 4.10 (m, 1H), 4.02 - 4.00 (m, 1H), 3.43 - 3.42 (m, 1H), 3.26 - 3.24 (m, 1 H), 2.49 - 2.40 (m, 1 H), 2.34 - 2.25 (m, 3H), 2.20 - 2.06 (m, 2H), 2.01 - 1.74 (m, 7H), 1.70 -1.61 (m, 2H).(xxxi) 2-(6-((R)-1-((3-isopropylbenzyl)carbamoyl)pyrrolidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetic acid (Compounds 204(a)(a) and 204(a)(b))Compound 204(a)(a) Compound 204(a)(b)

[0204] Compounds 204(a)(a) and 204(a)(b) were prepared via the procedure shown in Scheme 10, with the following modifications: (a) N-(3-isopropylbenzyl)-1H-imidazole-1-carboxamide was used instead of N-(3-fluoro-4-(trifluoromethyl)benzyl)-1H-imidazole-1-carboxamide in steps 3 and 7; (b) TEA and DMF were used instead of NMM and THF in step 3. N-(3-lsopropylbenzyl)-1H-imidazole-1 -carboxamide was prepared by reacting (3-isopropylphenyl)methanamine with GDI.Compound 204(a)(lsomer 1):

[0205] The absolute stereochemistry of Compound 204(a)(lsomer 1) was not assigned but corresponds to one of Compounds 204(a)(a) and 204(a)(b). Peak 1: retention time: 4.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 442.2 [M+H]+.1H NMR (400 MHz, DMSO-6) 6 11.96 (s, 1H), 7.88 (d, J = 7.6 Hz, 1H), 7.25 - 7.16 (m, 1H), 7.16 - 7.10 (m, 1H), 7.11 - 7.04 (m, 2H), 6.72 -6.65 (m, 1H), 4.32 - 4.15 (m, 2H), 4.15 - 4.09 (m, 1H), 4.0 - 3.94 (m, 1H), 3.47 - 3.38 (m, 1H), 3.29 - 3.19 (m, 2H), 2.92 - 2.78 (m, 1H), 2.45 - 2.36 (m, 1H), 2.37 - 2.24 (m, 3H), 2.21 - 2.05 (m, 2H), 2.06- 1.92 (m, 2H), 1.91 - 1.74 (m, 5H), 1.73 - 1.57 (m, 2H), 1.20 (d, J = 6.8 Hz, 6H).Compound 204(a)(lsomer 2):

[0206] The absolute stereochemistry of Compound 204(a)(lsomer 2) was not assigned but corresponds to the other of Compounds 204(a)(a) and 204(a)(b). Peak 2: retention time: 6.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 442.3 [M+H]+.1H NMR (400 MHz, DMSO-6) 5 11.76 (s, 1H), 7.87 (d, J= 8.0 Hz, 1H), 7.23 - 7.18 (m, 1H), 7.14- 7.05 (m, 3H), 6.72 -6.68 (m, 1H), 4.25 - 4.22 (m, 1H), 4.19 - 4.13 (m, 2H), 4.05 - 3.96 (m, 1H), 3.46 - 3.40 (m, 1H), 3.27 - 3.21 (m, 1H), 2.89 - 2.81 (m, 1H), 2.44 - 2.36 (m, 1H), 2.31 - 2.25 (m, 3H), 2.19 - 2.07 (m, 2H), 2.04 -1.96 (m, 1H), 1.95 - 1.87 (m, 2H), 1.84 - 1.73 (m, 4H), 1.71 - 1.60 (m, 2H), 1.20 (d, J = 6.8 Hz, 6H).(xxxii) 2-(6-((R)-1-((3-methylbenzyl)carbamoyl)pyrrolidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetic acid (Compounds 206(a)(a) and 206(a)(b))Compound 206(a)(a) Compound 206(a)(b)

[0207] Compounds 206(a)(a) and 206(a)(b) were prepared via the procedure shown in Scheme 10, with the following modifications: (a) N-(3-methylbenzyl)-1H-imidazole-1-carboxamide was used instead of N-(3-fluoro-4-(trifluoromethyl)benzyl)-1H-imidazole-1-carboxamide in steps 3 and 7; (b) TEA and DMF were used instead of NMM and THF in step 3. N-(3-Methylbenzyl)-1H-imidazole-1 -carboxamide was prepared by reacting m-tolylmethanamine hydrochloride with GDI.Compound 206(a)(lsomer 1):

[0208] The absolute stereochemistry of Compound 206(a)(lsomer 1) was not assigned but corresponds to one of Compounds 206(a)(a) and 206(a)(b). Peak 1: retention time: 4.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 414.2 [M+H]+.1H NMR (300 MHz, DMSO-6) 511.95 (s, 1H), 7.89 (d, J= 7.6 Hz, 1H), 7.21 - 7.13 (m, 1H), 7.08 - 7.00 (m, 3H), 6.72 - 6.65 (m, 1H), 4.30 -4.17 (m, 3H), 4.15 -4.00 (m, 1H), 3.50 - 3.41 (m, 1H), 3.34 - 3.22 (m, 1H), 2.47 -2.34 (m, 1H), 2.33 - 2.26 (m, 6H), 2.17 - 2.11 (m, 2H), 2.01 - 1.91 (m, 2H), 1.87 - 1.72 (m, 5H),1.69 - 1.60 (m, 2H).Compound 206(a)(lsomer 2):

[0209] The absolute stereochemistry of Compound 206(a)(lsomer 2) was not assigned but corresponds to the other of Compounds 206(a)(a) and 206(a)(b). Peak 2: retention time: 6.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 414.2 [M+H]+.1H NMR (400 MHz, DMSO-6) 5 11.93 (s, 1H), 7.88 - 7.84 (m, 1H), 7.18 - 7.14 (m, 1H), 7.07 - 6.97 (m, 3H), 6.68 - 6.65 (m, 1H), 4.25 -4.21 (m, 1H), 4.15 - 4.09 (m, 2H), 4.02 - 3.99 (m, 1H), 3.44 - 3.38 (m, 1H), 3.24 - 3.19 (m, 1H), 2.44 - 2.35 (m, 1H), 2.30 - 2.24 (m, 6H), 2.19 - 2.06 (m, 2H), 2.02 - 1.95 (m, 1H), 1.91 - 1.86 (m, 2H), 1.83- 1.70 (m, 4H), 1.70 - 1.59 (m, 2H).(xxxiii) 2-(6-((R)-1-((naphthalen-2-ylmethyl)carbamoyl)pyrrolidine-2-carboxamido)spiro[3.3]heptan-2-yl)acetic acid (Compounds 207(a)(a) and 207(a)(b))Compound 207(a)(a) Compound 207(a)(b)

[0210] Compounds 207(a)(a) and 207(a)(b) were prepared via the procedure shown in Scheme 10, with the following modification: N-(naphthalen-2-ylmethyl)-1H-imidazole-1-carboxamide was used instead of N-(3-fluoro-4-(trifluoromethyl)benzyl)-1H-imidazole-1-carboxamide in steps 3 and 7. N-(Naphthalen-2-ylmethyl)-1H-imidazole-1-carboxamide was prepared by reacting naphthalen-2-ylmethanamine with GDI.Compound 207(a)(lsomer 1):

[0211] The absolute stereochemistry of Compound 207(a)(lsomer 1) was not assigned but corresponds to one of Compounds 207(a)(a) and 207(a)(b). Peak 1: retention time: 4.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 450.2 [M+H]+.1H NMR (400 MHz, DMSO-6) 67.93 - 7.81 (m, 4H), 7.74 (s, 1H), 7.52 - 7.42 (m, 3H), 6.87 - 6.79 (m, 1H), 4.49 - 4.30 (m, 2H), 4.18 - 4.09 (m, 1 H), 4.06 - 3.95 (m, 1 H), 3.49 - 3.44 (m, 1 H), 3.30 - 3.27 (m, 1 H), 2.44 - 2.33 (m, 1 H), 2.31 -2.19 (m, 3H), 2.19 - 2.04 (m, 2H), 2.02 - 1.93 (m, 2H), 1.90 - 1.74 (m, 5H), 1.70 - 1.55 (m, 2H).Compound 207(a)(lsomer 2):

[0212] The absolute stereochemistry of Compound 207(a)(lsomer 2) was not assigned but corresponds to the other of Compounds 207(a)(a) and 207(a)(b). Peak 2: retention time: 6.5 min (step 4 of Scheme 4). LCMS (ES, m / z): 450.2 [M+H]+.1H NMR (400 MHz, DMSO-6) 5 11.87 (s, 1 H), 7.88 - 7.83 (m, 4H), 7.74 (s, 1 H), 7.52 - 7.39 (m, 3H), 6.85 - 6.82 (m, 1 H), 4.42 - 4.41 (m, 1H), 4.37 - 4.35 (m, 1H), 4.18 - 4.08 (m, 1H), 4.02 - 4.00 (m, 1H), 3.47 - 3.44 (m, 1H), 3.31 -3.28 (m, 1H), 2.41 -2.36 (m, 1H), 2.32 - 2.21 (m, 3H), 2.19 -2.08 (m, 2H), 2.02 - 1.81 (m, 7H), 1.69 - 1.58 (m, 2H).(xxxiv) (R)-4-(3-(1-(((5-isopropylthiazol-2-yl)methyl)carbamoyl)pyrrolidine-2-carboxamido)bicyclo[1.1.1]pentan-1-yl)benzoic acid (Compound 2(a))Compound 2(a)Scheme 11

[0213] Step 1: To a stirred solution of 3-((tert-butoxycarbonyl)amino)bicyclo[1.1.1]pentane-1-carboxylic acid (20.0 g, 88.0 mmol, 1 equiv), DCC (27.2 g, 132 mmol, 1.5 equiv) and DMAP (1.08 g, 8.80 mmol, 0.1 equiv) in DCM (200 mL) was added 2-hydroxyisoindoline-1, 3-dione (17.2 g, 106 mmol, 1.2 equiv) at room temperature. The resulting mixture was filtered. The filter cake was washed with DCM (3 x 5 mL). The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography [eluted with PE / EA (60:40)] to afford 1,3-dioxoisoindolin-2-yl 3-((tert-butoxycarbonyl)amino)bicyclo[1.1.1]pentane-1-carboxylate (4.0 g, 12% yield). LCMS (ES, m / z): 373.1 [M+H]+.

[0214] Step 2: To a flask under nitrogen atmosphere were added 1,3-dioxoisoindolin-2-yl 3-((tert-butoxycarbonyl)amino)bicyclo[1.1.1]pentane-1-carboxylate (4.00 g, 10.7 mmol, 1 equiv), methyl4-iodobenzoate (4.22 g, 16.1 mmol, 1.5 equiv), 5-methoxypicolinimidamide hydrochloride (324 mg, 2.14 mmol, 0.2 equiv), TBAI (3.97 g, 10.7 mmol, 1 equiv), NiCl2(dme) (756 mg, 2.15 mmol, 0.2 equiv), Zn (7.02 g, 107 mmol, 10 equiv) and DMAc (40 mL), followed by TFA (2 mL), at room temperature. The reaction mixture was stirred at room temperature for 2 h and filtered. The filter cake was washed with EtOAc (3 x 5 mL). The filtrate was poured into water (100 mL) and extracted with EtOAc (3 x 100 mL). The combined organic extracts were washed with water (2 x 100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography [eluting with PE / EA (80:20)] to afford methyl 4-(3-((tert-butoxycarbonyl)amino)bicyclo[1.1.1]pentan-1-yl)benzoate (200 mg, 6% yield). LCMS (ES, m / z): 318.0 [M+H]+.

[0215] Step 3: A solution of methyl 4-(3-((tert-butoxycarbonyl)amino)bicyclo[1.1.1]pentan-1-yl)benzoate (230 mg, 0.725 mmol, 1 equiv) in 4 M HCI in 1,4-dioxane (3 mL) was stirred at room temperature for 1 h. The resulting mixture was concentrated under reduced pressure to afford crude methyl 4-(3-aminobicyclo[1.1.1]pentan-1-yl)benzoate hydrochloride. The crude product was used directly in the subsequent step without further purification. LCMS (ES, m / z): 218.0 [M+H]+.

[0216] Step 4: A mixture of (2R)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid (495 mg, 2.30 mmol, 1 equiv), methyl 4-(3-aminobicyclo[1.1.1]pentan-1-yl)benzoate hydrochloride (500 mg, 2.30 mmol, 1 equiv), EDCI (429 mg, 2.76 mmol, 1.2 equiv) and NMM (700 mg, 6.9 mmol, 3.0 equiv) in DCM (5 mL) was stirred at room temperature for 1 h. The reaction was quenched with water (10 mL) and extracted with EtOAc (3 x 10 mL). The combined organic extracts were dried over anhydrous Na2SO4 and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography [eluting with PE / EA (1:1)] to afford tertbutyl (R)-2-((3-(4-(methoxycarbonyl)phenyl)bicyclo[1.1.1]pentan-1-yl)carbamoyl)pyrrolidine-1-carboxylate (700 mg, 73% yield). LCMS (ES, m / z): 415.2 [M+H]+.

[0217] Step 5: To a solution of 4 M HCI in 1,4-dioxane (10 mL) was added tert-butyl (R)-2-((3-(4-(methoxycarbonyl)phenyl)bicyclo[1.1.1]pentan-1-yl)carbamoyl)pyrrolidine-1 -carboxylate (700 mg, 1.69 mmol, 1 equiv) at room temperature. After stirring for 2 h, the mixture was concentrated under reduced pressure to afford methyl (R)-4-(3-(pyrrolidine-2-carboxamido)bicyclo[1.1.1]pentan-1-yl)benzoate hydrochloride (560 mg, crude). The crude product was used directly in the subsequent step without further purification. LCMS (ES, m / z): 315.2 [M+H]+.

[0218] Step 6: To a stirred solution of 4-nitrophenyl ((5-isopropylthiazol-2-yl)methyl)carbamate (500 mg, 1.55 mmol, 1 equiv) in MeCN (5 mL) were added K2CO3(649 mg, 4.69 mmol, 3.0 equiv) and methyl (R)-4-(3-(pyrrolidine-2-carboxamido)bicyclo[1.1.1 ]pentan-1-yl)benzoate hydrochloride (498 mg, 1.58 mmol, 1 equiv) at room temperature. The reaction mixture was stirred at 90 °C for 1 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by trituration with MeCN (20 mL) to afford methyl (R)-4-(3-(1-(((5-isopropylthiazol-2-yl)methyl)carbamoyl)pyrrolidine-2-carboxamido)bicyclo[1.1.1]pentan-1-yl)benzoate (80 mg, 9% yield). LCMS (ES, m / z): 497.0 [M+H]+. [4-Nitrophenyl ((5-isopropylthiazol-2-yl)methyl)carbamate was prepared in 4 steps: (a) cross-coupling of tert-butyl ((5-bromothiazol-2-yl)methyl)carbamate and 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane using Pd(dppf)CI2; (b) hydrogenation of the resulting alkene over Pd(OH)2 / C; (c) Boc deprotection with HCI in dioxane; (d) reaction of the resulting amine with 4-nitrophenyl carbonochloridate.]

[0219] Step 7: To a stirred solution of methyl (R)-4-(3-(1-(((5-isopropylthiazol-2-yl)methyl)carbamoyl)pyrrolidine-2-carboxamido)bicyclo[1.1.1]pentan-1-yl)benzoate (70 mg, 0.14 mmol, 1 equiv) in MeOH (1 mL) and H2O (0.2 mL) was added LiOH H2O (30 mg, 0.72 mmol, 5.0 equiv). The mixture was stirred at room temperature for 4 h. The pH was adjusted to 5 with 1 M HCI (0.5 mL). The resulting mixture was extracted with EA (3 x 20 mL). The combined organic extracts were dried over Na2SO4 and filtered. The filtrate was concentrated under vacuum. The residue was purified by trituration with acetonitrile (30 mL) to afford (R)-4-(3-(1-(((5-isopropylthiazol-2-yl)methyl)carbamoyl)pyrrolidine-2-carboxamido)bicyclo[1.1.1]pentan-1-yl)benzoic acid (21.3 mg, 30% yield).Compound 2(a):

[0220] LCMS (ES, m / z): 483.1 [M+H]+.1H NMR (400 MHz, DMSO-6) 6 12.87 (s, 1H), 8.44 (s, 1 H), 7.88 (d, J = 8.0 Hz, 2H), 7.43 - 7.32 (m, 3H), 7.24 - 7.09 (m, 1 H), 4.58 - 4.43 (m, 1 H), 4.41 -4.28 (m, 1H), 4.22 -4.09 (m, 1H), 3.47-3.39 (m, 1H), 3.30-3.22 (m, 1H), 3.20-3.11 (m, 1H), 2.27 (s, 6H), 2.06 - 1.94 (m, 1H), 1.93 - 1.79 (m, 3H), 1.32 - 1.21 (m, 6H).Example 2: In vitro biological activity

[0216] Compounds were tested for GIPR antagonism by a cAMP assay by the following manner:1) Prepare the cAMP assay buffer following the table below:Reagent Vol.1x HBSS with Ca2+and Mg2+14 mL1 M HEPES 75 pL7.5% (w / v) BSA stabilizer (pH 7.4) 100 pL500 mM IBMX 14 L2) Prepare the Eu-cAMP tracer working solution and Ulight-anti-cAMP working solution following the table below:Eu-cAMP tracer working solution Ulight-anti-cAMP working solutionReagent Vol. Reagent Vol.Eu-cAMP tracer Stock 20 pl Ulight-anti-cAMP Stock 10 pl cAMP detection Buffer 2 ml cAMP detection Buffer 2 ml3) Preparation of the compound source plate:a. Preparation of 10 doses of GIP starting from 10uM stock solution by 4-fold serial dilutions with water.b. Preparation of 10 doses of reference compound GIP3-30 starting from 2 mM stock solution by 4-fold serial dilutions with water.c. Preparation of 10 doses of reference compound and test compounds starting from 10 mM stock solution by 3-fold serial dilutions with 100% (v / v) DMSO.4) Preparation of assay plate:a. Before the assay, harvest cells stably expressing GIP receptors and count the cells using a Countess cell counter. Only cells with viability >85% are used for the following assay.b. Dilute cells to 1x105 cells / mL with the cAMP assay buffer.c. Seed cells at a density of 1000 cells / well in 384-well plate.5) Transfer 10 nL / well of GIP to each well of the assay plate with GIP receptor-expressing cells by an Echo.6) Centrifuge the cell plate at 1000 rpm for 1 min and then agitate at 600 rpm for 2 min. Incubate the plate at 37°C for 30 min.7) Add 5 pL / well of Eu-cAMP tracer working solution and 5 pL / well of Ulight-anti-cAMP working solution to each well of the plate. Centrifuge the plate at 1000 rpm for 1 min and then agitate at 600 rpm for 2 min. Incubate the plate at RT for 60 min.8) Read the plate by using an EnVison microplate reader (Aex=337 nm, Aem=615 nm and 665 nm), and plot the ratio of Emission665 nm to Emission615 nm against the concentrations of compounds to build the curve and calculate the EC50 and EC80 of GIP.9) Dilute cells to 1X105cells / mL with the cAMP assay buffer. Seed cells at a density of 1000 cells / well in 384-well plate.10) Transfer 50 nL / well of reference compound and 10 nL / well of test compounds to each well of the assay plate with GIP receptor-expressing cells by an Echo.11) Centrifuge the cell plate at 1000 rpm for 1 min and then agitate at 600 rpm for 2 min. Incubate the plate at 37 °C for either 10 min or 2 h.12) Transfer appropriate amount of GIP to reach its EC80 value to each well of the assay plate with GIP receptor-expressing cells by an Echo.13) Centrifuge the cell plate at 1000 rpm for 1 min and then agitate at 600 rpm for 2 min. Incubate the plate at 37°C for 30 min.14) Add 5 pL / well of Eu-cAMP tracer working solution and 5 pL / well of Ulight-anti-cAMP working solution to each well of the plate. Centrifuge the plate at 1000 rpm for 1 min and then agitate at 600 rpm for 2 min. Incubate the plate at RT for 60 min.15) Read the plate by using an EnVison microplate reader (Aex=337 nm, Aem=615 nm and 665 nm), and plot the ratio of Emission665 nm to Emission615 nm against the concentrations of compounds to build the curve and calculate the IC50.

[0217] Percent inhibition was then calculated in the following manner:1) Calculate the ratio of TR-FRET signal using following equation:Ratio = Aem (665 nm) / Aem (620 nm)) Calculate the % Inhibition (for antagonist) using following equation:Ratiocpd— RatioHCInhibition (%) = 100 — 100 xRatioLC— RatioHCRationc: The ratio of TR-FRET signal of high control (HC stands for high control).Ratiotc: The ratio of TR-FRET signal of low control (LC stands for low control).Ratiocpd: The ratio of TR-FRET signal of test compound-treated group (cpd stands for compound).) The IC50 is determined by fitting the dose response curve with Hill equation using XLfit.Table 2. Biological activity of selected compounds

[0218] Numerous modifications could be made to any of the embodiments described above without parting from the scope of the present invention. Any references, patents or scientific literature documents referred to in the present document are incorporated herein by reference in their entirety for all purposes.

Claims

Claims1. A compound of Formula (I):or a pharmaceutical acceptable salt, solvate, or prodrug thereof,wherein:X is -NR2- or -O-;X1is -NH- or-O-;provided that when X is O, then X1is other than O;m is between 0 and 2;R and R’ are independently H or a linear or branched Ci-Cealkyl, the linear or branched Ci-Cealkyl being optionally substituted with one or more substituents, the substituents being preferably selected from halogens; or R and R’ are taken together with their adjacent carbon atom to form a ring, the ring being optionally substituted with one or more substituents;R1, R1’ and R2are independently selected from the group consisting of -H, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, optionally substituted with one or more substituents, the substituents being preferably selected from halogens, linear or branched Ci-Cealkyl, C3- Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl, 5- to 10-membered heteroaryl, -CN, -OR3, -SR3, -NR4R4’, -NHC(=O)R5, -C(=O)-NR6R6’, -S(=O)2-R5, - NR4S(=O)2-R5, -S(=O)2-NR6R6’, wherein the linear or branched Ci-Cealkyl, C3- Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally further substituted with one or more substituents, preferably selected from halogens, -OR3, -NR4R4’, -NHC(=O)R5, or-S(=O)2-NR6R6’; or R1and R2are taken together with their adjacent atoms to form a ring, the ring being optionally substitutedwith one or more substituents; or R1and R1’ are taken together with their adjacent carbon atom to form a ring, the ring being optionally substituted with one or more substituents;R3is selected from the group consisting of -H, -C(=O)-NR6R6’, linear or branched Ci-Cealkyl, Ce-C aryl and 5- to 10-membered heteroaryl, wherein the linear or branched Ci-Cealkyl, Ce-C aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R4and R4’ are independently in each occurrence selected from the group consisting of -H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R5is selected from the group consisting of linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R6and R6’ are independently in each occurrence selected from the group consisting of -H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogen;is selected from the group consisting of 4- to 14-membered heterocycloalkyl, C6- Cwaryl and 5- to 10-membered heteroaryl, optionally substituted with one or more substituents, the substituents being preferably selected from linear or branched Ci-Cealkyl, halogen, -CF3, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl, 5- to 10-membered heteroaryl, -OR3, -SF5 or -SR3, wherein the linear or branched Ci-Cealkyl and Cs-Cscycloalkyl are optionally further substituted with one or more substituents, the substituents being preferably selected from halogens or -CF3;wherein:whereinis selected from the group consisting of Cs-Cscycloalkyl, 5- to 10- membered heteroaryl and 4- to 14-membered heterocycloalkyl, each being optionally substituted;n is between 0 and 5;p is between 0 and 5;Y1, Y2, Y3, Y4, Y5, Y6, Y7and Y8are independently -CR7= or-N=;R7is independently selected from -H, halogen, -CF3, -OR3and an optionally substituted linear or branched Ci-Cealkyl, with R3as defined above; andR8and R8’ are independently selected from -H, halogen and an optionally substituted linear or branched Ci-Cealkyl or R8and R8’ are taken together with their adjacent carbon atoms to form a C3-Ci2cycloalkyl or a 4- to 14-membered heterocycloalkyl, each being optionally substituted with one or more substituents,provided that whenis a Cearyl or a 6- membered heteroaryl substituted in para position, and R1and R2are taken together with their adjacent atoms to form a ring, then the ring is different from a 5- membered ring.

2. The compound of claim 1, wherein:X is -NR2- or -O-;X1is -NH- or-O-;provided that when X is O, then X1is other than O;m is between 0;R and R’ are independently H or a linear or branched Ci-Cealkyl, the linear or branched Ci-Cealkyl being optionally substituted with one or more substituents, the substituents being preferably selected from halogens; or R and R’ are taken together with their adjacent carbon atom to form a Cs-Cscycloalkyl, the Cs-Cscycloalkyl being optionally substituted with one or more substituents;R1, R1’ and R2are independently selected from the group consisting of -H, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, optionally substituted with one or more substituents, the substituents being preferably selected from halogens, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl, 5- to 10-memberedheteroaryl, -CN, -OR3, -SR3, -NR4R4’, -NHC(=O)R5, -C(=O)-NR6R6’,-S(=O)2-R5, -NR4S(=O)2-R5, -S(=O)2-NR6R6’, wherein the linear or branched Ci-Cealkyl, C3-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally further substituted with one or more substituents, preferably selected from halogens, -OR3, -NR4R4’, -NHC(=O)R5, or -S(=O)2-NR6R6’; or R1and R2are taken together with their adjacent atoms to form a 4- to 14-membered heterocycloalkyl, the 4- to 14-membered heterocycloalkyl being optionally substituted with one or more substituents; or R1and R1’ are taken together with their adjacent carbon atom to form a Cs-Cscycloalkyl, the Cs-Cscycloalkyl being optionally substituted with one or more substituents;R3is selected from the group consisting of -H, -C(=O)-NR6R6’, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R4and R4’ are independently in each occurrence selected from the group consisting of -H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R5is selected from the group consisting of linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R6and R6’ are independently in each occurrence selected from the group consisting of -H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogen;is selected from the group consisting of 4- to 14-membered heterocycloalkyl,Ce-C aryl and 5- to 10-membered heteroaryl, optionally substituted with one or more substituents, the substituents being preferably selected from linear or branched Ci-Cealkyl, halogen, -CF3, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl, 5- to 10-membered heteroaryl, -OR3, -SF5 or -SR3, wherein the linear or branched C1-Cealkyl and Cs-Cscycloalkyl are optionally further substituted with one or more substituents, the substituents being preferably selected from halogens or -CF3;from the group consisting of Cs-Cscycloalkyl, 5- to 10- membered heteroaryl and 4- to 14-membered heterocycloalkyl, each being optionally substituted;n is between 0 and 5;p is between 0 and 5;Y1, Y2, Y3, Y4, Y5, Y6, Y7and Y8are independently -CR7= or -N=;R7is independently selected from -H, halogen, -CF3, -OR3and an optionally substituted linear or branched Ci-Cealkyl, with R3as defined above; andR8and R8’ are independently selected from -H, halogen and an optionally substituted linear or branched Ci-Cealkyl;provided that when, a Cearyl or a 6-membered heteroaryl substituted in para position, and R1and R2are taken together with their adjacent atoms to form a 4- to 14-membered heterocycloalkyl, then the 4- to 14- membered heterocycloalkyl is different from 5-membered heterocycloalkyl.

3. The compound of claim 1 or 2, whereinis a 4- to 14-membered heterocycloalkyl or Ce-C aryl optionally substituted with one or more substituents, the substituents being preferably selected from halogen, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14- membered heterocycloalkyl, Ce-C aryl, 5- to 10-membered heteroaryl, -SFs, -OR3or - SR3, wherein the linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl are optionally further substituted with one or more substituents, the substituents being preferably selected from halogens or -CF3 and wherein R3is as defined above.R9is independently in each occurrence selected from the group consisting of halogen, - OR3, -SR3, -SF5, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, or two R9on adjacent atoms are taken together to form a Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl or 5- to 10-membered heteroaryl, wherein the Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents preferably selected from halogens, - CF3, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl; andwherein R3is selected from the group consisting of -H and linear or branched Ci-Cealkyl optionally substituted with one or more substituents preferably selected from halogens.

5. The compound of claim 4, wherein R9is independently selected from the group consisting of -Cl, -F, -CF3, -OCF3, -SCF3, -SF5, -OCH3, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, each optionally further substituted, preferably with one or more -CF3.The compound of claim 5, whereinThe compound of any one of claims 1 to 7, whereinis B5, B9, or B10,preferably B5or B10, whereinis a Cs-Cscycloalkyl group optionally substituted with one or more substituents.The compound of claim 8, whereinis a spiro Cs-Cscycloalkyl group (e.g. C7- Cscycloalkyl) optionally substituted with one or more substituents.

10. The compound of claim 8, whereinis a monocyclic C4-Cycycloalkyl group (e.g.C^Cecycloalkyl, or Cscycloalkyl) or a bridged bicyclic Cs-Cscycloalkyl group (e.g. Cs- Cycycloalkyl), each optionally substituted with one or more substituents.

11. The compound of claim 8, whereinis a monocyclic C^Cscycloalkyl group.

12. The compound of any one of claims 1 to 7, whereinis present and is selected from groups:optionally substituted with one or more substituents, or is preferably, optionally substituted with one or more substituents.

13. The compound of any one of claims 1 to 7, wherein B1, B5, B7, B9or B10is:9Hwherein p is between 0 and 5, andR7is independently selected from the group consisting of halogen, -CF3, -OR3and linear or branched Ci-Cealkyl, with R3selected from the group consisting of -H, -CF3, -CHF2 and linear or branched Ci-Cealkyl;R8and R8’ are independently selected from -H, halogen and an optionally substituted linear or branched Ci-Cealkyl;provided that whenis a Cearyl or a 6-membered heteroaryl substituted in para position, and R1and R2are taken together with their adjacent atoms to form a 4- to 14-membered heterocycloalkyl, then the 4- to 14-membered heterocycloalkyl is different from 5-membered heterocycloalkyl.

14. The compound of claim 13, wherein R7is independently selected from the group consisting of -Cl, -F, -CF3, -CHF2, -OCH3, -CH3, -CH2CH3, -CH2CH2CH3 and -CH(CH3)2.

15. The compound of any one of claims 1 to 7, whereinis:is a Cearyl or a 6-membered heteroaryl substituted in para position, andR1and R2are taken together with their adjacent atoms to form a 4- to 14-membered heterocycloalkyl, then the 4- to 14-membered heterocycloalkyl is different from a 5- membered heterocycloalkyl.

16. The compound of any one of claims 1 to 15, wherein R and R’ are independently selected from -H and -CH3.

17. The compound of any one of claims 1 to 15, wherein R and R’ are -H.

18. The compound of any one of claims 1 to 15, wherein R and R’ are -CH3.

19. The compound of any one of claims 1 to 15, wherein R is -H and R’ is -CH3.

20. The compound of any one of claims 1 to 19, wherein R1’ is -H.

21. The compound of any one of claims 1 to 20, wherein X is -NR2- and R2is as defined in claim 1 or 2.

22. The compound of any one of claims 1 to 20, wherein X is -O-.

23. The compound of any one of claims 1 to 22, wherein X1is -NH-.

24. The compound of any one of claims 1 to 22, wherein X1is -O-.

25. The compound of any one of claims 1 to 24, wherein the compound is of Formula la, or a pharmaceutical acceptable salt, solvate, or prodrug thereof:wherein R1, R2,are as defined in any one of claims 1 to 15.

26. The compound of any one of claims 1 to 24, wherein the compound is of Formula lb, or a pharmaceutical acceptable salt, solvate, or prodrug thereof:wherein R1, R2,are as defined in any one of claims 1 to 15.

27. The compound of claim 25 or 26, wherein R1and R2are independently selected from the group consisting of -H, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, optionally substituted with one or more substituents, the substituents being preferably selected from halogens, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl, 5- to 10-membered heteroaryl, -CN, -OR3, -SR3, -NR4R4’, -NHC(=O)R5, -C(=O)-NR6R6’,- S(=O)2-R5, -NR4S(=O)2-R5, -S(=O)2-NR6R6’, wherein the linear or branched Ci-Cealkyl, C3- Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally further substituted with one or more substituents, preferably selected from halogens, -OR3, -NR4R4’, -NHC(=O)R5, or -S(=O)2-NR6R6’;R3is selected from the group consisting of -H, -C(=O)-NR6R6’, linear or branched Ci- Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the linear or branched Ci-Cealkyl, Ce-C aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R4and R4’ are independently in each occurrence selected from the group consisting of - H, linear or branched Ci-Cealkyl, Ce-C aryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R5is selected from the group consisting of linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R6and R6’ are independently in each occurrence selected from the group consisting of - H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogen.

28. The compound of claim 27, wherein R1and R2are independently selected from the group consisting of -H, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, optionally substituted with one or more substituents, the substituents being preferably selected from halogens, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl, -CN, -OCH3, -OCF3, and -SF5.

29. The compound of claim 28, wherein R1and R2are independently selected from the group consisting of -H, linear or branched Ci-Cealkyl, Ce-Cwaryl, -CH₂-C₃-C₈cycloalkyl and - CH2PI-1.

30. The compound of claim 29, wherein R1and R2are independently selected from the group consisting of -H, -CH3, -CH2CH3, -CH2(CH3)2, phenyl, cyclopropyl, cyclopentyl, cyclohexyl, -CH2-cyclopropyl, -CH2-cyclohexyl and -CH2Ph.

31. The compound of claim 30, wherein R1is selected from the group consisting of -CH3, - CH2CH3, phenyl, cyclopropyl and -CH2-cyclopropyl.

32. The compound of claim 30, wherein R2is selected from the group consisting of -H, -CH3, -CH2(CH3)2, phenyl, cyclopropyl, cyclopentyl, cyclohexyl, -CH2-cyclohexyl and -CH2Ph.

33. The compound of any one of claims 26 to 32, wherein R1and R2are different.

34. The compound of any one of claims 26 to 32, wherein R1and R2are identical.

35. The compound of claim 25 or 26, wherein R1and R2are taken together with their adjacent atoms to form a 4- to 14-membered heterocycloalkyl, the 4- to 14-membered heterocycloalkyl being optionally substituted with one or more substituents.

36. The compound of claim 35, wherein R1and R2are taken together with their adjacent atoms to form a 6- to 14-membered heterocycloalkyl, the 6- to 14-membered heterocycloalkyl being optionally substituted with one or more substituents.

37. The compound of claim 36, wherein the 6- to 14-membered heterocycloalkyl iswhereinq is between 1 and 2;X5is -CH2-, -NR11-, -S- or-O-;R11is selected from the group consisting of -H, linear or branched Ci-Cealkyl, C3- Cscycloalkyl, 4- to 14-membered heterocycloalkyl and Ce-C aryl, optionally substituted with one or more substituents; andwherein the 6- to 14-membered heterocycloalkyl is optionally further substituted with one or more substituents.

38. The compound of claim 37, wherein the 6- to 14-membered heterocycloalkyl is of formula39. The compound of claim 35, wherein R1and R2are taken together with their adjacent atoms to form a 4- or 5-membered heterocycloalkyl, the 4- or 5-membered heterocycloalkyl being optionally substituted with one or more substituents.

40. The compound of claim 39, wherein the 4- or 5-membered heterocycloalkyl is of formula41. The compound of any one of claims 35 to 40, wherein the heterocycloalkyl is substituted with one or more R10substituents independently in each occurrence selected from the group consisting of halogen, -CN, OR3, SR3, -NR4R4’, -NR4C(=O)R5, -C(=O)-NR6R6’, =0 (oxo), -S(=O)2-R5, -NR4S(=O)2R5, -S(=O)2-NR6R6’, linear or branched Ci-C6alkyl, C3- Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, or two R10are taken together with their adjacent carbon atom(s) to form a fused, spiro or bridged C3-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl or 5- to 10-membered heteroaryl, wherein the Ci-Cealkyl, C3-Cscycloalkyl, 4- to 14- membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents preferably selected from halogens, -CN, OR3, - NR4R4’, -NHC(=O)R5, -C(=O)-NR6R6’, -CF3, linear or branched Ci-C6alkyl, C3-C8cycloalkyl,4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl, wherein R3, R4, R4’, R5, R6and R6’ are previously defined.

42. The compound of claim 41, wherein the substituted 5-membered heterocycloalkyl is of43. The compound of any one of claims 35 to 40, wherein the heterocycloalkyl is unsubstituted.

44. The compound of any one of claims 1 to 24, wherein the compound is of Formula Ic, or a pharmaceutical acceptable salt, solvate, or prodrug thereof:

45. The compound of claim 44, wherein R1is selected from the group consisting of -H, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, optionally substituted with one or more substituents, the substituents being preferably selected from halogens, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-C aryl, 5- to 10-membered heteroaryl, -CN, -OR3, -SR3, -NR4R4’, -NHC(=O)R5, -C(=O)-NR6R6’,-S(=O)2-R5, - NR4S(=O)2-R5, -S(=O)2-NR6R6’, wherein the linear or branched Ci-Cealkyl, C3- Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally further substituted with one or more substituents, preferably selected from halogens, -OR3, -NR4R4’, -NHC(=O)R5, or -S(=O)2-NR6R6’;R3is selected from the group consisting of -H, -C(=O)-NR6R6’, linear or branched Ci- Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the linear or branched Ci- Cealkyl, Ce-C aryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R4and R4’ are independently in each occurrence selected from the group consisting of - H, linear or branched Ci-Cealkyl, Ce-C aryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R5is selected from the group consisting of linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogens;R6and R6’ are independently in each occurrence selected from the group consisting of - H, linear or branched Ci-Cealkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, wherein the Ce-Cwaryl and 5- to 10-membered heteroaryl are optionally substituted with one or more substituents, the substituents being preferably selected from halogen.

46. The compound of claim 45, wherein R1is selected from the group consisting of -H, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl and 5- to 10-membered heteroaryl, optionally substituted with one or more substituents, the substituents being preferably selected from halogens, linear or branched Ci-Cealkyl, Cs-Cscycloalkyl, 4- to 14-membered heterocycloalkyl, Ce-Cwaryl, 5- to 10-membered heteroaryl, -CN, -OCH3, -OCF3, and -SF5.

47. The compound of claim 46, wherein R1is selected from the group consisting of linear or branched Ci-Cealkyl and Ce-Cwaryl.

48. The compound of claim 42, wherein R1is -CH3 or phenyl.

49. The compound of claim 1, which is one of Compounds 1 to 236 of Table 1 of the description, ora pharmaceutically acceptable salt, solvate, or prodrug thereof.

50. The compound of any one of claims 1 to 49, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the compound is in the form of a racemate or any enantiomer thereof.

51. A pharmaceutical composition comprising: a compound according to any one of claims 1 to 50, or a pharmaceutically acceptable salt, solvate, or prodrug thereof; and a pharmaceutically acceptable carrier, diluent or excipient.

52. Use of a compound as defined in any one of claims 1 to 50, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, for the preparation of a pharmaceutical composition for the treatment or prevention of a condition, a disease or a disorder for which modulating the glucose-dependent insulinotropic polypeptide receptor (GIPR) is indicated.

53. Use of a compound as defined in any one of claims 1 to 50, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, for the preparation of a pharmaceutical composition for the treatment or prevention of a condition, a disease or a disorder selected from metabolic diseases and obesity.

54. Use of a compound as defined in any one of claims 1 to 50, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, for the preparation of a pharmaceutical composition for the treatment or prevention of a condition, a disease or a disorder selected from diabetes (e.g. Type 1 diabetes mellitus (T1D), Type 2 diabetes mellitus (T2DM), including pre-diabetes), idiopathic T1D (Type 1b), latent autoimmune diabetes in adults (LADA), early-onset T2DM (EOD), youth-onset atypical diabetes (YOAD), maturity onset diabetes of the young (MODY), malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease (e.g., acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules, or chronic kidney disease (CKD)), diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, sleep apnea (e.g. obstructive sleep apnea (OSA)), obesity (including hypothalamic obesity and monogenic obesity) and related comorbidities (e.g., osteoarthritis and urine incontinence), eating disorders (including binge eating syndrome, bulimia nervosa, and syndromic obesity such as Prader-Willi and Bardet-Biedl syndromes), weight gain such as weight gain caused by use of other agents (e.g., caused by use of steroids and / or antipsychotics, or caused by treatment of depression, or caused by use of agents on cognitive function), excessive sugar craving, dyslipidemia [including hyperlipidemia, hypertriglyceridemia, increased total cholesterol, high LDL (low-density lipoprotein) cholesterol, and low HDL (high-density lipoprotein) cholesterol], hyperinsulinemia,nonalcoholic fatty liver disease [NAFLD, including related diseases such as steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma], cardiovascular disease, atherosclerosis (including coronary artery disease), peripheral vascular disease, hypertension, endothelial dysfunction, impaired vascular compliance, heart failure (e.g. congestive heart failure, heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF)), myocardial infarction (e.g. necrosis and apoptosis), stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, post-prandial lipemia, metabolic acidosis, ketosis, arthritis, osteoporosis, osteoarthritis, Parkinson’s disease, left ventricular hypertrophy, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, syndrome X, premenstrual syndrome, angina pectoris, thrombosis, atherosclerosis, transient ischemic attacks, vascular restenosis, impaired glucose metabolism, conditions of impaired fasting plasma glucose, hyperuricemia, gout, erectile dysfunction, skin and connective tissue disorders, psoriasis, foot ulcerations, ulcerative colitis, hyper apo B lipoproteinemia, Alzheimer’s Disease, schizophrenia, impaired cognition, inflammatory bowel disease, short bowel syndrome, Crohn’s disease, colitis, irritable bowel syndrome, polycystic ovary syndrome (PCOS), and addiction (e.g., addiction to alcohol, nicotine, and / or drug).

55. Use of a compound as defined in any one of claims 1 to 50, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, for the manufacture of a medicament for the treatment or prevention of a condition, a disease or a disorder for which modulating the glucose-dependent insulinotropic polypeptide receptor (GIPR) is indicated.

56. Use of a compound as defined in any one of claims 1 to 50, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, for the manufacture of a medicament for the treatment or prevention of a condition, a disease or a disorder selected from metabolic diseases and obesity.

57. Use of a compound as defined in any one of claims 1 to 50, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, for the manufacture of a medicament for the treatment or prevention of a condition, a disease or a disorder selected from diabetes (e.g. Type 1 diabetes mellitus (T1D), Type 2 diabetes mellitus (T2DM), including pre-diabetes), idiopathic T1 D (Type 1 b), latent autoimmune diabetes in adults (L DA), early-onset T2DM(EOD), youth-onset atypical diabetes (YOAD), maturity onset diabetes of the young (MODY), malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease (e.g., acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules, or chronic kidney disease (CKD)), diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, sleep apnea (e.g. obstructive sleep apnea (OSA)), obesity (including hypothalamic obesity and monogenic obesity) and related comorbidities (e.g., osteoarthritis and urine incontinence), eating disorders (including binge eating syndrome, bulimia nervosa, and syndromic obesity such as Prader-Willi and Bardet-Biedl syndromes), weight gain such as weight gain caused by use of other agents (e.g., caused by use of steroids and / or antipsychotics, or caused by treatment of depression, or caused by use of agents on cognitive function), excessive sugar craving, dyslipidemia [including hyperlipidemia, hypertriglyceridemia, increased total cholesterol, high LDL (low-density lipoprotein) cholesterol, and low HDL (high-density lipoprotein) cholesterol], hyperinsulinemia, nonalcoholic fatty liver disease [NAFLD, including related diseases such as steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma], cardiovascular disease, atherosclerosis (including coronary artery disease), peripheral vascular disease, hypertension, endothelial dysfunction, impaired vascular compliance, heart failure (e.g. congestive heart failure, heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF)), myocardial infarction (e.g. necrosis and apoptosis), stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, post-prandial lipemia, metabolic acidosis, ketosis, arthritis, osteoporosis, osteoarthritis, Parkinson’s disease, left ventricular hypertrophy, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, syndrome X, premenstrual syndrome, angina pectoris, thrombosis, atherosclerosis, transient ischemic attacks, vascular restenosis, impaired glucose metabolism, conditions of impaired fasting plasma glucose, hyperuricemia, gout, erectile dysfunction, skin and connective tissue disorders, psoriasis, foot ulcerations, ulcerative colitis, hyper apo B lipoproteinemia, Alzheimer’s Disease, schizophrenia, impaired cognition, inflammatory bowel disease, short bowel syndrome, Crohn’s disease, colitis, irritable bowel syndrome, polycystic ovary syndrome (PCOS), and addiction (e.g., addiction to alcohol, nicotine, and / or drug).

58. A method for treating or preventing a disorder for which modulation of the glucosedependent insulinotropic polypeptide receptor (GIPR) is indicated comprising administering to a patient in need thereof a compound as defined in any one of claims 1 to 50, or a pharmaceutically acceptable salt, solvate or prodrug thereof.

59. A method for treating or preventing a condition, a disease or a disorder selected from metabolic diseases and obesity comprising administering to a patient in need thereof a compound as defined in any one of claims 1 to 50, or a pharmaceutically acceptable salt, solvate or prodrug thereof.

60. A method for treating or preventing a condition, a disease or a disorder comprising administering to a patient in need thereof a compound as defined in any one of claims 1 to 50, or a pharmaceutical acceptable salt, solvate, or prodrug thereof, wherein the condition, disease or disorder is selected from diabetes (e.g. Type 1 diabetes mellitus (T1D), Type 2 diabetes mellitus (T2DM), including pre-diabetes), idiopathic T1D (Type 1b), latent autoimmune diabetes in adults (L DA), early-onset T2DM (EOD), youth-onset atypical diabetes (YOAD), maturity onset diabetes of the young (MODY), malnutrition- related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease (e.g., acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules, or chronic kidney disease (CKD)), diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, sleep apnea (e.g. obstructive sleep apnea (OSA)), obesity (including hypothalamic obesity and monogenic obesity) and related comorbidities (e.g., osteoarthritis and urine incontinence), eating disorders (including binge eating syndrome, bulimia nervosa, and syndromic obesity such as Prader-Willi and Bardet-Biedl syndromes), weight gain such as weight gain caused by use of other agents (e.g., caused by use of steroids and / or antipsychotics, or caused by treatment of depression, or caused by use of agents on cognitive function), excessive sugar craving, dyslipidemia [including hyperlipidemia, hypertriglyceridemia, increased total cholesterol, high LDL (low-density lipoprotein) cholesterol, and low HDL (high-density lipoprotein) cholesterol], hyperinsulinemia, nonalcoholic fatty liver disease [NAFLD, including related diseases such as steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma], cardiovascular disease, atherosclerosis (including coronary artery disease), peripheral vascular disease, hypertension, endothelial dysfunction, impaired vascular compliance, heart failure (e.g. congestive heart failure, heart failure withpreserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF)), myocardial infarction (e.g. necrosis and apoptosis), stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, post-prandial lipemia, metabolic acidosis, ketosis, arthritis, osteoporosis, osteoarthritis, Parkinson’s disease, left ventricular hypertrophy, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, syndrome X, premenstrual syndrome, angina pectoris, thrombosis, atherosclerosis, transient ischemic attacks, vascular restenosis, impaired glucose metabolism, conditions of impaired fasting plasma glucose, hyperuricemia, gout, erectile dysfunction, skin and connective tissue disorders, psoriasis, foot ulcerations, ulcerative colitis, hyper apo B lipoproteinemia, Alzheimer’s Disease, schizophrenia, impaired cognition, inflammatory bowel disease, short bowel syndrome, Crohn’s disease, colitis, irritable bowel syndrome, polycystic ovary syndrome (PCOS), and addiction (e.g., addiction to alcohol, nicotine, and / or drug).

61. A compound according to any one of claims 1 to 50, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, for use in the treatment or prevention of a condition, a disease, or a disorder for which modulation of the glucose-dependent insulinotropic polypeptide receptor (GIPR) is indicated.

62. A compound according to any one of claims 1 to 50, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, for use in the treatment or prevention of a condition, a disease or a disorder selected from metabolic diseases and obesity.

63. A compound according to any one of claims 1 to 50, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, for use in the treatment or prevention of a condition, a disease or a disorder selected from diabetes (e.g. Type 1 diabetes mellitus (T 1 D), Type 2 diabetes mellitus (T2DM), including pre-diabetes), idiopathic T1D (Type 1b), latent autoimmune diabetes in adults (LADA), early-onset T2DM (EOD), youth-onset atypical diabetes (YOAD), maturity onset diabetes of the young (MODY), malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease (e.g., acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules, or chronic kidney disease (CKD)), diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, sleep apnea (e.g. obstructive sleep apnea (OSA)), obesity(including hypothalamic obesity and monogenic obesity) and related comorbidities (e.g., osteoarthritis and urine incontinence), eating disorders (including binge eating syndrome, bulimia nervosa, and syndromic obesity such as Prader-Willi and Bardet-Biedl syndromes), weight gain such as weight gain caused by use of other agents (e.g., caused by use of steroids and / or antipsychotics, or caused by treatment of depression, or caused by use of agents on cognitive function), excessive sugar craving, dyslipidemia [including hyperlipidemia, hypertriglyceridemia, increased total cholesterol, high LDL (low-density lipoprotein) cholesterol, and low HDL (high-density lipoprotein) cholesterol], hyperinsulinemia, nonalcoholic fatty liver disease [NAFLD, including related diseases such as steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma], cardiovascular disease, atherosclerosis (including coronary artery disease), peripheral vascular disease, hypertension, endothelial dysfunction, impaired vascular compliance, heart failure (e.g. congestive heart failure, heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF)), myocardial infarction (e.g. necrosis and apoptosis), stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, post-prandial lipemia, metabolic acidosis, ketosis, arthritis, osteoporosis, osteoarthritis, Parkinson’s disease, left ventricular hypertrophy, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, syndrome X, premenstrual syndrome, angina pectoris, thrombosis, atherosclerosis, transient ischemic attacks, vascular restenosis, impaired glucose metabolism, conditions of impaired fasting plasma glucose, hyperuricemia, gout, erectile dysfunction, skin and connective tissue disorders, psoriasis, foot ulcerations, ulcerative colitis, hyper apo B lipoproteinemia, Alzheimer’s Disease, schizophrenia, impaired cognition, inflammatory bowel disease, short bowel syndrome, Crohn’s disease, colitis, irritable bowel syndrome, polycystic ovary syndrome (PCOS), and addiction (e.g., addiction to alcohol, nicotine, and / or drug).